id	sid	tid	token	lemma	pos
ajlm-1363	1	1	abstract	abstract	ADJ
ajlm-1363	1	2	introduction	introduction	NOUN
ajlm-1363	1	3	methods	method	NOUN
ajlm-1363	1	4	results	result	VERB
ajlm-1363	1	5	discussion	discussion	NOUN
ajlm-1363	1	6	acknowledgements	acknowledgement	NOUN
ajlm-1363	1	7	references	reference	NOUN
ajlm-1363	1	8	about	about	ADP
ajlm-1363	1	9	the	the	DET
ajlm-1363	1	10	author(s	author(s	NOUN
ajlm-1363	1	11	)	)	PUNCT
ajlm-1363	1	12	jean	jean	PROPN
ajlm-1363	1	13	f.	f.	PROPN
ajlm-1363	1	14	kloppers	kloppers	PROPN
ajlm-1363	1	15	department	department	PROPN
ajlm-1363	1	16	of	of	ADP
ajlm-1363	1	17	haematology	haematology	NOUN
ajlm-1363	1	18	and	and	CCONJ
ajlm-1363	1	19	cell	cell	NOUN
ajlm-1363	1	20	biology	biology	NOUN
ajlm-1363	1	21	,	,	PUNCT
ajlm-1363	1	22	school	school	NOUN
ajlm-1363	1	23	of	of	ADP
ajlm-1363	1	24	pathology	pathology	NOUN
ajlm-1363	1	25	,	,	PUNCT
ajlm-1363	1	26	faculty	faculty	NOUN
ajlm-1363	1	27	of	of	ADP
ajlm-1363	1	28	health	health	NOUN
ajlm-1363	1	29	sciences	sciences	PROPN
ajlm-1363	1	30	,	,	PUNCT
ajlm-1363	1	31	university	university	NOUN
ajlm-1363	1	32	of	of	ADP
ajlm-1363	1	33	the	the	DET
ajlm-1363	1	34	free	free	ADJ
ajlm-1363	1	35	state	state	PROPN
ajlm-1363	1	36	,	,	PUNCT
ajlm-1363	1	37	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	38	,	,	PUNCT
ajlm-1363	1	39	south	south	PROPN
ajlm-1363	1	40	africa	africa	PROPN
ajlm-1363	1	41	department	department	PROPN
ajlm-1363	1	42	of	of	ADP
ajlm-1363	1	43	haematology	haematology	NOUN
ajlm-1363	1	44	and	and	CCONJ
ajlm-1363	1	45	cell	cell	NOUN
ajlm-1363	1	46	biology	biology	NOUN
ajlm-1363	1	47	,	,	PUNCT
ajlm-1363	1	48	universitas	universita	NOUN
ajlm-1363	1	49	academic	academic	ADJ
ajlm-1363	1	50	unit	unit	NOUN
ajlm-1363	1	51	,	,	PUNCT
ajlm-1363	1	52	national	national	PROPN
ajlm-1363	1	53	health	health	PROPN
ajlm-1363	1	54	laboratory	laboratory	PROPN
ajlm-1363	1	55	services	services	PROPN
ajlm-1363	1	56	,	,	PUNCT
ajlm-1363	1	57	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	58	,	,	PUNCT
ajlm-1363	1	59	south	south	PROPN
ajlm-1363	1	60	africa	africa	PROPN
ajlm-1363	1	61	andré	andré	PROPN
ajlm-1363	1	62	de	de	PROPN
ajlm-1363	1	63	kock	kock	PROPN
ajlm-1363	1	64	department	department	PROPN
ajlm-1363	1	65	of	of	ADP
ajlm-1363	1	66	haematology	haematology	NOUN
ajlm-1363	1	67	and	and	CCONJ
ajlm-1363	1	68	cell	cell	NOUN
ajlm-1363	1	69	biology	biology	NOUN
ajlm-1363	1	70	,	,	PUNCT
ajlm-1363	1	71	school	school	NOUN
ajlm-1363	1	72	of	of	ADP
ajlm-1363	1	73	pathology	pathology	NOUN
ajlm-1363	1	74	,	,	PUNCT
ajlm-1363	1	75	faculty	faculty	NOUN
ajlm-1363	1	76	of	of	ADP
ajlm-1363	1	77	health	health	NOUN
ajlm-1363	1	78	sciences	sciences	PROPN
ajlm-1363	1	79	,	,	PUNCT
ajlm-1363	1	80	university	university	NOUN
ajlm-1363	1	81	of	of	ADP
ajlm-1363	1	82	the	the	DET
ajlm-1363	1	83	free	free	ADJ
ajlm-1363	1	84	state	state	PROPN
ajlm-1363	1	85	,	,	PUNCT
ajlm-1363	1	86	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	87	,	,	PUNCT
ajlm-1363	1	88	south	south	PROPN
ajlm-1363	1	89	africa	africa	PROPN
ajlm-1363	1	90	department	department	PROPN
ajlm-1363	1	91	of	of	ADP
ajlm-1363	1	92	haematology	haematology	NOUN
ajlm-1363	1	93	and	and	CCONJ
ajlm-1363	1	94	cell	cell	NOUN
ajlm-1363	1	95	biology	biology	NOUN
ajlm-1363	1	96	,	,	PUNCT
ajlm-1363	1	97	universitas	universita	NOUN
ajlm-1363	1	98	academic	academic	ADJ
ajlm-1363	1	99	unit	unit	NOUN
ajlm-1363	1	100	,	,	PUNCT
ajlm-1363	1	101	national	national	PROPN
ajlm-1363	1	102	health	health	PROPN
ajlm-1363	1	103	laboratory	laboratory	PROPN
ajlm-1363	1	104	services	services	PROPN
ajlm-1363	1	105	,	,	PUNCT
ajlm-1363	1	106	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	107	,	,	PUNCT
ajlm-1363	1	108	south	south	PROPN
ajlm-1363	1	109	africa	africa	PROPN
ajlm-1363	1	110	johané	johané	PROPN
ajlm-1363	1	111	cronjé	cronjé	VERB
ajlm-1363	1	112	department	department	PROPN
ajlm-1363	1	113	of	of	ADP
ajlm-1363	1	114	haematology	haematology	NOUN
ajlm-1363	1	115	and	and	CCONJ
ajlm-1363	1	116	cell	cell	NOUN
ajlm-1363	1	117	biology	biology	NOUN
ajlm-1363	1	118	,	,	PUNCT
ajlm-1363	1	119	school	school	NOUN
ajlm-1363	1	120	of	of	ADP
ajlm-1363	1	121	pathology	pathology	NOUN
ajlm-1363	1	122	,	,	PUNCT
ajlm-1363	1	123	faculty	faculty	NOUN
ajlm-1363	1	124	of	of	ADP
ajlm-1363	1	125	health	health	NOUN
ajlm-1363	1	126	sciences	sciences	PROPN
ajlm-1363	1	127	,	,	PUNCT
ajlm-1363	1	128	university	university	NOUN
ajlm-1363	1	129	of	of	ADP
ajlm-1363	1	130	the	the	DET
ajlm-1363	1	131	free	free	ADJ
ajlm-1363	1	132	state	state	PROPN
ajlm-1363	1	133	,	,	PUNCT
ajlm-1363	1	134	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	135	,	,	PUNCT
ajlm-1363	1	136	south	south	PROPN
ajlm-1363	1	137	africa	africa	PROPN
ajlm-1363	1	138	department	department	PROPN
ajlm-1363	1	139	of	of	ADP
ajlm-1363	1	140	haematology	haematology	NOUN
ajlm-1363	1	141	and	and	CCONJ
ajlm-1363	1	142	cell	cell	NOUN
ajlm-1363	1	143	biology	biology	NOUN
ajlm-1363	1	144	,	,	PUNCT
ajlm-1363	1	145	universitas	universita	NOUN
ajlm-1363	1	146	academic	academic	ADJ
ajlm-1363	1	147	unit	unit	NOUN
ajlm-1363	1	148	,	,	PUNCT
ajlm-1363	1	149	national	national	PROPN
ajlm-1363	1	150	health	health	PROPN
ajlm-1363	1	151	laboratory	laboratory	PROPN
ajlm-1363	1	152	services	services	PROPN
ajlm-1363	1	153	,	,	PUNCT
ajlm-1363	1	154	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	155	,	,	PUNCT
ajlm-1363	1	156	south	south	PROPN
ajlm-1363	1	157	africa	africa	PROPN
ajlm-1363	1	158	anne	anne	PROPN
ajlm-1363	1	159	-	-	PUNCT
ajlm-1363	1	160	cecilia	cecilia	PROPN
ajlm-1363	1	161	van	van	PROPN
ajlm-1363	1	162	marle	marle	PROPN
ajlm-1363	1	163	department	department	PROPN
ajlm-1363	1	164	of	of	ADP
ajlm-1363	1	165	haematology	haematology	NOUN
ajlm-1363	1	166	and	and	CCONJ
ajlm-1363	1	167	cell	cell	NOUN
ajlm-1363	1	168	biology	biology	NOUN
ajlm-1363	1	169	,	,	PUNCT
ajlm-1363	1	170	school	school	NOUN
ajlm-1363	1	171	of	of	ADP
ajlm-1363	1	172	pathology	pathology	NOUN
ajlm-1363	1	173	,	,	PUNCT
ajlm-1363	1	174	faculty	faculty	NOUN
ajlm-1363	1	175	of	of	ADP
ajlm-1363	1	176	health	health	NOUN
ajlm-1363	1	177	sciences	sciences	PROPN
ajlm-1363	1	178	,	,	PUNCT
ajlm-1363	1	179	university	university	NOUN
ajlm-1363	1	180	of	of	ADP
ajlm-1363	1	181	the	the	DET
ajlm-1363	1	182	free	free	ADJ
ajlm-1363	1	183	state	state	PROPN
ajlm-1363	1	184	,	,	PUNCT
ajlm-1363	1	185	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	186	,	,	PUNCT
ajlm-1363	1	187	south	south	PROPN
ajlm-1363	1	188	africa	africa	PROPN
ajlm-1363	1	189	department	department	PROPN
ajlm-1363	1	190	of	of	ADP
ajlm-1363	1	191	haematology	haematology	NOUN
ajlm-1363	1	192	and	and	CCONJ
ajlm-1363	1	193	cell	cell	NOUN
ajlm-1363	1	194	biology	biology	NOUN
ajlm-1363	1	195	,	,	PUNCT
ajlm-1363	1	196	universitas	universita	NOUN
ajlm-1363	1	197	academic	academic	ADJ
ajlm-1363	1	198	unit	unit	NOUN
ajlm-1363	1	199	,	,	PUNCT
ajlm-1363	1	200	national	national	PROPN
ajlm-1363	1	201	health	health	PROPN
ajlm-1363	1	202	laboratory	laboratory	PROPN
ajlm-1363	1	203	services	services	PROPN
ajlm-1363	1	204	,	,	PUNCT
ajlm-1363	1	205	bloemfontein	bloemfontein	PROPN
ajlm-1363	1	206	,	,	PUNCT
ajlm-1363	1	207	south	south	PROPN
ajlm-1363	1	208	africa	africa	PROPN
ajlm-1363	1	209	citation	citation	PROPN
ajlm-1363	1	210	kloppers	klopper	VERB
ajlm-1363	1	211	jf	jf	PROPN
ajlm-1363	1	212	,	,	PUNCT
ajlm-1363	1	213	de	de	PROPN
ajlm-1363	1	214	kock	kock	PROPN
ajlm-1363	1	215	a	a	PROPN
ajlm-1363	1	216	,	,	PUNCT
ajlm-1363	1	217	cronjé	cronjé	PROPN
ajlm-1363	1	218	j	j	PROPN
ajlm-1363	1	219	,	,	PUNCT
ajlm-1363	1	220	van	van	PROPN
ajlm-1363	1	221	marle	marle	PROPN
ajlm-1363	1	222	a	a	PROPN
ajlm-1363	1	223	-	-	PUNCT
ajlm-1363	1	224	c.	c.	NOUN
ajlm-1363	1	225	molecular	molecular	ADJ
ajlm-1363	1	226	characterisation	characterisation	NOUN
ajlm-1363	1	227	of	of	ADP
ajlm-1363	1	228	npm1	npm1	NOUN
ajlm-1363	1	229	and	and	CCONJ
ajlm-1363	1	230	flt3	flt3	NOUN
ajlm-1363	1	231	-	-	PUNCT
ajlm-1363	1	232	itd	itd	NOUN
ajlm-1363	1	233	mutations	mutation	NOUN
ajlm-1363	1	234	in	in	ADP
ajlm-1363	1	235	a	a	DET
ajlm-1363	1	236	central	central	ADJ
ajlm-1363	1	237	south	south	ADJ
ajlm-1363	1	238	african	african	ADJ
ajlm-1363	1	239	adult	adult	PROPN
ajlm-1363	1	240	de	de	X
ajlm-1363	1	241	novo	novo	PROPN
ajlm-1363	1	242	acute	acute	PROPN
ajlm-1363	1	243	myeloid	myeloid	PROPN
ajlm-1363	1	244	leukaemia	leukaemia	NOUN
ajlm-1363	1	245	cohort	cohort	NOUN
ajlm-1363	1	246	.	.	PUNCT
ajlm-1363	2	1	afr	afr	PROPN
ajlm-1363	2	2	j	j	PROPN
ajlm-1363	2	3	lab	lab	PROPN
ajlm-1363	2	4	med	med	PROPN
ajlm-1363	2	5	.	.	PUNCT
ajlm-1363	3	1	2021;10(1	2021;10(1	NUM
ajlm-1363	3	2	)	)	PUNCT
ajlm-1363	3	3	,	,	PUNCT
ajlm-1363	3	4	a1363	a1363	PROPN
ajlm-1363	3	5	.	.	PUNCT
ajlm-1363	3	6	https://doi.org/10.4102/ajlm.v10i1.1363	https://doi.org/10.4102/ajlm.v10i1.1363	NOUN
ajlm-1363	3	7	original	original	ADJ
ajlm-1363	3	8	research	research	NOUN
ajlm-1363	3	9	molecular	molecular	ADJ
ajlm-1363	3	10	characterisation	characterisation	NOUN
ajlm-1363	3	11	of	of	ADP
ajlm-1363	3	12	npm1	npm1	NOUN
ajlm-1363	3	13	and	and	CCONJ
ajlm-1363	3	14	flt3	flt3	NOUN
ajlm-1363	3	15	-	-	PUNCT
ajlm-1363	3	16	itd	itd	NOUN
ajlm-1363	3	17	mutations	mutation	NOUN
ajlm-1363	3	18	in	in	ADP
ajlm-1363	3	19	a	a	DET
ajlm-1363	3	20	central	central	ADJ
ajlm-1363	3	21	south	south	ADJ
ajlm-1363	3	22	african	african	ADJ
ajlm-1363	3	23	adult	adult	PROPN
ajlm-1363	3	24	de	de	X
ajlm-1363	3	25	novo	novo	PROPN
ajlm-1363	3	26	acute	acute	PROPN
ajlm-1363	3	27	myeloid	myeloid	PROPN
ajlm-1363	3	28	leukaemia	leukaemia	PROPN
ajlm-1363	3	29	cohort	cohort	PROPN
ajlm-1363	3	30	jean	jean	PROPN
ajlm-1363	3	31	f.	f.	PROPN
ajlm-1363	3	32	kloppers	kloppers	PROPN
ajlm-1363	3	33	,	,	PUNCT
ajlm-1363	3	34	andré	andré	PROPN
ajlm-1363	3	35	de	de	PROPN
ajlm-1363	3	36	kock	kock	PROPN
ajlm-1363	3	37	,	,	PUNCT
ajlm-1363	3	38	johané	johané	PROPN
ajlm-1363	3	39	cronjé	cronjé	PROPN
ajlm-1363	3	40	,	,	PUNCT
ajlm-1363	3	41	anne	anne	PROPN
ajlm-1363	3	42	-	-	PUNCT
ajlm-1363	3	43	cecilia	cecilia	PROPN
ajlm-1363	3	44	van	van	PROPN
ajlm-1363	3	45	marle	marle	PROPN
ajlm-1363	3	46	received	receive	VERB
ajlm-1363	3	47	:	:	PUNCT
ajlm-1363	3	48	17	17	NUM
ajlm-1363	3	49	aug	aug	PROPN
ajlm-1363	3	50	.	.	PROPN
ajlm-1363	3	51	2020	2020	NUM
ajlm-1363	3	52	;	;	PUNCT
ajlm-1363	3	53	accepted	accept	VERB
ajlm-1363	3	54	:	:	PUNCT
ajlm-1363	3	55	19	19	NUM
ajlm-1363	3	56	mar	mar	PROPN
ajlm-1363	3	57	.	.	PROPN
ajlm-1363	3	58	2021	2021	NUM
ajlm-1363	3	59	;	;	PUNCT
ajlm-1363	3	60	published	publish	VERB
ajlm-1363	3	61	:	:	PUNCT
ajlm-1363	3	62	30	30	NUM
ajlm-1363	3	63	june	june	PROPN
ajlm-1363	3	64	2021	2021	NUM
ajlm-1363	3	65	copyright	copyright	NOUN
ajlm-1363	3	66	:	:	PUNCT
ajlm-1363	3	67	©	©	PROPN
ajlm-1363	3	68	2021	2021	NUM
ajlm-1363	3	69	.	.	PUNCT
ajlm-1363	4	1	the	the	DET
ajlm-1363	4	2	author(s	author(s	PROPN
ajlm-1363	4	3	)	)	PUNCT
ajlm-1363	4	4	.	.	PUNCT
ajlm-1363	5	1	licensee	licensee	NOUN
ajlm-1363	5	2	:	:	PUNCT
ajlm-1363	5	3	aosis	aosis	NOUN
ajlm-1363	5	4	.	.	PUNCT
ajlm-1363	6	1	this	this	PRON
ajlm-1363	6	2	is	be	AUX
ajlm-1363	6	3	an	an	DET
ajlm-1363	6	4	open	open	ADJ
ajlm-1363	6	5	access	access	NOUN
ajlm-1363	6	6	article	article	NOUN
ajlm-1363	6	7	distributed	distribute	VERB
ajlm-1363	6	8	under	under	ADP
ajlm-1363	6	9	the	the	DET
ajlm-1363	6	10	terms	term	NOUN
ajlm-1363	6	11	of	of	ADP
ajlm-1363	6	12	the	the	DET
ajlm-1363	6	13	creative	creative	ADJ
ajlm-1363	6	14	commons	common	NOUN
ajlm-1363	6	15	attribution	attribution	NOUN
ajlm-1363	6	16	license	license	NOUN
ajlm-1363	6	17	,	,	PUNCT
ajlm-1363	6	18	which	which	PRON
ajlm-1363	6	19	permits	permit	VERB
ajlm-1363	6	20	unrestricted	unrestricted	ADJ
ajlm-1363	6	21	use	use	NOUN
ajlm-1363	6	22	,	,	PUNCT
ajlm-1363	6	23	distribution	distribution	NOUN
ajlm-1363	6	24	,	,	PUNCT
ajlm-1363	6	25	and	and	CCONJ
ajlm-1363	6	26	reproduction	reproduction	NOUN
ajlm-1363	6	27	in	in	ADP
ajlm-1363	6	28	any	any	DET
ajlm-1363	6	29	medium	medium	NOUN
ajlm-1363	6	30	,	,	PUNCT
ajlm-1363	6	31	provided	provide	VERB
ajlm-1363	6	32	the	the	DET
ajlm-1363	6	33	original	original	ADJ
ajlm-1363	6	34	work	work	NOUN
ajlm-1363	6	35	is	be	AUX
ajlm-1363	6	36	properly	properly	ADV
ajlm-1363	6	37	cited	cite	VERB
ajlm-1363	6	38	.	.	PUNCT
ajlm-1363	7	1	abstract	abstract	ADJ
ajlm-1363	7	2	background	background	NOUN
ajlm-1363	7	3	:	:	PUNCT
ajlm-1363	7	4	recognition	recognition	NOUN
ajlm-1363	7	5	of	of	ADP
ajlm-1363	7	6	molecular	molecular	ADJ
ajlm-1363	7	7	abnormalities	abnormality	NOUN
ajlm-1363	7	8	in	in	ADP
ajlm-1363	7	9	acute	acute	ADJ
ajlm-1363	7	10	myeloid	myeloid	NOUN
ajlm-1363	7	11	leukaemia	leukaemia	NOUN
ajlm-1363	7	12	(	(	PUNCT
ajlm-1363	7	13	aml	aml	PROPN
ajlm-1363	7	14	)	)	PUNCT
ajlm-1363	7	15	has	have	AUX
ajlm-1363	7	16	improved	improve	VERB
ajlm-1363	7	17	our	our	PRON
ajlm-1363	7	18	understanding	understanding	NOUN
ajlm-1363	7	19	of	of	ADP
ajlm-1363	7	20	its	its	PRON
ajlm-1363	7	21	biology	biology	NOUN
ajlm-1363	7	22	.	.	PUNCT
ajlm-1363	8	1	npm1	npm1	NOUN
ajlm-1363	8	2	and	and	CCONJ
ajlm-1363	8	3	flt3	flt3	PROPN
ajlm-1363	8	4	-	-	PUNCT
ajlm-1363	8	5	itd	itd	NOUN
ajlm-1363	8	6	mutations	mutation	NOUN
ajlm-1363	8	7	are	be	AUX
ajlm-1363	8	8	recurrent	recurrent	ADJ
ajlm-1363	8	9	in	in	ADP
ajlm-1363	8	10	aml	aml	NOUN
ajlm-1363	8	11	and	and	CCONJ
ajlm-1363	8	12	clinically	clinically	ADV
ajlm-1363	8	13	significant	significant	ADJ
ajlm-1363	8	14	.	.	PUNCT
ajlm-1363	9	1	npm1	npm1	NOUN
ajlm-1363	9	2	mutations	mutation	NOUN
ajlm-1363	9	3	are	be	AUX
ajlm-1363	9	4	associated	associate	VERB
ajlm-1363	9	5	with	with	ADP
ajlm-1363	9	6	a	a	DET
ajlm-1363	9	7	favourable	favourable	ADJ
ajlm-1363	9	8	prognosis	prognosis	NOUN
ajlm-1363	9	9	,	,	PUNCT
ajlm-1363	9	10	while	while	SCONJ
ajlm-1363	9	11	flt3	flt3	NOUN
ajlm-1363	9	12	-	-	PUNCT
ajlm-1363	9	13	itd	itd	NOUN
ajlm-1363	9	14	mutations	mutation	NOUN
ajlm-1363	9	15	are	be	AUX
ajlm-1363	9	16	an	an	DET
ajlm-1363	9	17	independent	independent	ADJ
ajlm-1363	9	18	poor	poor	ADJ
ajlm-1363	9	19	prognostic	prognostic	ADJ
ajlm-1363	9	20	factor	factor	NOUN
ajlm-1363	9	21	in	in	ADP
ajlm-1363	9	22	aml	aml	PROPN
ajlm-1363	9	23	.	.	PUNCT
ajlm-1363	10	1	objective	objective	NOUN
ajlm-1363	10	2	:	:	PUNCT
ajlm-1363	10	3	this	this	DET
ajlm-1363	10	4	study	study	NOUN
ajlm-1363	10	5	described	describe	VERB
ajlm-1363	10	6	the	the	DET
ajlm-1363	10	7	prevalence	prevalence	NOUN
ajlm-1363	10	8	and	and	CCONJ
ajlm-1363	10	9	molecular	molecular	ADJ
ajlm-1363	10	10	characteristics	characteristic	NOUN
ajlm-1363	10	11	of	of	ADP
ajlm-1363	10	12	the	the	DET
ajlm-1363	10	13	npm1	npm1	NOUN
ajlm-1363	10	14	and	and	CCONJ
ajlm-1363	10	15	flt3	flt3	NOUN
ajlm-1363	10	16	-	-	PUNCT
ajlm-1363	10	17	itd	itd	NOUN
ajlm-1363	10	18	mutations	mutation	NOUN
ajlm-1363	10	19	in	in	ADP
ajlm-1363	10	20	a	a	DET
ajlm-1363	10	21	newly	newly	ADV
ajlm-1363	10	22	diagnosed	diagnose	VERB
ajlm-1363	10	23	aml	aml	NOUN
ajlm-1363	10	24	patient	patient	PROPN
ajlm-1363	10	25	cohort	cohort	NOUN
ajlm-1363	10	26	in	in	ADP
ajlm-1363	10	27	central	central	PROPN
ajlm-1363	10	28	south	south	PROPN
ajlm-1363	10	29	africa	africa	PROPN
ajlm-1363	10	30	.	.	PUNCT
ajlm-1363	11	1	methods	method	NOUN
ajlm-1363	11	2	:	:	PUNCT
ajlm-1363	11	3	the	the	DET
ajlm-1363	11	4	study	study	NOUN
ajlm-1363	11	5	included	include	VERB
ajlm-1363	11	6	40	40	NUM
ajlm-1363	11	7	de	de	PROPN
ajlm-1363	11	8	novo	novo	PROPN
ajlm-1363	11	9	aml	aml	PROPN
ajlm-1363	11	10	patients	patient	NOUN
ajlm-1363	11	11	.	.	PUNCT
ajlm-1363	12	1	an	an	DET
ajlm-1363	12	2	npm1	npm1	NOUN
ajlm-1363	12	3	and	and	CCONJ
ajlm-1363	12	4	flt3	flt3	PROPN
ajlm-1363	12	5	-	-	PUNCT
ajlm-1363	12	6	itd	itd	NOUN
ajlm-1363	12	7	multiplex	multiplex	PROPN
ajlm-1363	12	8	polymerase	polymerase	NOUN
ajlm-1363	12	9	chain	chain	NOUN
ajlm-1363	12	10	reaction	reaction	NOUN
ajlm-1363	12	11	assay	assay	PROPN
ajlm-1363	12	12	was	be	AUX
ajlm-1363	12	13	optimised	optimise	VERB
ajlm-1363	12	14	to	to	PART
ajlm-1363	12	15	screen	screen	VERB
ajlm-1363	12	16	patients	patient	NOUN
ajlm-1363	12	17	for	for	ADP
ajlm-1363	12	18	the	the	DET
ajlm-1363	12	19	respective	respective	ADJ
ajlm-1363	12	20	mutations	mutation	NOUN
ajlm-1363	12	21	and	and	CCONJ
ajlm-1363	12	22	were	be	AUX
ajlm-1363	12	23	confirmed	confirm	VERB
ajlm-1363	12	24	using	use	VERB
ajlm-1363	12	25	sanger	sanger	PROPN
ajlm-1363	12	26	sequencing	sequencing	NOUN
ajlm-1363	12	27	.	.	PUNCT
ajlm-1363	13	1	the	the	DET
ajlm-1363	13	2	prevalence	prevalence	NOUN
ajlm-1363	13	3	of	of	ADP
ajlm-1363	13	4	the	the	DET
ajlm-1363	13	5	npm1	npm1	NOUN
ajlm-1363	13	6	and	and	CCONJ
ajlm-1363	13	7	flt3	flt3	NOUN
ajlm-1363	13	8	-	-	PUNCT
ajlm-1363	13	9	itd	itd	NOUN
ajlm-1363	13	10	mutations	mutation	NOUN
ajlm-1363	13	11	were	be	AUX
ajlm-1363	13	12	determined	determine	VERB
ajlm-1363	13	13	,	,	PUNCT
ajlm-1363	13	14	and	and	CCONJ
ajlm-1363	13	15	mutation	mutation	NOUN
ajlm-1363	13	16	-	-	PUNCT
ajlm-1363	13	17	specific	specific	ADJ
ajlm-1363	13	18	characteristics	characteristic	NOUN
ajlm-1363	13	19	were	be	AUX
ajlm-1363	13	20	described	describe	VERB
ajlm-1363	13	21	in	in	ADP
ajlm-1363	13	22	relation	relation	NOUN
ajlm-1363	13	23	to	to	ADP
ajlm-1363	13	24	patients	patient	NOUN
ajlm-1363	13	25	’	'	PUNCT
ajlm-1363	13	26	demographic	demographic	ADJ
ajlm-1363	13	27	information	information	NOUN
ajlm-1363	13	28	and	and	CCONJ
ajlm-1363	13	29	aml	aml	PROPN
ajlm-1363	13	30	classifications	classification	NOUN
ajlm-1363	13	31	.	.	PUNCT
ajlm-1363	14	1	results	result	NOUN
ajlm-1363	14	2	:	:	PUNCT
ajlm-1363	14	3	the	the	DET
ajlm-1363	14	4	patients	patient	NOUN
ajlm-1363	14	5	’	'	PUNCT
ajlm-1363	14	6	median	median	ADJ
ajlm-1363	14	7	age	age	NOUN
ajlm-1363	14	8	was	be	AUX
ajlm-1363	14	9	38.5	38.5	NUM
ajlm-1363	14	10	years	year	NOUN
ajlm-1363	14	11	,	,	PUNCT
ajlm-1363	14	12	with	with	ADP
ajlm-1363	14	13	77.5	77.5	NUM
ajlm-1363	14	14	%	%	NOUN
ajlm-1363	14	15	(	(	PUNCT
ajlm-1363	14	16	n	n	NOUN
ajlm-1363	14	17	=	=	SYM
ajlm-1363	14	18	31	31	NUM
ajlm-1363	14	19	)	)	PUNCT
ajlm-1363	14	20	of	of	ADP
ajlm-1363	14	21	patients	patient	NOUN
ajlm-1363	14	22	being	be	AUX
ajlm-1363	14	23	self	self	NOUN
ajlm-1363	14	24	-	-	PUNCT
ajlm-1363	14	25	proclaimed	proclaim	VERB
ajlm-1363	14	26	black	black	ADJ
ajlm-1363	14	27	africans	africans	PROPN
ajlm-1363	14	28	.	.	PUNCT
ajlm-1363	15	1	aml	aml	NOUN
ajlm-1363	15	2	with	with	ADP
ajlm-1363	15	3	recurrent	recurrent	ADJ
ajlm-1363	15	4	genetic	genetic	ADJ
ajlm-1363	15	5	abnormalities	abnormality	NOUN
ajlm-1363	15	6	was	be	AUX
ajlm-1363	15	7	most	most	ADV
ajlm-1363	15	8	prevalent	prevalent	ADJ
ajlm-1363	15	9	(	(	PUNCT
ajlm-1363	15	10	57.5	57.5	NUM
ajlm-1363	15	11	%	%	NOUN
ajlm-1363	15	12	;	;	PUNCT
ajlm-1363	15	13	n	n	PROPN
ajlm-1363	15	14	=	=	SYM
ajlm-1363	15	15	23	23	NUM
ajlm-1363	15	16	)	)	PUNCT
ajlm-1363	15	17	,	,	PUNCT
ajlm-1363	15	18	of	of	ADP
ajlm-1363	15	19	which	which	PRON
ajlm-1363	15	20	acute	acute	ADJ
ajlm-1363	15	21	promyelocytic	promyelocytic	ADJ
ajlm-1363	15	22	leukaemia	leukaemia	NOUN
ajlm-1363	15	23	(	(	PUNCT
ajlm-1363	15	24	apl	apl	PROPN
ajlm-1363	15	25	)	)	PUNCT
ajlm-1363	15	26	was	be	AUX
ajlm-1363	15	27	most	most	ADV
ajlm-1363	15	28	common	common	ADJ
ajlm-1363	15	29	(	(	PUNCT
ajlm-1363	15	30	40.0	40.0	NUM
ajlm-1363	15	31	%	%	NOUN
ajlm-1363	15	32	;	;	PUNCT
ajlm-1363	15	33	n	n	PROPN
ajlm-1363	15	34	=	=	SYM
ajlm-1363	15	35	16	16	NUM
ajlm-1363	15	36	)	)	PUNCT
ajlm-1363	15	37	.	.	PUNCT
ajlm-1363	16	1	none	none	NOUN
ajlm-1363	16	2	of	of	ADP
ajlm-1363	16	3	the	the	DET
ajlm-1363	16	4	patients	patient	NOUN
ajlm-1363	16	5	had	have	VERB
ajlm-1363	16	6	the	the	DET
ajlm-1363	16	7	npm1	npm1	NOUN
ajlm-1363	16	8	mutation	mutation	NOUN
ajlm-1363	16	9	.	.	PUNCT
ajlm-1363	17	1	flt3	flt3	PROPN
ajlm-1363	17	2	-	-	PUNCT
ajlm-1363	17	3	itd	itd	PROPN
ajlm-1363	17	4	was	be	AUX
ajlm-1363	17	5	present	present	ADJ
ajlm-1363	17	6	in	in	ADP
ajlm-1363	17	7	37.5	37.5	NUM
ajlm-1363	17	8	%	%	NOUN
ajlm-1363	17	9	(	(	PUNCT
ajlm-1363	17	10	6/16	6/16	NUM
ajlm-1363	17	11	)	)	PUNCT
ajlm-1363	17	12	of	of	ADP
ajlm-1363	17	13	apl	apl	NOUN
ajlm-1363	17	14	patients	patient	NOUN
ajlm-1363	17	15	and	and	CCONJ
ajlm-1363	17	16	in	in	ADP
ajlm-1363	17	17	one	one	NUM
ajlm-1363	17	18	(	(	PUNCT
ajlm-1363	17	19	20.0	20.0	NUM
ajlm-1363	17	20	%	%	NOUN
ajlm-1363	17	21	)	)	PUNCT
ajlm-1363	17	22	of	of	ADP
ajlm-1363	17	23	five	five	NUM
ajlm-1363	17	24	aml	aml	NOUN
ajlm-1363	17	25	patients	patient	NOUN
ajlm-1363	17	26	with	with	ADP
ajlm-1363	17	27	a	a	DET
ajlm-1363	17	28	t(8;21	t(8;21	PROPN
ajlm-1363	17	29	)	)	PUNCT
ajlm-1363	17	30	translocation	translocation	NOUN
ajlm-1363	17	31	.	.	PUNCT
ajlm-1363	18	1	most	most	ADJ
ajlm-1363	18	2	patients	patient	NOUN
ajlm-1363	18	3	had	have	VERB
ajlm-1363	18	4	an	an	DET
ajlm-1363	18	5	flt3	flt3	NOUN
ajlm-1363	18	6	-	-	PUNCT
ajlm-1363	18	7	itd	itd	NOUN
ajlm-1363	18	8	allele	allele	NOUN
ajlm-1363	18	9	ratio	ratio	NOUN
ajlm-1363	18	10	of	of	ADP
ajlm-1363	18	11	≥	≥	NOUN
ajlm-1363	18	12	50	50	NUM
ajlm-1363	18	13	%	%	NOUN
ajlm-1363	18	14	and	and	CCONJ
ajlm-1363	18	15	it	it	PRON
ajlm-1363	18	16	d	d	ADJ
ajlm-1363	18	17	lengths	length	NOUN
ajlm-1363	18	18	of	of	ADP
ajlm-1363	18	19	>	>	SYM
ajlm-1363	18	20	39	39	NUM
ajlm-1363	18	21	bp	bp	PROPN
ajlm-1363	18	22	.	.	PUNCT
ajlm-1363	19	1	conclusion	conclusion	NOUN
ajlm-1363	19	2	:	:	PUNCT
ajlm-1363	19	3	flt3	flt3	ADJ
ajlm-1363	19	4	-	-	PUNCT
ajlm-1363	19	5	itd	itd	NOUN
ajlm-1363	19	6	mutations	mutation	NOUN
ajlm-1363	19	7	were	be	AUX
ajlm-1363	19	8	mainly	mainly	ADV
ajlm-1363	19	9	found	find	VERB
ajlm-1363	19	10	in	in	ADP
ajlm-1363	19	11	apl	apl	NOUN
ajlm-1363	19	12	cases	case	NOUN
ajlm-1363	19	13	at	at	ADP
ajlm-1363	19	14	a	a	DET
ajlm-1363	19	15	similar	similar	ADJ
ajlm-1363	19	16	prevalence	prevalence	NOUN
ajlm-1363	19	17	as	as	SCONJ
ajlm-1363	19	18	reported	report	VERB
ajlm-1363	19	19	in	in	ADP
ajlm-1363	19	20	the	the	DET
ajlm-1363	19	21	literature	literature	NOUN
ajlm-1363	19	22	.	.	PUNCT
ajlm-1363	20	1	high	high	ADJ
ajlm-1363	20	2	flt3	flt3	PROPN
ajlm-1363	20	3	-	-	PUNCT
ajlm-1363	20	4	itd	itd	NOUN
ajlm-1363	20	5	allele	allele	NOUN
ajlm-1363	20	6	ratios	ratio	NOUN
ajlm-1363	20	7	and	and	CCONJ
ajlm-1363	20	8	long	long	ADV
ajlm-1363	20	9	it	it	PRON
ajlm-1363	20	10	d	d	NOUN
ajlm-1363	20	11	lengths	length	NOUN
ajlm-1363	20	12	predominated	predominate	VERB
ajlm-1363	20	13	.	.	PUNCT
ajlm-1363	21	1	no	no	DET
ajlm-1363	21	2	npm1	npm1	PROPN
ajlm-1363	21	3	mutations	mutation	NOUN
ajlm-1363	21	4	were	be	AUX
ajlm-1363	21	5	detected	detect	VERB
ajlm-1363	21	6	.	.	PUNCT
ajlm-1363	22	1	keywords	keyword	NOUN
ajlm-1363	22	2	:	:	PUNCT
ajlm-1363	22	3	acute	acute	ADJ
ajlm-1363	22	4	myeloid	myeloid	ADJ
ajlm-1363	22	5	leukaemia	leukaemia	NOUN
ajlm-1363	22	6	;	;	PUNCT
ajlm-1363	22	7	aml	aml	PROPN
ajlm-1363	22	8	;	;	PUNCT
ajlm-1363	22	9	npm1	npm1	NOUN
ajlm-1363	22	10	;	;	PUNCT
ajlm-1363	22	11	flt3	flt3	NOUN
ajlm-1363	22	12	-	-	PUNCT
ajlm-1363	22	13	itd	itd	NOUN
ajlm-1363	22	14	;	;	PUNCT
ajlm-1363	22	15	frequency	frequency	NOUN
ajlm-1363	22	16	;	;	PUNCT
ajlm-1363	22	17	south	south	PROPN
ajlm-1363	22	18	africa	africa	PROPN
ajlm-1363	22	19	.	.	PUNCT
ajlm-1363	23	1	introduction	introduction	NOUN
ajlm-1363	23	2	over	over	ADP
ajlm-1363	23	3	the	the	DET
ajlm-1363	23	4	past	past	ADJ
ajlm-1363	23	5	decade	decade	NOUN
ajlm-1363	23	6	,	,	PUNCT
ajlm-1363	23	7	the	the	DET
ajlm-1363	23	8	field	field	NOUN
ajlm-1363	23	9	of	of	ADP
ajlm-1363	23	10	acute	acute	ADJ
ajlm-1363	23	11	myeloid	myeloid	NOUN
ajlm-1363	23	12	leukaemia	leukaemia	NOUN
ajlm-1363	23	13	(	(	PUNCT
ajlm-1363	23	14	aml	aml	NOUN
ajlm-1363	23	15	)	)	PUNCT
ajlm-1363	23	16	diagnostics	diagnostic	NOUN
ajlm-1363	23	17	has	have	AUX
ajlm-1363	23	18	shifted	shift	VERB
ajlm-1363	23	19	from	from	ADP
ajlm-1363	23	20	a	a	DET
ajlm-1363	23	21	primarily	primarily	ADV
ajlm-1363	23	22	clinicopathological	clinicopathological	ADJ
ajlm-1363	23	23	assessment	assessment	NOUN
ajlm-1363	23	24	to	to	ADP
ajlm-1363	23	25	an	an	DET
ajlm-1363	23	26	integrated	integrated	ADJ
ajlm-1363	23	27	approach	approach	NOUN
ajlm-1363	23	28	,	,	PUNCT
ajlm-1363	23	29	including	include	VERB
ajlm-1363	23	30	morphology	morphology	NOUN
ajlm-1363	23	31	,	,	PUNCT
ajlm-1363	23	32	immunophenotyping	immunophenotyping	NOUN
ajlm-1363	23	33	,	,	PUNCT
ajlm-1363	23	34	cytogenetics	cytogenetic	NOUN
ajlm-1363	23	35	,	,	PUNCT
ajlm-1363	23	36	and	and	CCONJ
ajlm-1363	23	37	molecular	molecular	ADJ
ajlm-1363	23	38	genetics.1,2	genetics.1,2	ADJ
ajlm-1363	23	39	in	in	ADP
ajlm-1363	23	40	an	an	DET
ajlm-1363	23	41	era	era	NOUN
ajlm-1363	23	42	of	of	ADP
ajlm-1363	23	43	precision	precision	NOUN
ajlm-1363	23	44	medicine	medicine	NOUN
ajlm-1363	23	45	,	,	PUNCT
ajlm-1363	23	46	the	the	DET
ajlm-1363	23	47	use	use	NOUN
ajlm-1363	23	48	of	of	ADP
ajlm-1363	23	49	molecular	molecular	ADJ
ajlm-1363	23	50	genetic	genetic	ADJ
ajlm-1363	23	51	data	datum	NOUN
ajlm-1363	23	52	,	,	PUNCT
ajlm-1363	23	53	in	in	ADP
ajlm-1363	23	54	particular	particular	ADJ
ajlm-1363	23	55	,	,	PUNCT
ajlm-1363	23	56	has	have	AUX
ajlm-1363	23	57	fundamentally	fundamentally	ADV
ajlm-1363	23	58	shaped	shape	VERB
ajlm-1363	23	59	the	the	DET
ajlm-1363	23	60	diagnostic	diagnostic	ADJ
ajlm-1363	23	61	approach	approach	NOUN
ajlm-1363	23	62	to	to	ADP
ajlm-1363	23	63	patients	patient	NOUN
ajlm-1363	23	64	with	with	ADP
ajlm-1363	23	65	aml.3	aml.3	PROPN
ajlm-1363	23	66	genetic	genetic	ADJ
ajlm-1363	23	67	profiling	profiling	NOUN
ajlm-1363	23	68	has	have	AUX
ajlm-1363	23	69	led	lead	VERB
ajlm-1363	23	70	to	to	ADP
ajlm-1363	23	71	more	more	ADV
ajlm-1363	23	72	accurate	accurate	ADJ
ajlm-1363	23	73	diagnostic	diagnostic	ADJ
ajlm-1363	23	74	classification	classification	NOUN
ajlm-1363	23	75	and	and	CCONJ
ajlm-1363	23	76	improved	improve	VERB
ajlm-1363	23	77	risk	risk	NOUN
ajlm-1363	23	78	stratification	stratification	NOUN
ajlm-1363	23	79	and	and	CCONJ
ajlm-1363	23	80	identification	identification	NOUN
ajlm-1363	23	81	of	of	ADP
ajlm-1363	23	82	potential	potential	ADJ
ajlm-1363	23	83	therapeutic	therapeutic	ADJ
ajlm-1363	23	84	targets.1	targets.1	PROPN
ajlm-1363	23	85	acute	acute	NOUN
ajlm-1363	23	86	myeloid	myeloid	NOUN
ajlm-1363	23	87	leukaemia	leukaemia	NOUN
ajlm-1363	23	88	is	be	AUX
ajlm-1363	23	89	a	a	DET
ajlm-1363	23	90	genetically	genetically	ADV
ajlm-1363	23	91	heterogeneous	heterogeneous	ADJ
ajlm-1363	23	92	disease.2	disease.2	ADJ
ajlm-1363	23	93	recurrent	recurrent	ADJ
ajlm-1363	23	94	structural	structural	ADJ
ajlm-1363	23	95	chromosomal	chromosomal	ADJ
ajlm-1363	23	96	aberrations	aberration	NOUN
ajlm-1363	23	97	detected	detect	VERB
ajlm-1363	23	98	by	by	ADP
ajlm-1363	23	99	conventional	conventional	ADJ
ajlm-1363	23	100	cytogenetics	cytogenetic	NOUN
ajlm-1363	23	101	were	be	AUX
ajlm-1363	23	102	previously	previously	ADV
ajlm-1363	23	103	considered	consider	VERB
ajlm-1363	23	104	the	the	DET
ajlm-1363	23	105	most	most	ADV
ajlm-1363	23	106	relevant	relevant	ADJ
ajlm-1363	23	107	prognostic	prognostic	ADJ
ajlm-1363	23	108	variable	variable	NOUN
ajlm-1363	23	109	in	in	ADP
ajlm-1363	23	110	addition	addition	NOUN
ajlm-1363	23	111	to	to	ADP
ajlm-1363	23	112	the	the	DET
ajlm-1363	23	113	patient	patient	NOUN
ajlm-1363	23	114	’s	’s	PART
ajlm-1363	23	115	age	age	NOUN
ajlm-1363	23	116	and	and	CCONJ
ajlm-1363	23	117	performance	performance	NOUN
ajlm-1363	24	1	status.2,3	status.2,3	PROPN
ajlm-1363	24	2	three	three	NUM
ajlm-1363	24	3	main	main	ADJ
ajlm-1363	24	4	cytogenetic	cytogenetic	ADJ
ajlm-1363	24	5	risk	risk	NOUN
ajlm-1363	24	6	groups	group	NOUN
ajlm-1363	24	7	(	(	PUNCT
ajlm-1363	24	8	low	low	ADJ
ajlm-1363	24	9	,	,	PUNCT
ajlm-1363	24	10	intermediate	intermediate	ADJ
ajlm-1363	24	11	,	,	PUNCT
ajlm-1363	24	12	and	and	CCONJ
ajlm-1363	24	13	high	high	ADJ
ajlm-1363	24	14	)	)	PUNCT
ajlm-1363	24	15	were	be	AUX
ajlm-1363	24	16	defined	define	VERB
ajlm-1363	24	17	,	,	PUNCT
ajlm-1363	24	18	with	with	ADP
ajlm-1363	24	19	approximately	approximately	ADV
ajlm-1363	24	20	50	50	NUM
ajlm-1363	24	21	%	%	NOUN
ajlm-1363	24	22	of	of	ADP
ajlm-1363	24	23	patients	patient	NOUN
ajlm-1363	24	24	having	have	VERB
ajlm-1363	24	25	a	a	DET
ajlm-1363	24	26	normal	normal	ADJ
ajlm-1363	24	27	karyotype	karyotype	NOUN
ajlm-1363	24	28	and	and	CCONJ
ajlm-1363	24	29	falling	fall	VERB
ajlm-1363	24	30	into	into	ADP
ajlm-1363	24	31	the	the	DET
ajlm-1363	24	32	intermediate	intermediate	ADJ
ajlm-1363	24	33	cytogenetic	cytogenetic	ADJ
ajlm-1363	24	34	risk	risk	NOUN
ajlm-1363	24	35	group.3,4	group.3,4	ADJ
ajlm-1363	24	36	the	the	DET
ajlm-1363	24	37	recognition	recognition	NOUN
ajlm-1363	24	38	of	of	ADP
ajlm-1363	24	39	additional	additional	ADJ
ajlm-1363	24	40	molecular	molecular	ADJ
ajlm-1363	24	41	abnormalities	abnormality	NOUN
ajlm-1363	24	42	,	,	PUNCT
ajlm-1363	24	43	especially	especially	ADV
ajlm-1363	24	44	in	in	ADP
ajlm-1363	24	45	cytogenetically	cytogenetically	PROPN
ajlm-1363	24	46	normal	normal	ADJ
ajlm-1363	24	47	aml	aml	NOUN
ajlm-1363	24	48	(	(	PUNCT
ajlm-1363	24	49	cn	cn	PROPN
ajlm-1363	24	50	-	-	PUNCT
ajlm-1363	24	51	aml	aml	NOUN
ajlm-1363	24	52	)	)	PUNCT
ajlm-1363	24	53	,	,	PUNCT
ajlm-1363	24	54	has	have	AUX
ajlm-1363	24	55	helped	help	VERB
ajlm-1363	24	56	to	to	PART
ajlm-1363	24	57	improve	improve	VERB
ajlm-1363	24	58	our	our	PRON
ajlm-1363	24	59	understanding	understanding	NOUN
ajlm-1363	24	60	of	of	ADP
ajlm-1363	24	61	the	the	DET
ajlm-1363	24	62	disease	disease	NOUN
ajlm-1363	24	63	biology	biology	NOUN
ajlm-1363	24	64	and	and	CCONJ
ajlm-1363	24	65	better	well	ADV
ajlm-1363	24	66	predict	predict	VERB
ajlm-1363	24	67	outcomes.3,4	outcomes.3,4	ADJ
ajlm-1363	24	68	mutational	mutational	ADJ
ajlm-1363	24	69	analysis	analysis	NOUN
ajlm-1363	24	70	performed	perform	VERB
ajlm-1363	24	71	on	on	ADP
ajlm-1363	24	72	diagnostic	diagnostic	ADJ
ajlm-1363	24	73	samples	sample	NOUN
ajlm-1363	24	74	of	of	ADP
ajlm-1363	24	75	aml	aml	NOUN
ajlm-1363	24	76	patients	patient	NOUN
ajlm-1363	24	77	enrolled	enrol	VERB
ajlm-1363	24	78	in	in	ADP
ajlm-1363	24	79	the	the	DET
ajlm-1363	24	80	eastern	eastern	ADJ
ajlm-1363	24	81	cooperative	cooperative	ADJ
ajlm-1363	24	82	oncology	oncology	NOUN
ajlm-1363	24	83	group	group	NOUN
ajlm-1363	24	84	e1900	e1900	PROPN
ajlm-1363	24	85	trial	trial	NOUN
ajlm-1363	24	86	demonstrated	demonstrate	VERB
ajlm-1363	24	87	somatic	somatic	ADJ
ajlm-1363	24	88	mutations	mutation	NOUN
ajlm-1363	24	89	in	in	ADP
ajlm-1363	24	90	as	as	ADV
ajlm-1363	24	91	many	many	ADJ
ajlm-1363	24	92	as	as	ADP
ajlm-1363	24	93	97.3	97.3	NUM
ajlm-1363	24	94	%	%	NOUN
ajlm-1363	24	95	of	of	ADP
ajlm-1363	24	96	these	these	DET
ajlm-1363	24	97	patients.5	patients.5	NOUN
ajlm-1363	24	98	the	the	DET
ajlm-1363	24	99	cancer	cancer	NOUN
ajlm-1363	24	100	genome	genome	NOUN
ajlm-1363	24	101	atlas	atlas	PROPN
ajlm-1363	24	102	research	research	PROPN
ajlm-1363	24	103	group6	group6	PROPN
ajlm-1363	24	104	has	have	AUX
ajlm-1363	24	105	shown	show	VERB
ajlm-1363	24	106	that	that	SCONJ
ajlm-1363	24	107	,	,	PUNCT
ajlm-1363	24	108	on	on	ADP
ajlm-1363	24	109	average	average	ADJ
ajlm-1363	24	110	,	,	PUNCT
ajlm-1363	24	111	patients	patient	NOUN
ajlm-1363	24	112	with	with	ADP
ajlm-1363	24	113	aml	aml	PROPN
ajlm-1363	24	114	have	have	VERB
ajlm-1363	24	115	13	13	NUM
ajlm-1363	24	116	acquired	acquire	VERB
ajlm-1363	24	117	mutations	mutation	NOUN
ajlm-1363	24	118	at	at	ADP
ajlm-1363	24	119	the	the	DET
ajlm-1363	24	120	time	time	NOUN
ajlm-1363	24	121	of	of	ADP
ajlm-1363	24	122	diagnosis	diagnosis	NOUN
ajlm-1363	24	123	across	across	ADP
ajlm-1363	24	124	the	the	DET
ajlm-1363	24	125	entire	entire	ADJ
ajlm-1363	24	126	genome	genome	NOUN
ajlm-1363	24	127	.	.	PUNCT
ajlm-1363	25	1	two	two	NUM
ajlm-1363	25	2	genes	gene	NOUN
ajlm-1363	25	3	in	in	ADP
ajlm-1363	25	4	which	which	PRON
ajlm-1363	25	5	recurrent	recurrent	ADJ
ajlm-1363	25	6	mutations	mutation	NOUN
ajlm-1363	25	7	,	,	PUNCT
ajlm-1363	25	8	which	which	PRON
ajlm-1363	25	9	often	often	ADV
ajlm-1363	25	10	co	co	VERB
ajlm-1363	25	11	-	-	VERB
ajlm-1363	25	12	occur	occur	VERB
ajlm-1363	25	13	,	,	PUNCT
ajlm-1363	25	14	with	with	ADP
ajlm-1363	25	15	known	know	VERB
ajlm-1363	25	16	clinical	clinical	ADJ
ajlm-1363	25	17	significance	significance	NOUN
ajlm-1363	25	18	have	have	AUX
ajlm-1363	25	19	been	be	AUX
ajlm-1363	25	20	identified	identify	VERB
ajlm-1363	25	21	in	in	ADP
ajlm-1363	25	22	patients	patient	NOUN
ajlm-1363	25	23	with	with	ADP
ajlm-1363	25	24	aml	aml	PROPN
ajlm-1363	25	25	include	include	VERB
ajlm-1363	25	26	the	the	DET
ajlm-1363	25	27	gene	gene	NOUN
ajlm-1363	25	28	encoding	encode	VERB
ajlm-1363	25	29	nucleophosmin	nucleophosmin	NOUN
ajlm-1363	25	30	protein-1	protein-1	PROPN
ajlm-1363	25	31	(	(	PUNCT
ajlm-1363	25	32	npm1	npm1	NOUN
ajlm-1363	25	33	)	)	PUNCT
ajlm-1363	25	34	and	and	CCONJ
ajlm-1363	25	35	one	one	NUM
ajlm-1363	25	36	of	of	ADP
ajlm-1363	25	37	the	the	DET
ajlm-1363	25	38	signalling	signal	VERB
ajlm-1363	25	39	genes	gene	NOUN
ajlm-1363	25	40	,	,	PUNCT
ajlm-1363	25	41	fms	fms	PROPN
ajlm-1363	25	42	(	(	PUNCT
ajlm-1363	25	43	feline	feline	PROPN
ajlm-1363	25	44	mcdonough	mcdonough	PROPN
ajlm-1363	25	45	sarcoma	sarcoma	PROPN
ajlm-1363	25	46	gene)-related	gene)-related	PROPN
ajlm-1363	25	47	tyrosine	tyrosine	NOUN
ajlm-1363	25	48	kinase	kinase	NOUN
ajlm-1363	25	49	3	3	NUM
ajlm-1363	25	50	(	(	PUNCT
ajlm-1363	25	51	flt3).3,6	flt3).3,6	VERB
ajlm-1363	25	52	npm1	npm1	NOUN
ajlm-1363	25	53	mutations	mutation	NOUN
ajlm-1363	25	54	are	be	AUX
ajlm-1363	25	55	associated	associate	VERB
ajlm-1363	25	56	with	with	ADP
ajlm-1363	25	57	a	a	DET
ajlm-1363	25	58	favourable	favourable	ADJ
ajlm-1363	25	59	prognosis,3	prognosis,3	NOUN
ajlm-1363	25	60	while	while	SCONJ
ajlm-1363	25	61	the	the	DET
ajlm-1363	25	62	flt3	flt3	NOUN
ajlm-1363	25	63	-	-	PUNCT
ajlm-1363	25	64	internal	internal	ADJ
ajlm-1363	25	65	tandem	tandem	NOUN
ajlm-1363	25	66	duplication	duplication	NOUN
ajlm-1363	25	67	(	(	PUNCT
ajlm-1363	25	68	it	it	PRON
ajlm-1363	25	69	d	d	NOUN
ajlm-1363	25	70	)	)	PUNCT
ajlm-1363	25	71	mutation	mutation	NOUN
ajlm-1363	25	72	is	be	AUX
ajlm-1363	25	73	considered	consider	VERB
ajlm-1363	25	74	an	an	DET
ajlm-1363	25	75	independent	independent	ADJ
ajlm-1363	25	76	poor	poor	ADJ
ajlm-1363	25	77	prognostic	prognostic	ADJ
ajlm-1363	25	78	factor	factor	NOUN
ajlm-1363	25	79	in	in	ADP
ajlm-1363	25	80	patients	patient	NOUN
ajlm-1363	25	81	with	with	ADP
ajlm-1363	25	82	aml.7	aml.7	PROPN
ajlm-1363	25	83	however	however	ADV
ajlm-1363	25	84	,	,	PUNCT
ajlm-1363	25	85	the	the	DET
ajlm-1363	25	86	co	co	NOUN
ajlm-1363	25	87	-	-	NOUN
ajlm-1363	25	88	occurrence	occurrence	NOUN
ajlm-1363	25	89	of	of	ADP
ajlm-1363	25	90	these	these	DET
ajlm-1363	25	91	two	two	NUM
ajlm-1363	25	92	gene	gene	NOUN
ajlm-1363	25	93	mutations	mutation	NOUN
ajlm-1363	25	94	modulates	modulate	VERB
ajlm-1363	25	95	their	their	PRON
ajlm-1363	25	96	prognostic	prognostic	ADJ
ajlm-1363	25	97	impacts.3,7	impacts.3,7	ADJ
ajlm-1363	25	98	nucleophosmin	nucleophosmin	NOUN
ajlm-1363	25	99	is	be	AUX
ajlm-1363	25	100	a	a	DET
ajlm-1363	25	101	nucleolar	nucleolar	ADJ
ajlm-1363	25	102	phosphoprotein	phosphoprotein	NOUN
ajlm-1363	25	103	that	that	PRON
ajlm-1363	25	104	shuttles	shuttle	VERB
ajlm-1363	25	105	between	between	ADP
ajlm-1363	25	106	the	the	DET
ajlm-1363	25	107	nucleus	nucleus	NOUN
ajlm-1363	25	108	and	and	CCONJ
ajlm-1363	25	109	the	the	DET
ajlm-1363	25	110	cytoplasm.3	cytoplasm.3	PROPN
ajlm-1363	25	111	nucleophosmin	nucleophosmin	PROPN
ajlm-1363	25	112	protein-1	protein-1	PROPN
ajlm-1363	25	113	is	be	AUX
ajlm-1363	25	114	thought	think	VERB
ajlm-1363	25	115	to	to	PART
ajlm-1363	25	116	be	be	AUX
ajlm-1363	25	117	involved	involve	VERB
ajlm-1363	25	118	in	in	ADP
ajlm-1363	25	119	many	many	ADJ
ajlm-1363	25	120	cellular	cellular	ADJ
ajlm-1363	25	121	functions	function	NOUN
ajlm-1363	25	122	,	,	PUNCT
ajlm-1363	25	123	including	include	VERB
ajlm-1363	25	124	protein	protein	NOUN
ajlm-1363	25	125	synthesis	synthesis	NOUN
ajlm-1363	25	126	,	,	PUNCT
ajlm-1363	25	127	dna	dna	NOUN
ajlm-1363	25	128	replication	replication	NOUN
ajlm-1363	25	129	,	,	PUNCT
ajlm-1363	25	130	and	and	CCONJ
ajlm-1363	25	131	regulation	regulation	NOUN
ajlm-1363	25	132	of	of	ADP
ajlm-1363	25	133	the	the	DET
ajlm-1363	25	134	cell	cell	NOUN
ajlm-1363	25	135	cycle.3	cycle.3	NUM
ajlm-1363	25	136	the	the	DET
ajlm-1363	25	137	reported	report	VERB
ajlm-1363	25	138	frequency	frequency	NOUN
ajlm-1363	25	139	of	of	ADP
ajlm-1363	25	140	npm1	npm1	NOUN
ajlm-1363	25	141	mutations	mutation	NOUN
ajlm-1363	25	142	in	in	ADP
ajlm-1363	25	143	patients	patient	NOUN
ajlm-1363	25	144	with	with	ADP
ajlm-1363	25	145	aml	aml	PROPN
ajlm-1363	25	146	varies	vary	VERB
ajlm-1363	25	147	between	between	ADP
ajlm-1363	25	148	27	27	NUM
ajlm-1363	25	149	%	%	NOUN
ajlm-1363	25	150	and	and	CCONJ
ajlm-1363	25	151	30	30	NUM
ajlm-1363	25	152	%	%	NOUN
ajlm-1363	25	153	and	and	CCONJ
ajlm-1363	25	154	is	be	AUX
ajlm-1363	25	155	considered	consider	VERB
ajlm-1363	25	156	the	the	DET
ajlm-1363	25	157	most	most	ADV
ajlm-1363	25	158	frequently	frequently	ADV
ajlm-1363	25	159	identified	identify	VERB
ajlm-1363	25	160	molecular	molecular	ADJ
ajlm-1363	25	161	abnormality	abnormality	NOUN
ajlm-1363	25	162	in	in	ADP
ajlm-1363	25	163	cn	cn	PROPN
ajlm-1363	25	164	-	-	PUNCT
ajlm-1363	25	165	aml	aml	PROPN
ajlm-1363	25	166	,	,	PUNCT
ajlm-1363	25	167	occurring	occur	VERB
ajlm-1363	25	168	in	in	ADP
ajlm-1363	25	169	45	45	NUM
ajlm-1363	25	170	%	%	NOUN
ajlm-1363	25	171	–	–	PUNCT
ajlm-1363	25	172	60	60	NUM
ajlm-1363	25	173	%	%	NOUN
ajlm-1363	25	174	of	of	ADP
ajlm-1363	25	175	cases.4,6,8,9	cases.4,6,8,9	NOUN
ajlm-1363	25	176	four	four	NUM
ajlm-1363	25	177	common	common	ADJ
ajlm-1363	25	178	mutations	mutation	NOUN
ajlm-1363	25	179	cause	cause	VERB
ajlm-1363	25	180	mutant	mutant	ADJ
ajlm-1363	25	181	npm1	npm1	NOUN
ajlm-1363	25	182	(	(	PUNCT
ajlm-1363	25	183	one	one	NUM
ajlm-1363	25	184	4	4	NUM
ajlm-1363	25	185	bp	bp	NOUN
ajlm-1363	25	186	duplication	duplication	NOUN
ajlm-1363	25	187	and	and	CCONJ
ajlm-1363	25	188	three	three	NUM
ajlm-1363	25	189	separate	separate	ADJ
ajlm-1363	25	190	4	4	NUM
ajlm-1363	25	191	bp	bp	NOUN
ajlm-1363	25	192	insertions	insertion	NOUN
ajlm-1363	25	193	)	)	PUNCT
ajlm-1363	25	194	.	.	PUNCT
ajlm-1363	26	1	these	these	DET
ajlm-1363	26	2	mutations	mutation	NOUN
ajlm-1363	26	3	are	be	AUX
ajlm-1363	26	4	all	all	PRON
ajlm-1363	26	5	restricted	restrict	VERB
ajlm-1363	26	6	to	to	ADP
ajlm-1363	26	7	exon	exon	NOUN
ajlm-1363	26	8	12	12	NUM
ajlm-1363	26	9	,	,	PUNCT
ajlm-1363	26	10	the	the	DET
ajlm-1363	26	11	region	region	NOUN
ajlm-1363	26	12	that	that	PRON
ajlm-1363	26	13	encodes	encode	VERB
ajlm-1363	26	14	the	the	DET
ajlm-1363	26	15	c	c	NOUN
ajlm-1363	26	16	-	-	PUNCT
ajlm-1363	26	17	terminus	terminus	NOUN
ajlm-1363	26	18	of	of	ADP
ajlm-1363	26	19	npm-1	npm-1	NUM
ajlm-1363	26	20	,	,	PUNCT
ajlm-1363	26	21	and	and	CCONJ
ajlm-1363	26	22	result	result	VERB
ajlm-1363	26	23	in	in	ADP
ajlm-1363	26	24	a	a	DET
ajlm-1363	26	25	frame	frame	NOUN
ajlm-1363	26	26	shift.10	shift.10	NOUN
ajlm-1363	26	27	the	the	DET
ajlm-1363	26	28	flt3	flt3	PROPN
ajlm-1363	26	29	gene	gene	NOUN
ajlm-1363	26	30	encodes	encode	VERB
ajlm-1363	26	31	a	a	DET
ajlm-1363	26	32	class	class	NOUN
ajlm-1363	26	33	iii	iii	NOUN
ajlm-1363	26	34	receptor	receptor	NOUN
ajlm-1363	26	35	tyrosine	tyrosine	PROPN
ajlm-1363	26	36	kinase	kinase	PROPN
ajlm-1363	26	37	.	.	PUNCT
ajlm-1363	27	1	mutations	mutation	NOUN
ajlm-1363	27	2	in	in	ADP
ajlm-1363	27	3	signalling	signal	VERB
ajlm-1363	27	4	genes	gene	NOUN
ajlm-1363	27	5	such	such	ADJ
ajlm-1363	27	6	as	as	ADP
ajlm-1363	27	7	flt3	flt3	NOUN
ajlm-1363	27	8	,	,	PUNCT
ajlm-1363	27	9	which	which	PRON
ajlm-1363	27	10	lead	lead	VERB
ajlm-1363	27	11	to	to	ADP
ajlm-1363	27	12	constitutive	constitutive	ADJ
ajlm-1363	27	13	activation	activation	NOUN
ajlm-1363	27	14	of	of	ADP
ajlm-1363	27	15	the	the	DET
ajlm-1363	27	16	receptor	receptor	NOUN
ajlm-1363	27	17	tyrosine	tyrosine	PROPN
ajlm-1363	27	18	kinase	kinase	PROPN
ajlm-1363	27	19	,	,	PUNCT
ajlm-1363	27	20	confer	confer	VERB
ajlm-1363	27	21	survival	survival	NOUN
ajlm-1363	27	22	and	and	CCONJ
ajlm-1363	27	23	proliferative	proliferative	ADJ
ajlm-1363	27	24	advantage	advantage	NOUN
ajlm-1363	27	25	to	to	ADP
ajlm-1363	27	26	cells.3,9	cells.3,9	PROPN
ajlm-1363	27	27	fms	fms	PROPN
ajlm-1363	27	28	-	-	PUNCT
ajlm-1363	27	29	related	relate	VERB
ajlm-1363	27	30	tyrosine	tyrosine	NOUN
ajlm-1363	27	31	kinase	kinase	NOUN
ajlm-1363	27	32	3	3	NUM
ajlm-1363	27	33	mutations	mutation	NOUN
ajlm-1363	27	34	occur	occur	VERB
ajlm-1363	27	35	in	in	ADP
ajlm-1363	27	36	approximately	approximately	ADV
ajlm-1363	27	37	one	one	NUM
ajlm-1363	27	38	-	-	PUNCT
ajlm-1363	27	39	third	third	NOUN
ajlm-1363	27	40	of	of	ADP
ajlm-1363	27	41	patients	patient	NOUN
ajlm-1363	27	42	with	with	ADP
ajlm-1363	27	43	aml	aml	PROPN
ajlm-1363	27	44	,	,	PUNCT
ajlm-1363	27	45	and	and	CCONJ
ajlm-1363	27	46	the	the	DET
ajlm-1363	27	47	it	it	PRON
ajlm-1363	27	48	d	d	PROPN
ajlm-1363	27	49	mutation	mutation	NOUN
ajlm-1363	27	50	is	be	AUX
ajlm-1363	27	51	considered	consider	VERB
ajlm-1363	27	52	the	the	DET
ajlm-1363	27	53	second	second	ADJ
ajlm-1363	27	54	most	most	ADV
ajlm-1363	27	55	common	common	ADJ
ajlm-1363	27	56	molecular	molecular	ADJ
ajlm-1363	27	57	abnormality	abnormality	NOUN
ajlm-1363	27	58	in	in	ADP
ajlm-1363	27	59	cn	cn	PROPN
ajlm-1363	27	60	-	-	NOUN
ajlm-1363	27	61	aml	aml	NOUN
ajlm-1363	27	62	(	(	PUNCT
ajlm-1363	27	63	28	28	NUM
ajlm-1363	27	64	%	%	NOUN
ajlm-1363	27	65	–	–	PUNCT
ajlm-1363	27	66	34	34	NUM
ajlm-1363	27	67	%	%	NOUN
ajlm-1363	27	68	of	of	ADP
ajlm-1363	27	69	cases).4,9	cases).4,9	ADJ
ajlm-1363	27	70	fms	fms	PROPN
ajlm-1363	27	71	-	-	PUNCT
ajlm-1363	27	72	related	relate	VERB
ajlm-1363	27	73	tyrosine	tyrosine	NOUN
ajlm-1363	27	74	kinase	kinase	NOUN
ajlm-1363	27	75	3	3	NUM
ajlm-1363	27	76	-	-	PUNCT
ajlm-1363	27	77	itd	itd	NOUN
ajlm-1363	27	78	mutations	mutation	NOUN
ajlm-1363	27	79	usually	usually	ADV
ajlm-1363	27	80	occur	occur	VERB
ajlm-1363	27	81	between	between	ADP
ajlm-1363	27	82	exons	exon	NOUN
ajlm-1363	27	83	14	14	NUM
ajlm-1363	27	84	and	and	CCONJ
ajlm-1363	27	85	15	15	NUM
ajlm-1363	27	86	and	and	CCONJ
ajlm-1363	27	87	can	can	AUX
ajlm-1363	27	88	range	range	VERB
ajlm-1363	27	89	between	between	ADP
ajlm-1363	27	90	3	3	NUM
ajlm-1363	27	91	bp	bp	PROPN
ajlm-1363	27	92	and	and	CCONJ
ajlm-1363	27	93	more	more	ADJ
ajlm-1363	27	94	than	than	ADP
ajlm-1363	27	95	400	400	NUM
ajlm-1363	27	96	bp	bp	NOUN
ajlm-1363	27	97	in	in	ADP
ajlm-1363	27	98	size.11	size.11	PROPN
ajlm-1363	27	99	the	the	DET
ajlm-1363	27	100	limited	limited	ADJ
ajlm-1363	27	101	reports	report	NOUN
ajlm-1363	27	102	on	on	ADP
ajlm-1363	27	103	the	the	DET
ajlm-1363	27	104	prevalence	prevalence	NOUN
ajlm-1363	27	105	of	of	ADP
ajlm-1363	27	106	the	the	DET
ajlm-1363	27	107	flt3	flt3	NOUN
ajlm-1363	27	108	-	-	PUNCT
ajlm-1363	27	109	itd	itd	NOUN
ajlm-1363	27	110	and	and	CCONJ
ajlm-1363	27	111	npm1	npm1	NOUN
ajlm-1363	27	112	mutations	mutation	NOUN
ajlm-1363	27	113	in	in	ADP
ajlm-1363	27	114	african	african	ADJ
ajlm-1363	27	115	aml	aml	PROPN
ajlm-1363	27	116	populations	population	NOUN
ajlm-1363	27	117	indicate	indicate	VERB
ajlm-1363	27	118	lower	low	ADJ
ajlm-1363	27	119	frequencies	frequency	NOUN
ajlm-1363	27	120	than	than	SCONJ
ajlm-1363	27	121	reported	report	VERB
ajlm-1363	27	122	internationally	internationally	ADV
ajlm-1363	27	123	.	.	PUNCT
ajlm-1363	28	1	in	in	ADP
ajlm-1363	28	2	an	an	DET
ajlm-1363	28	3	egyptian	egyptian	ADJ
ajlm-1363	28	4	study	study	NOUN
ajlm-1363	28	5	that	that	PRON
ajlm-1363	28	6	included	include	VERB
ajlm-1363	28	7	123	123	NUM
ajlm-1363	28	8	aml	aml	NOUN
ajlm-1363	28	9	patients	patient	NOUN
ajlm-1363	28	10	,	,	PUNCT
ajlm-1363	28	11	flt3	flt3	NOUN
ajlm-1363	28	12	-	-	PUNCT
ajlm-1363	28	13	itd	itd	NOUN
ajlm-1363	28	14	and	and	CCONJ
ajlm-1363	28	15	npm1	npm1	NOUN
ajlm-1363	28	16	mutations	mutation	NOUN
ajlm-1363	28	17	were	be	AUX
ajlm-1363	28	18	detected	detect	VERB
ajlm-1363	28	19	in	in	ADP
ajlm-1363	28	20	17.9	17.9	NUM
ajlm-1363	28	21	%	%	NOUN
ajlm-1363	28	22	and	and	CCONJ
ajlm-1363	28	23	19.5	19.5	NUM
ajlm-1363	28	24	%	%	NOUN
ajlm-1363	28	25	of	of	ADP
ajlm-1363	28	26	patients.12	patients.12	NOUN
ajlm-1363	28	27	another	another	DET
ajlm-1363	28	28	study	study	NOUN
ajlm-1363	28	29	by	by	ADP
ajlm-1363	28	30	sofan	sofan	PROPN
ajlm-1363	28	31	et	et	PROPN
ajlm-1363	28	32	al	al	PROPN
ajlm-1363	28	33	.	.	PROPN
ajlm-1363	29	1	(	(	PUNCT
ajlm-1363	29	2	2014	2014	NUM
ajlm-1363	29	3	)	)	PUNCT
ajlm-1363	29	4	detected	detect	VERB
ajlm-1363	29	5	npm1	npm1	NOUN
ajlm-1363	29	6	mutations	mutation	NOUN
ajlm-1363	29	7	in	in	ADP
ajlm-1363	29	8	28	28	NUM
ajlm-1363	29	9	%	%	NOUN
ajlm-1363	29	10	of	of	ADP
ajlm-1363	29	11	cn	cn	PROPN
ajlm-1363	29	12	-	-	PUNCT
ajlm-1363	29	13	aml.13	aml.13	NOUN
ajlm-1363	29	14	contrary	contrary	ADJ
ajlm-1363	29	15	to	to	ADP
ajlm-1363	29	16	these	these	DET
ajlm-1363	29	17	findings	finding	NOUN
ajlm-1363	29	18	,	,	PUNCT
ajlm-1363	29	19	no	no	DET
ajlm-1363	29	20	npm1	npm1	NOUN
ajlm-1363	29	21	mutations	mutation	NOUN
ajlm-1363	29	22	were	be	AUX
ajlm-1363	29	23	found	find	VERB
ajlm-1363	29	24	in	in	ADP
ajlm-1363	29	25	a	a	DET
ajlm-1363	29	26	study	study	NOUN
ajlm-1363	29	27	of	of	ADP
ajlm-1363	29	28	100	100	NUM
ajlm-1363	29	29	sudanese	sudanese	ADJ
ajlm-1363	29	30	aml	aml	PROPN
ajlm-1363	29	31	patients.14	patients.14	PROPN
ajlm-1363	29	32	the	the	DET
ajlm-1363	29	33	frequency	frequency	NOUN
ajlm-1363	29	34	of	of	ADP
ajlm-1363	29	35	npm1	npm1	NOUN
ajlm-1363	29	36	and	and	CCONJ
ajlm-1363	29	37	flt3	flt3	NOUN
ajlm-1363	29	38	-	-	PUNCT
ajlm-1363	29	39	itd	itd	NOUN
ajlm-1363	29	40	mutations	mutation	NOUN
ajlm-1363	29	41	in	in	ADP
ajlm-1363	29	42	a	a	DET
ajlm-1363	29	43	south	south	ADJ
ajlm-1363	29	44	african	african	ADJ
ajlm-1363	29	45	adult	adult	PROPN
ajlm-1363	29	46	de	de	X
ajlm-1363	29	47	novo	novo	PROPN
ajlm-1363	29	48	aml	aml	PROPN
ajlm-1363	29	49	cohort	cohort	NOUN
ajlm-1363	29	50	was	be	AUX
ajlm-1363	29	51	7.5	7.5	NUM
ajlm-1363	29	52	%	%	NOUN
ajlm-1363	29	53	and	and	CCONJ
ajlm-1363	29	54	12%.15	12%.15	NUM
ajlm-1363	29	55	this	this	DET
ajlm-1363	29	56	study	study	NOUN
ajlm-1363	29	57	investigated	investigate	VERB
ajlm-1363	29	58	the	the	DET
ajlm-1363	29	59	presence	presence	NOUN
ajlm-1363	29	60	and	and	CCONJ
ajlm-1363	29	61	molecular	molecular	ADJ
ajlm-1363	29	62	characteristics	characteristic	NOUN
ajlm-1363	29	63	of	of	ADP
ajlm-1363	29	64	the	the	DET
ajlm-1363	29	65	npm1	npm1	NOUN
ajlm-1363	29	66	and	and	CCONJ
ajlm-1363	29	67	flt3	flt3	NOUN
ajlm-1363	29	68	-	-	PUNCT
ajlm-1363	29	69	itd	itd	NOUN
ajlm-1363	29	70	mutations	mutation	NOUN
ajlm-1363	29	71	in	in	ADP
ajlm-1363	29	72	a	a	DET
ajlm-1363	29	73	newly	newly	ADV
ajlm-1363	29	74	diagnosed	diagnose	VERB
ajlm-1363	29	75	aml	aml	NOUN
ajlm-1363	29	76	population	population	NOUN
ajlm-1363	29	77	in	in	ADP
ajlm-1363	29	78	central	central	PROPN
ajlm-1363	29	79	south	south	PROPN
ajlm-1363	29	80	africa	africa	PROPN
ajlm-1363	29	81	.	.	PUNCT
ajlm-1363	30	1	the	the	DET
ajlm-1363	30	2	study	study	NOUN
ajlm-1363	30	3	further	far	ADV
ajlm-1363	30	4	aimed	aim	VERB
ajlm-1363	30	5	to	to	PART
ajlm-1363	30	6	describe	describe	VERB
ajlm-1363	30	7	the	the	DET
ajlm-1363	30	8	npm1	npm1	NOUN
ajlm-1363	30	9	and	and	CCONJ
ajlm-1363	30	10	flt3	flt3	NOUN
ajlm-1363	30	11	-	-	PUNCT
ajlm-1363	30	12	itd	itd	NOUN
ajlm-1363	30	13	mutations	mutation	NOUN
ajlm-1363	30	14	in	in	ADP
ajlm-1363	30	15	relation	relation	NOUN
ajlm-1363	30	16	to	to	PART
ajlm-1363	30	17	patient	patient	VERB
ajlm-1363	30	18	demographics	demographic	NOUN
ajlm-1363	30	19	and	and	CCONJ
ajlm-1363	30	20	specific	specific	ADJ
ajlm-1363	30	21	aml	aml	NOUN
ajlm-1363	30	22	classifications	classification	NOUN
ajlm-1363	30	23	.	.	PUNCT
ajlm-1363	31	1	methods	method	NOUN
ajlm-1363	31	2	ethical	ethical	ADJ
ajlm-1363	31	3	considerations	consideration	NOUN
ajlm-1363	31	4	approval	approval	NOUN
ajlm-1363	31	5	for	for	ADP
ajlm-1363	31	6	the	the	DET
ajlm-1363	31	7	study	study	NOUN
ajlm-1363	31	8	was	be	AUX
ajlm-1363	31	9	obtained	obtain	VERB
ajlm-1363	31	10	from	from	ADP
ajlm-1363	31	11	the	the	DET
ajlm-1363	31	12	health	health	PROPN
ajlm-1363	31	13	sciences	sciences	PROPN
ajlm-1363	31	14	research	research	PROPN
ajlm-1363	31	15	ethics	ethic	NOUN
ajlm-1363	31	16	committee	committee	NOUN
ajlm-1363	31	17	from	from	ADP
ajlm-1363	31	18	the	the	DET
ajlm-1363	31	19	university	university	NOUN
ajlm-1363	31	20	of	of	ADP
ajlm-1363	31	21	the	the	DET
ajlm-1363	31	22	free	free	ADJ
ajlm-1363	31	23	state	state	NOUN
ajlm-1363	31	24	(	(	PUNCT
ajlm-1363	31	25	study	study	VERB
ajlm-1363	31	26	approval	approval	NOUN
ajlm-1363	31	27	number	number	NOUN
ajlm-1363	31	28	:	:	PUNCT
ajlm-1363	31	29	ufs	ufs	NOUN
ajlm-1363	31	30	-	-	NOUN
ajlm-1363	31	31	hsd2018/1174/2711	hsd2018/1174/2711	NOUN
ajlm-1363	31	32	)	)	PUNCT
ajlm-1363	31	33	and	and	CCONJ
ajlm-1363	31	34	the	the	DET
ajlm-1363	31	35	free	free	ADJ
ajlm-1363	31	36	state	state	PROPN
ajlm-1363	31	37	province	province	PROPN
ajlm-1363	31	38	department	department	PROPN
ajlm-1363	31	39	of	of	ADP
ajlm-1363	31	40	health	health	PROPN
ajlm-1363	31	41	(	(	PUNCT
ajlm-1363	31	42	study	study	NOUN
ajlm-1363	31	43	approval	approval	NOUN
ajlm-1363	31	44	number	number	NOUN
ajlm-1363	31	45	:	:	PUNCT
ajlm-1363	31	46	fs_201810_016	fs_201810_016	PROPN
ajlm-1363	31	47	)	)	PUNCT
ajlm-1363	31	48	.	.	PUNCT
ajlm-1363	32	1	written	write	VERB
ajlm-1363	32	2	informed	informed	ADJ
ajlm-1363	32	3	consent	consent	NOUN
ajlm-1363	32	4	was	be	AUX
ajlm-1363	32	5	obtained	obtain	VERB
ajlm-1363	32	6	from	from	ADP
ajlm-1363	32	7	all	all	DET
ajlm-1363	32	8	participants	participant	NOUN
ajlm-1363	32	9	prior	prior	ADV
ajlm-1363	32	10	to	to	ADP
ajlm-1363	32	11	sample	sample	NOUN
ajlm-1363	32	12	collection	collection	NOUN
ajlm-1363	32	13	.	.	PUNCT
ajlm-1363	33	1	samples	sample	NOUN
ajlm-1363	33	2	were	be	AUX
ajlm-1363	33	3	allocated	allocate	VERB
ajlm-1363	33	4	study	study	NOUN
ajlm-1363	33	5	numbers	number	NOUN
ajlm-1363	33	6	to	to	PART
ajlm-1363	33	7	ensure	ensure	VERB
ajlm-1363	33	8	patient	patient	ADJ
ajlm-1363	33	9	confidentiality	confidentiality	NOUN
ajlm-1363	33	10	,	,	PUNCT
ajlm-1363	33	11	and	and	CCONJ
ajlm-1363	33	12	patient	patient	ADJ
ajlm-1363	33	13	data	datum	NOUN
ajlm-1363	33	14	were	be	AUX
ajlm-1363	33	15	stored	store	VERB
ajlm-1363	33	16	on	on	ADP
ajlm-1363	33	17	password	password	NOUN
ajlm-1363	33	18	-	-	PUNCT
ajlm-1363	33	19	protected	protect	VERB
ajlm-1363	33	20	devices	device	NOUN
ajlm-1363	33	21	,	,	PUNCT
ajlm-1363	33	22	which	which	PRON
ajlm-1363	33	23	were	be	AUX
ajlm-1363	33	24	only	only	ADV
ajlm-1363	33	25	accessible	accessible	ADJ
ajlm-1363	33	26	to	to	ADP
ajlm-1363	33	27	the	the	DET
ajlm-1363	33	28	researchers	researcher	NOUN
ajlm-1363	33	29	.	.	PUNCT
ajlm-1363	34	1	study	study	NOUN
ajlm-1363	34	2	population	population	NOUN
ajlm-1363	34	3	all	all	DET
ajlm-1363	34	4	adult	adult	NOUN
ajlm-1363	34	5	patients	patient	NOUN
ajlm-1363	34	6	(	(	PUNCT
ajlm-1363	34	7	n	n	NOUN
ajlm-1363	34	8	=	=	SYM
ajlm-1363	34	9	40	40	NUM
ajlm-1363	34	10	;	;	PUNCT
ajlm-1363	34	11	coded	code	VERB
ajlm-1363	34	12	fn1	fn1	NOUN
ajlm-1363	34	13	–	–	PUNCT
ajlm-1363	34	14	fn40	fn40	PROPN
ajlm-1363	34	15	)	)	PUNCT
ajlm-1363	34	16	that	that	PRON
ajlm-1363	34	17	were	be	AUX
ajlm-1363	34	18	diagnosed	diagnose	VERB
ajlm-1363	34	19	with	with	ADP
ajlm-1363	34	20	de	de	X
ajlm-1363	34	21	novo	novo	PROPN
ajlm-1363	34	22	aml	aml	PROPN
ajlm-1363	34	23	at	at	ADP
ajlm-1363	34	24	the	the	DET
ajlm-1363	34	25	universitas	universita	NOUN
ajlm-1363	34	26	academic	academic	ADJ
ajlm-1363	34	27	hospital	hospital	NOUN
ajlm-1363	34	28	in	in	ADP
ajlm-1363	34	29	bloemfontein	bloemfontein	PROPN
ajlm-1363	34	30	,	,	PUNCT
ajlm-1363	34	31	south	south	PROPN
ajlm-1363	34	32	africa	africa	PROPN
ajlm-1363	34	33	,	,	PUNCT
ajlm-1363	34	34	during	during	ADP
ajlm-1363	34	35	the	the	DET
ajlm-1363	34	36	study	study	NOUN
ajlm-1363	34	37	period	period	NOUN
ajlm-1363	34	38	(	(	PUNCT
ajlm-1363	34	39	november	november	PROPN
ajlm-1363	34	40	2018	2018	NUM
ajlm-1363	34	41	–	–	PUNCT
ajlm-1363	34	42	december	december	PROPN
ajlm-1363	34	43	2019	2019	NUM
ajlm-1363	34	44	)	)	PUNCT
ajlm-1363	34	45	,	,	PUNCT
ajlm-1363	34	46	and	and	CCONJ
ajlm-1363	34	47	who	who	PRON
ajlm-1363	34	48	were	be	AUX
ajlm-1363	34	49	able	able	ADJ
ajlm-1363	34	50	to	to	PART
ajlm-1363	34	51	give	give	VERB
ajlm-1363	34	52	written	write	VERB
ajlm-1363	34	53	informed	informed	ADJ
ajlm-1363	34	54	consent	consent	NOUN
ajlm-1363	34	55	were	be	AUX
ajlm-1363	34	56	included	include	VERB
ajlm-1363	34	57	in	in	ADP
ajlm-1363	34	58	this	this	DET
ajlm-1363	34	59	study	study	NOUN
ajlm-1363	34	60	.	.	PUNCT
ajlm-1363	35	1	all	all	DET
ajlm-1363	35	2	aml	aml	PROPN
ajlm-1363	35	3	patients	patient	NOUN
ajlm-1363	35	4	were	be	AUX
ajlm-1363	35	5	included	include	VERB
ajlm-1363	35	6	regardless	regardless	ADV
ajlm-1363	35	7	of	of	ADP
ajlm-1363	35	8	cytogenetic	cytogenetic	ADJ
ajlm-1363	35	9	findings	finding	NOUN
ajlm-1363	35	10	.	.	PUNCT
ajlm-1363	36	1	patients	patient	NOUN
ajlm-1363	36	2	’	'	PUNCT
ajlm-1363	36	3	demographic	demographic	ADJ
ajlm-1363	36	4	variables	variable	NOUN
ajlm-1363	36	5	(	(	PUNCT
ajlm-1363	36	6	age	age	NOUN
ajlm-1363	36	7	,	,	PUNCT
ajlm-1363	36	8	sex	sex	NOUN
ajlm-1363	36	9	,	,	PUNCT
ajlm-1363	36	10	and	and	CCONJ
ajlm-1363	36	11	self	self	NOUN
ajlm-1363	36	12	-	-	PUNCT
ajlm-1363	36	13	proclaimed	proclaim	VERB
ajlm-1363	36	14	ethnic	ethnic	ADJ
ajlm-1363	36	15	background	background	NOUN
ajlm-1363	36	16	)	)	PUNCT
ajlm-1363	36	17	and	and	CCONJ
ajlm-1363	36	18	disease	disease	NOUN
ajlm-1363	36	19	-	-	PUNCT
ajlm-1363	36	20	specific	specific	ADJ
ajlm-1363	36	21	characteristics	characteristic	NOUN
ajlm-1363	36	22	(	(	PUNCT
ajlm-1363	36	23	aml	aml	NOUN
ajlm-1363	36	24	classification	classification	NOUN
ajlm-1363	36	25	according	accord	VERB
ajlm-1363	36	26	to	to	ADP
ajlm-1363	36	27	the	the	DET
ajlm-1363	36	28	world	world	PROPN
ajlm-1363	36	29	health	health	PROPN
ajlm-1363	36	30	organization	organization	NOUN
ajlm-1363	36	31	’s	’s	PART
ajlm-1363	36	32	classification	classification	NOUN
ajlm-1363	36	33	of	of	ADP
ajlm-1363	36	34	tumours	tumour	NOUN
ajlm-1363	36	35	of	of	ADP
ajlm-1363	36	36	haemopoietic	haemopoietic	ADJ
ajlm-1363	36	37	and	and	CCONJ
ajlm-1363	36	38	lymphoid	lymphoid	ADJ
ajlm-1363	36	39	tissues	tissue	NOUN
ajlm-1363	36	40	,	,	PUNCT
ajlm-1363	36	41	revised	revise	VERB
ajlm-1363	36	42	4th	4th	ADJ
ajlm-1363	36	43	edition16	edition16	NOUN
ajlm-1363	36	44	)	)	PUNCT
ajlm-1363	36	45	were	be	AUX
ajlm-1363	36	46	obtained	obtain	VERB
ajlm-1363	36	47	from	from	ADP
ajlm-1363	36	48	patients	patient	NOUN
ajlm-1363	36	49	’	'	PUNCT
ajlm-1363	36	50	medical	medical	ADJ
ajlm-1363	36	51	records	record	NOUN
ajlm-1363	36	52	.	.	PUNCT
ajlm-1363	37	1	based	base	VERB
ajlm-1363	37	2	on	on	ADP
ajlm-1363	37	3	the	the	DET
ajlm-1363	37	4	laboratory	laboratory	NOUN
ajlm-1363	37	5	information	information	NOUN
ajlm-1363	37	6	records	record	NOUN
ajlm-1363	37	7	that	that	PRON
ajlm-1363	37	8	were	be	AUX
ajlm-1363	37	9	reviewed	review	VERB
ajlm-1363	37	10	,	,	PUNCT
ajlm-1363	37	11	none	none	NOUN
ajlm-1363	37	12	of	of	ADP
ajlm-1363	37	13	the	the	DET
ajlm-1363	37	14	patients	patient	NOUN
ajlm-1363	37	15	had	have	VERB
ajlm-1363	37	16	any	any	DET
ajlm-1363	37	17	previous	previous	ADJ
ajlm-1363	37	18	clonal	clonal	ADJ
ajlm-1363	37	19	myeloid	myeloid	ADJ
ajlm-1363	37	20	disorder	disorder	NOUN
ajlm-1363	37	21	.	.	PUNCT
ajlm-1363	38	1	blood	blood	NOUN
ajlm-1363	38	2	samples	sample	NOUN
ajlm-1363	38	3	were	be	AUX
ajlm-1363	38	4	obtained	obtain	VERB
ajlm-1363	38	5	from	from	ADP
ajlm-1363	38	6	each	each	DET
ajlm-1363	38	7	participant	participant	NOUN
ajlm-1363	38	8	for	for	ADP
ajlm-1363	38	9	this	this	DET
ajlm-1363	38	10	study	study	NOUN
ajlm-1363	38	11	during	during	ADP
ajlm-1363	38	12	routine	routine	ADJ
ajlm-1363	38	13	blood	blood	NOUN
ajlm-1363	38	14	collection	collection	NOUN
ajlm-1363	38	15	by	by	ADP
ajlm-1363	38	16	the	the	DET
ajlm-1363	38	17	treating	treat	VERB
ajlm-1363	38	18	physician	physician	NOUN
ajlm-1363	38	19	.	.	PUNCT
ajlm-1363	39	1	dna	dna	PROPN
ajlm-1363	39	2	extraction	extraction	NOUN
ajlm-1363	39	3	genomic	genomic	NOUN
ajlm-1363	39	4	dna	dna	PROPN
ajlm-1363	39	5	was	be	AUX
ajlm-1363	39	6	extracted	extract	VERB
ajlm-1363	39	7	from	from	ADP
ajlm-1363	39	8	whole	whole	ADJ
ajlm-1363	39	9	blood	blood	NOUN
ajlm-1363	39	10	samples	sample	NOUN
ajlm-1363	39	11	using	use	VERB
ajlm-1363	39	12	the	the	DET
ajlm-1363	39	13	wizard	wizard	ADJ
ajlm-1363	39	14	®	®	NOUN
ajlm-1363	39	15	genomic	genomic	PROPN
ajlm-1363	39	16	dna	dna	PROPN
ajlm-1363	39	17	purification	purification	NOUN
ajlm-1363	39	18	kit	kit	NOUN
ajlm-1363	39	19	(	(	PUNCT
ajlm-1363	39	20	promega	promega	PROPN
ajlm-1363	39	21	,	,	PUNCT
ajlm-1363	39	22	madison	madison	PROPN
ajlm-1363	39	23	,	,	PUNCT
ajlm-1363	39	24	wisconsin	wisconsin	PROPN
ajlm-1363	39	25	,	,	PUNCT
ajlm-1363	39	26	united	united	PROPN
ajlm-1363	39	27	states	states	PROPN
ajlm-1363	39	28	)	)	PUNCT
ajlm-1363	39	29	.	.	PUNCT
ajlm-1363	40	1	dna	dna	PROPN
ajlm-1363	40	2	samples	sample	NOUN
ajlm-1363	40	3	were	be	AUX
ajlm-1363	40	4	quantified	quantify	VERB
ajlm-1363	40	5	using	use	VERB
ajlm-1363	40	6	the	the	DET
ajlm-1363	40	7	biodrop	biodrop	NOUN
ajlm-1363	40	8	™	™	PART
ajlm-1363	40	9	µlite	µlite	ADJ
ajlm-1363	40	10	instrument	instrument	NOUN
ajlm-1363	40	11	(	(	PUNCT
ajlm-1363	40	12	biodrop	biodrop	NOUN
ajlm-1363	40	13	,	,	PUNCT
ajlm-1363	40	14	cambridge	cambridge	PROPN
ajlm-1363	40	15	,	,	PUNCT
ajlm-1363	40	16	united	united	ADJ
ajlm-1363	40	17	kingdom	kingdom	PROPN
ajlm-1363	40	18	)	)	PUNCT
ajlm-1363	40	19	.	.	PUNCT
ajlm-1363	41	1	npm1	npm1	NOUN
ajlm-1363	41	2	and	and	CCONJ
ajlm-1363	41	3	flt3	flt3	PROPN
ajlm-1363	41	4	-	-	PUNCT
ajlm-1363	41	5	itd	itd	NOUN
ajlm-1363	41	6	multiplex	multiplex	PROPN
ajlm-1363	41	7	pcr	pcr	PROPN
ajlm-1363	41	8	optimisation	optimisation	NOUN
ajlm-1363	41	9	anonymised	anonymise	VERB
ajlm-1363	41	10	samples	sample	NOUN
ajlm-1363	41	11	that	that	PRON
ajlm-1363	41	12	were	be	AUX
ajlm-1363	41	13	positive	positive	ADJ
ajlm-1363	41	14	and	and	CCONJ
ajlm-1363	41	15	negative	negative	ADJ
ajlm-1363	41	16	for	for	ADP
ajlm-1363	41	17	the	the	DET
ajlm-1363	41	18	npm1	npm1	NOUN
ajlm-1363	41	19	and	and	CCONJ
ajlm-1363	41	20	flt3	flt3	NOUN
ajlm-1363	41	21	-	-	PUNCT
ajlm-1363	41	22	itd	itd	NOUN
ajlm-1363	41	23	mutations	mutation	NOUN
ajlm-1363	41	24	and	and	CCONJ
ajlm-1363	41	25	formed	form	VERB
ajlm-1363	41	26	part	part	NOUN
ajlm-1363	41	27	of	of	ADP
ajlm-1363	41	28	an	an	DET
ajlm-1363	41	29	external	external	ADJ
ajlm-1363	41	30	quality	quality	NOUN
ajlm-1363	41	31	control	control	NOUN
ajlm-1363	41	32	programme	programme	NOUN
ajlm-1363	41	33	(	(	PUNCT
ajlm-1363	41	34	generously	generously	ADV
ajlm-1363	41	35	donated	donate	VERB
ajlm-1363	41	36	by	by	ADP
ajlm-1363	41	37	the	the	DET
ajlm-1363	41	38	department	department	PROPN
ajlm-1363	41	39	of	of	ADP
ajlm-1363	41	40	haematology	haematology	NOUN
ajlm-1363	41	41	at	at	ADP
ajlm-1363	41	42	charlotte	charlotte	PROPN
ajlm-1363	41	43	maxeke	maxeke	PROPN
ajlm-1363	41	44	johannesburg	johannesburg	PROPN
ajlm-1363	41	45	academic	academic	ADJ
ajlm-1363	41	46	hospital	hospital	NOUN
ajlm-1363	41	47	,	,	PUNCT
ajlm-1363	41	48	national	national	PROPN
ajlm-1363	41	49	health	health	PROPN
ajlm-1363	41	50	laboratory	laboratory	PROPN
ajlm-1363	41	51	service	service	PROPN
ajlm-1363	41	52	,	,	PUNCT
ajlm-1363	41	53	johannesburg	johannesburg	PROPN
ajlm-1363	41	54	,	,	PUNCT
ajlm-1363	41	55	south	south	PROPN
ajlm-1363	41	56	africa	africa	PROPN
ajlm-1363	41	57	)	)	PUNCT
ajlm-1363	41	58	were	be	AUX
ajlm-1363	41	59	used	use	VERB
ajlm-1363	41	60	to	to	PART
ajlm-1363	41	61	optimise	optimise	VERB
ajlm-1363	41	62	the	the	DET
ajlm-1363	41	63	assay	assay	NOUN
ajlm-1363	41	64	.	.	PUNCT
ajlm-1363	42	1	published	publish	VERB
ajlm-1363	42	2	primers	primer	NOUN
ajlm-1363	42	3	,	,	PUNCT
ajlm-1363	42	4	fluorescently	fluorescently	ADV
ajlm-1363	42	5	labelled	label	VERB
ajlm-1363	42	6	with	with	ADP
ajlm-1363	42	7	hexadecimal	hexadecimal	ADJ
ajlm-1363	42	8	colour	colour	NOUN
ajlm-1363	42	9	and	and	CCONJ
ajlm-1363	42	10	fluorescein	fluorescein	NOUN
ajlm-1363	42	11	amidites	amidites	PROPN
ajlm-1363	42	12	fluorophores17	fluorophores17	NOUN
ajlm-1363	42	13	were	be	AUX
ajlm-1363	42	14	used	use	VERB
ajlm-1363	42	15	in	in	ADP
ajlm-1363	42	16	the	the	DET
ajlm-1363	42	17	assay	assay	NOUN
ajlm-1363	42	18	(	(	PUNCT
ajlm-1363	42	19	npm1	npm1	NOUN
ajlm-1363	42	20	forward	forward	ADV
ajlm-1363	42	21	:	:	PUNCT
ajlm-1363	43	1	5’gtt	5’gtt	NUM
ajlm-1363	43	2	tct	tct	NOUN
ajlm-1363	43	3	ttt	ttt	PROPN
ajlm-1363	43	4	ttt	ttt	PROPN
ajlm-1363	43	5	ttt	ttt	PROPN
ajlm-1363	43	6	ttt	ttt	PROPN
ajlm-1363	43	7	cca	cca	PROPN
ajlm-1363	43	8	ggc	ggc	PROPN
ajlm-1363	43	9	tat	tat	PROPN
ajlm-1363	43	10	tca	tca	PROPN
ajlm-1363	43	11	ag3	ag3	PROPN
ajlm-1363	43	12	’	'	PUNCT
ajlm-1363	43	13	;	;	PUNCT
ajlm-1363	43	14	reverse	reverse	VERB
ajlm-1363	43	15	:	:	PUNCT
ajlm-1363	43	16	5’hex	5’hex	NUM
ajlm-1363	43	17	cac	cac	PROPN
ajlm-1363	43	18	ggt	ggt	PROPN
ajlm-1363	43	19	agg	agg	PROPN
ajlm-1363	44	1	gaa	gaa	PROPN
ajlm-1363	45	1	agt	agt	PROPN
ajlm-1363	45	2	tct	tct	PROPN
ajlm-1363	45	3	cac	cac	PROPN
ajlm-1363	45	4	tct	tct	PROPN
ajlm-1363	45	5	gc3	gc3	PROPN
ajlm-1363	45	6	’	'	PUNCT
ajlm-1363	45	7	;	;	PUNCT
ajlm-1363	45	8	and	and	CCONJ
ajlm-1363	45	9	flt3	flt3	NOUN
ajlm-1363	45	10	-	-	PUNCT
ajlm-1363	45	11	itd	itd	NOUN
ajlm-1363	45	12	forward	forward	ADV
ajlm-1363	45	13	:	:	PUNCT
ajlm-1363	45	14	5’famagca	5’famagca	NUM
ajlm-1363	45	15	att	att	PROPN
ajlm-1363	45	16	tag	tag	NOUN
ajlm-1363	45	17	gta	gta	PROPN
ajlm-1363	45	18	tga	tga	PROPN
ajlm-1363	45	19	aag	aag	PROPN
ajlm-1363	45	20	cca	cca	PROPN
ajlm-1363	45	21	gcta3	gcta3	PROPN
ajlm-1363	45	22	’	'	PUNCT
ajlm-1363	45	23	;	;	PUNCT
ajlm-1363	45	24	reverse	reverse	VERB
ajlm-1363	45	25	:	:	PUNCT
ajlm-1363	45	26	5’ctt	5’ctt	PROPN
ajlm-1363	45	27	tca	tca	PROPN
ajlm-1363	45	28	gca	gca	PROPN
ajlm-1363	45	29	ttt	ttt	PROPN
ajlm-1363	45	30	tga	tga	PROPN
ajlm-1363	45	31	cgg	cgg	PROPN
ajlm-1363	45	32	caa	caa	PROPN
ajlm-1363	45	33	cc3	cc3	PROPN
ajlm-1363	45	34	’	'	PUNCT
ajlm-1363	45	35	)	)	PUNCT
ajlm-1363	45	36	.	.	PUNCT
ajlm-1363	46	1	primers	primer	NOUN
ajlm-1363	46	2	were	be	AUX
ajlm-1363	46	3	evaluated	evaluate	VERB
ajlm-1363	46	4	for	for	ADP
ajlm-1363	46	5	target	target	NOUN
ajlm-1363	46	6	-	-	PUNCT
ajlm-1363	46	7	specificity	specificity	NOUN
ajlm-1363	46	8	using	use	VERB
ajlm-1363	46	9	the	the	DET
ajlm-1363	46	10	basic	basic	ADJ
ajlm-1363	46	11	local	local	ADJ
ajlm-1363	46	12	alignment	alignment	NOUN
ajlm-1363	46	13	search	search	NOUN
ajlm-1363	46	14	tool	tool	NOUN
ajlm-1363	46	15	(	(	PUNCT
ajlm-1363	46	16	available	available	ADJ
ajlm-1363	46	17	at	at	ADP
ajlm-1363	46	18	https://blast.ncbi.nlm.nih.gov/blast.cgi	https://blast.ncbi.nlm.nih.gov/blast.cgi	PROPN
ajlm-1363	46	19	)	)	PUNCT
ajlm-1363	46	20	from	from	ADP
ajlm-1363	46	21	the	the	DET
ajlm-1363	46	22	national	national	ADJ
ajlm-1363	46	23	center	center	NOUN
ajlm-1363	46	24	for	for	ADP
ajlm-1363	46	25	biotechnology	biotechnology	NOUN
ajlm-1363	46	26	information	information	NOUN
ajlm-1363	46	27	(	(	PUNCT
ajlm-1363	46	28	ncbi	ncbi	PROPN
ajlm-1363	46	29	,	,	PUNCT
ajlm-1363	46	30	bethesda	bethesda	NOUN
ajlm-1363	46	31	,	,	PUNCT
ajlm-1363	46	32	maryland	maryland	PROPN
ajlm-1363	46	33	,	,	PUNCT
ajlm-1363	46	34	united	united	PROPN
ajlm-1363	46	35	states	states	PROPN
ajlm-1363	46	36	)	)	PUNCT
ajlm-1363	46	37	.	.	PUNCT
ajlm-1363	47	1	a	a	DET
ajlm-1363	47	2	polymerase	polymerase	NOUN
ajlm-1363	47	3	chain	chain	NOUN
ajlm-1363	47	4	reaction	reaction	NOUN
ajlm-1363	47	5	(	(	PUNCT
ajlm-1363	47	6	pcr	pcr	NOUN
ajlm-1363	47	7	)	)	PUNCT
ajlm-1363	47	8	mixture	mixture	NOUN
ajlm-1363	47	9	was	be	AUX
ajlm-1363	47	10	prepared	prepare	VERB
ajlm-1363	47	11	with	with	ADP
ajlm-1363	47	12	the	the	DET
ajlm-1363	47	13	gotaq	gotaq	PROPN
ajlm-1363	47	14	®	®	NOUN
ajlm-1363	47	15	dna	dna	NOUN
ajlm-1363	47	16	polymerase	polymerase	NOUN
ajlm-1363	47	17	(	(	PUNCT
ajlm-1363	47	18	promega	promega	PROPN
ajlm-1363	47	19	madison	madison	PROPN
ajlm-1363	47	20	,	,	PUNCT
ajlm-1363	47	21	wisconsin	wisconsin	PROPN
ajlm-1363	47	22	,	,	PUNCT
ajlm-1363	47	23	united	united	PROPN
ajlm-1363	47	24	states	states	PROPN
ajlm-1363	47	25	)	)	PUNCT
ajlm-1363	47	26	reagents	reagent	NOUN
ajlm-1363	47	27	.	.	PUNCT
ajlm-1363	48	1	components	component	NOUN
ajlm-1363	48	2	of	of	ADP
ajlm-1363	48	3	the	the	DET
ajlm-1363	48	4	kit	kit	NOUN
ajlm-1363	48	5	were	be	AUX
ajlm-1363	48	6	manually	manually	ADV
ajlm-1363	48	7	mixed	mixed	ADJ
ajlm-1363	48	8	and	and	CCONJ
ajlm-1363	48	9	the	the	DET
ajlm-1363	48	10	mixture	mixture	NOUN
ajlm-1363	48	11	consisted	consist	VERB
ajlm-1363	48	12	of	of	ADP
ajlm-1363	48	13	5	5	NUM
ajlm-1363	48	14	µl	µl	ADP
ajlm-1363	48	15	5х	5х	NUM
ajlm-1363	48	16	gotaq	gotaq	NOUN
ajlm-1363	48	17	buffer	buffer	NOUN
ajlm-1363	48	18	,	,	PUNCT
ajlm-1363	48	19	2	2	NUM
ajlm-1363	48	20	µl	µl	NOUN
ajlm-1363	48	21	of	of	ADP
ajlm-1363	48	22	mgcl2	mgcl2	PROPN
ajlm-1363	48	23	,	,	PUNCT
ajlm-1363	48	24	0.5	0.5	NUM
ajlm-1363	48	25	µl	µl	NOUN
ajlm-1363	48	26	of	of	ADP
ajlm-1363	48	27	dntps	dntps	NOUN
ajlm-1363	48	28	,	,	PUNCT
ajlm-1363	48	29	and	and	CCONJ
ajlm-1363	48	30	0.2	0.2	NUM
ajlm-1363	48	31	µl	µl	NOUN
ajlm-1363	48	32	of	of	ADP
ajlm-1363	48	33	gotaq	gotaq	PROPN
ajlm-1363	48	34	dna	dna	PROPN
ajlm-1363	48	35	polymerase	polymerase	NOUN
ajlm-1363	48	36	(	(	PUNCT
ajlm-1363	48	37	5	5	NUM
ajlm-1363	48	38	u/µl	u/µl	NOUN
ajlm-1363	48	39	)	)	PUNCT
ajlm-1363	48	40	.	.	PUNCT
ajlm-1363	49	1	additionally	additionally	ADV
ajlm-1363	49	2	,	,	PUNCT
ajlm-1363	49	3	1	1	NUM
ajlm-1363	49	4	µl	µl	NOUN
ajlm-1363	49	5	of	of	ADP
ajlm-1363	49	6	genomic	genomic	ADJ
ajlm-1363	49	7	dna	dna	NOUN
ajlm-1363	49	8	(	(	PUNCT
ajlm-1363	49	9	100	100	NUM
ajlm-1363	49	10	ng/µl	ng/µl	NUM
ajlm-1363	49	11	)	)	PUNCT
ajlm-1363	49	12	,	,	PUNCT
ajlm-1363	49	13	14.3	14.3	NUM
ajlm-1363	49	14	µl	µl	NOUN
ajlm-1363	49	15	of	of	ADP
ajlm-1363	49	16	nuclease	nuclease	NOUN
ajlm-1363	49	17	-	-	PUNCT
ajlm-1363	49	18	free	free	ADJ
ajlm-1363	49	19	water	water	NOUN
ajlm-1363	49	20	,	,	PUNCT
ajlm-1363	49	21	and	and	CCONJ
ajlm-1363	49	22	1	1	NUM
ajlm-1363	49	23	µl	µl	ADP
ajlm-1363	49	24	each	each	PRON
ajlm-1363	49	25	of	of	ADP
ajlm-1363	49	26	the	the	DET
ajlm-1363	49	27	forward	forward	NOUN
ajlm-1363	49	28	and	and	CCONJ
ajlm-1363	49	29	reverse	reverse	ADJ
ajlm-1363	49	30	primers	primer	NOUN
ajlm-1363	49	31	(	(	PUNCT
ajlm-1363	49	32	5	5	NUM
ajlm-1363	49	33	µm	µm	NOUN
ajlm-1363	49	34	)	)	PUNCT
ajlm-1363	49	35	(	(	PUNCT
ajlm-1363	49	36	for	for	ADP
ajlm-1363	49	37	flt3	flt3	PROPN
ajlm-1363	49	38	and	and	CCONJ
ajlm-1363	49	39	npm1	npm1	NOUN
ajlm-1363	49	40	)	)	PUNCT
ajlm-1363	49	41	were	be	AUX
ajlm-1363	49	42	added	add	VERB
ajlm-1363	49	43	to	to	ADP
ajlm-1363	49	44	the	the	DET
ajlm-1363	49	45	pcr	pcr	NOUN
ajlm-1363	49	46	mixture	mixture	NOUN
ajlm-1363	49	47	.	.	PUNCT
ajlm-1363	50	1	a	a	DET
ajlm-1363	50	2	temperature	temperature	NOUN
ajlm-1363	50	3	gradient	gradient	NOUN
ajlm-1363	50	4	experiment	experiment	NOUN
ajlm-1363	50	5	was	be	AUX
ajlm-1363	50	6	used	use	VERB
ajlm-1363	50	7	to	to	PART
ajlm-1363	50	8	determine	determine	VERB
ajlm-1363	50	9	the	the	DET
ajlm-1363	50	10	optimal	optimal	ADJ
ajlm-1363	50	11	pcr	pcr	NOUN
ajlm-1363	50	12	annealing	anneal	VERB
ajlm-1363	50	13	temperature	temperature	NOUN
ajlm-1363	50	14	for	for	ADP
ajlm-1363	50	15	the	the	DET
ajlm-1363	50	16	primers	primer	NOUN
ajlm-1363	50	17	.	.	PUNCT
ajlm-1363	51	1	the	the	DET
ajlm-1363	51	2	gradient	gradient	ADJ
ajlm-1363	51	3	temperatures	temperature	NOUN
ajlm-1363	51	4	ranged	range	VERB
ajlm-1363	51	5	between	between	ADP
ajlm-1363	51	6	65	65	NUM
ajlm-1363	51	7	°	°	NOUN
ajlm-1363	51	8	c	c	NOUN
ajlm-1363	51	9	and	and	CCONJ
ajlm-1363	51	10	70	70	NUM
ajlm-1363	51	11	°	°	NOUN
ajlm-1363	51	12	c	c	VERB
ajlm-1363	51	13	.	.	PUNCT
ajlm-1363	52	1	the	the	DET
ajlm-1363	52	2	subsequent	subsequent	ADJ
ajlm-1363	52	3	pcr	pcr	ADJ
ajlm-1363	52	4	cycling	cycling	NOUN
ajlm-1363	52	5	conditions	condition	NOUN
ajlm-1363	52	6	were	be	AUX
ajlm-1363	52	7	one	one	NUM
ajlm-1363	52	8	cycle	cycle	NOUN
ajlm-1363	52	9	at	at	ADP
ajlm-1363	52	10	95	95	NUM
ajlm-1363	52	11	°	°	ADP
ajlm-1363	52	12	c	c	NOUN
ajlm-1363	52	13	for	for	ADP
ajlm-1363	52	14	10	10	NUM
ajlm-1363	52	15	min	min	NOUN
ajlm-1363	52	16	,	,	PUNCT
ajlm-1363	52	17	45	45	NUM
ajlm-1363	52	18	cycles	cycle	NOUN
ajlm-1363	52	19	of	of	ADP
ajlm-1363	52	20	95	95	NUM
ajlm-1363	52	21	°	°	ADP
ajlm-1363	52	22	c	c	NOUN
ajlm-1363	52	23	for	for	ADP
ajlm-1363	52	24	20	20	NUM
ajlm-1363	52	25	s	s	NOUN
ajlm-1363	52	26	,	,	PUNCT
ajlm-1363	52	27	65	65	NUM
ajlm-1363	52	28	°	°	NOUN
ajlm-1363	52	29	c	c	NOUN
ajlm-1363	52	30	for	for	ADP
ajlm-1363	52	31	40	40	NUM
ajlm-1363	52	32	s	s	NOUN
ajlm-1363	52	33	,	,	PUNCT
ajlm-1363	52	34	and	and	CCONJ
ajlm-1363	52	35	72	72	NUM
ajlm-1363	52	36	°	°	NOUN
ajlm-1363	52	37	c	c	NOUN
ajlm-1363	52	38	for	for	ADP
ajlm-1363	52	39	40	40	NUM
ajlm-1363	52	40	s	s	NOUN
ajlm-1363	52	41	,	,	PUNCT
ajlm-1363	52	42	and	and	CCONJ
ajlm-1363	52	43	a	a	DET
ajlm-1363	52	44	final	final	ADJ
ajlm-1363	52	45	step	step	NOUN
ajlm-1363	52	46	of	of	ADP
ajlm-1363	52	47	one	one	NUM
ajlm-1363	52	48	cycle	cycle	NOUN
ajlm-1363	52	49	at	at	ADP
ajlm-1363	52	50	72	72	NUM
ajlm-1363	52	51	°	°	ADP
ajlm-1363	52	52	c	c	NOUN
ajlm-1363	52	53	for	for	ADP
ajlm-1363	52	54	32	32	NUM
ajlm-1363	52	55	min	min	NOUN
ajlm-1363	52	56	.	.	PROPN
ajlm-1363	52	57	polymerase	polymerase	NOUN
ajlm-1363	52	58	chain	chain	NOUN
ajlm-1363	52	59	reaction	reaction	NOUN
ajlm-1363	52	60	products	product	NOUN
ajlm-1363	52	61	were	be	AUX
ajlm-1363	52	62	subjected	subject	VERB
ajlm-1363	52	63	to	to	ADP
ajlm-1363	52	64	capillary	capillary	ADJ
ajlm-1363	52	65	electrophoresis	electrophoresis	NOUN
ajlm-1363	52	66	(	(	PUNCT
ajlm-1363	52	67	3500	3500	NUM
ajlm-1363	52	68	genetic	genetic	ADJ
ajlm-1363	52	69	analyser	analyser	NOUN
ajlm-1363	52	70	,	,	PUNCT
ajlm-1363	52	71	applied	apply	VERB
ajlm-1363	52	72	biosystems	biosystem	NOUN
ajlm-1363	52	73	,	,	PUNCT
ajlm-1363	52	74	foster	foster	ADJ
ajlm-1363	52	75	city	city	NOUN
ajlm-1363	52	76	,	,	PUNCT
ajlm-1363	52	77	california	california	PROPN
ajlm-1363	52	78	,	,	PUNCT
ajlm-1363	52	79	united	united	PROPN
ajlm-1363	52	80	states	states	PROPN
ajlm-1363	52	81	)	)	PUNCT
ajlm-1363	52	82	.	.	PUNCT
ajlm-1363	53	1	briefly	briefly	NOUN
ajlm-1363	53	2	,	,	PUNCT
ajlm-1363	53	3	1	1	NUM
ajlm-1363	53	4	µl	µl	ADP
ajlm-1363	53	5	of	of	ADP
ajlm-1363	53	6	each	each	DET
ajlm-1363	53	7	sample	sample	NOUN
ajlm-1363	53	8	was	be	AUX
ajlm-1363	53	9	mixed	mix	VERB
ajlm-1363	53	10	with	with	ADP
ajlm-1363	53	11	9.5	9.5	NUM
ajlm-1363	53	12	µl	µl	NOUN
ajlm-1363	53	13	of	of	ADP
ajlm-1363	53	14	hi	hi	ADJ
ajlm-1363	53	15	-	-	PUNCT
ajlm-1363	53	16	di	di	NOUN
ajlm-1363	53	17	™	™	NOUN
ajlm-1363	53	18	formamide	formamide	ADV
ajlm-1363	53	19	(	(	PUNCT
ajlm-1363	53	20	applied	apply	VERB
ajlm-1363	53	21	biosystems	biosystem	NOUN
ajlm-1363	53	22	,	,	PUNCT
ajlm-1363	53	23	foster	foster	ADJ
ajlm-1363	53	24	city	city	NOUN
ajlm-1363	53	25	,	,	PUNCT
ajlm-1363	53	26	california	california	PROPN
ajlm-1363	53	27	,	,	PUNCT
ajlm-1363	53	28	united	united	PROPN
ajlm-1363	53	29	states	states	PROPN
ajlm-1363	53	30	)	)	PUNCT
ajlm-1363	53	31	and	and	CCONJ
ajlm-1363	53	32	0.5	0.5	NUM
ajlm-1363	53	33	µl	µl	ADP
ajlm-1363	53	34	genescan	genescan	ADJ
ajlm-1363	53	35	™	™	NOUN
ajlm-1363	53	36	600	600	NUM
ajlm-1363	53	37	liz	liz	NOUN
ajlm-1363	53	38	™	™	ADJ
ajlm-1363	53	39	size	size	NOUN
ajlm-1363	53	40	standard	standard	NOUN
ajlm-1363	53	41	(	(	PUNCT
ajlm-1363	53	42	applied	apply	VERB
ajlm-1363	53	43	biosystems	biosystem	NOUN
ajlm-1363	53	44	,	,	PUNCT
ajlm-1363	53	45	foster	foster	ADJ
ajlm-1363	53	46	city	city	NOUN
ajlm-1363	53	47	,	,	PUNCT
ajlm-1363	53	48	california	california	PROPN
ajlm-1363	53	49	,	,	PUNCT
ajlm-1363	53	50	united	united	PROPN
ajlm-1363	53	51	states	states	PROPN
ajlm-1363	53	52	)	)	PUNCT
ajlm-1363	53	53	.	.	PUNCT
ajlm-1363	54	1	the	the	DET
ajlm-1363	54	2	optimal	optimal	ADJ
ajlm-1363	54	3	primer	primer	NOUN
ajlm-1363	54	4	concentrations	concentration	NOUN
ajlm-1363	54	5	(	(	PUNCT
ajlm-1363	54	6	5	5	NUM
ajlm-1363	54	7	µm	µm	NOUN
ajlm-1363	54	8	)	)	PUNCT
ajlm-1363	54	9	and	and	CCONJ
ajlm-1363	54	10	dna	dna	PROPN
ajlm-1363	54	11	limit	limit	NOUN
ajlm-1363	54	12	of	of	ADP
ajlm-1363	54	13	detection	detection	NOUN
ajlm-1363	54	14	were	be	AUX
ajlm-1363	54	15	determined	determine	VERB
ajlm-1363	54	16	as	as	ADP
ajlm-1363	54	17	part	part	NOUN
ajlm-1363	54	18	of	of	ADP
ajlm-1363	54	19	the	the	DET
ajlm-1363	54	20	optimisation	optimisation	NOUN
ajlm-1363	54	21	procedure	procedure	NOUN
ajlm-1363	54	22	.	.	PUNCT
ajlm-1363	55	1	the	the	DET
ajlm-1363	55	2	npm1	npm1	NOUN
ajlm-1363	55	3	and	and	CCONJ
ajlm-1363	55	4	flt3	flt3	PROPN
ajlm-1363	55	5	-	-	PUNCT
ajlm-1363	55	6	itd	itd	PROPN
ajlm-1363	55	7	multiplex	multiplex	PROPN
ajlm-1363	55	8	pcr	pcr	PROPN
ajlm-1363	55	9	assay	assay	PROPN
ajlm-1363	55	10	had	have	VERB
ajlm-1363	55	11	a	a	DET
ajlm-1363	55	12	lower	low	ADJ
ajlm-1363	55	13	limit	limit	NOUN
ajlm-1363	55	14	of	of	ADP
ajlm-1363	55	15	detection	detection	NOUN
ajlm-1363	55	16	of	of	ADP
ajlm-1363	55	17	0.8	0.8	NUM
ajlm-1363	55	18	ng/µl	ng/µl	NUM
ajlm-1363	55	19	.	.	PUNCT
ajlm-1363	56	1	capillary	capillary	ADJ
ajlm-1363	56	2	electrophoretic	electrophoretic	ADJ
ajlm-1363	56	3	results	result	NOUN
ajlm-1363	56	4	were	be	AUX
ajlm-1363	56	5	analysed	analyse	VERB
ajlm-1363	56	6	using	use	VERB
ajlm-1363	56	7	genemapper	genemapper	ADJ
ajlm-1363	56	8	version	version	NOUN
ajlm-1363	56	9	6	6	NUM
ajlm-1363	56	10	software	software	NOUN
ajlm-1363	56	11	(	(	PUNCT
ajlm-1363	56	12	applied	apply	VERB
ajlm-1363	56	13	biosystems	biosystem	NOUN
ajlm-1363	56	14	,	,	PUNCT
ajlm-1363	56	15	foster	foster	ADJ
ajlm-1363	56	16	city	city	NOUN
ajlm-1363	56	17	,	,	PUNCT
ajlm-1363	56	18	california	california	PROPN
ajlm-1363	56	19	,	,	PUNCT
ajlm-1363	56	20	united	united	PROPN
ajlm-1363	56	21	states	states	PROPN
ajlm-1363	56	22	)	)	PUNCT
ajlm-1363	56	23	.	.	PUNCT
ajlm-1363	57	1	npm1	npm1	NOUN
ajlm-1363	57	2	and	and	CCONJ
ajlm-1363	57	3	flt3	flt3	PROPN
ajlm-1363	57	4	-	-	PUNCT
ajlm-1363	57	5	itd	itd	NOUN
ajlm-1363	57	6	detection	detection	NOUN
ajlm-1363	57	7	in	in	ADP
ajlm-1363	57	8	acute	acute	ADJ
ajlm-1363	57	9	myeloid	myeloid	ADJ
ajlm-1363	57	10	leukaemia	leukaemia	NOUN
ajlm-1363	57	11	patients	patient	NOUN
ajlm-1363	57	12	the	the	DET
ajlm-1363	57	13	optimised	optimise	VERB
ajlm-1363	57	14	npm1	npm1	NOUN
ajlm-1363	57	15	and	and	CCONJ
ajlm-1363	57	16	flt3	flt3	PROPN
ajlm-1363	57	17	-	-	PUNCT
ajlm-1363	57	18	itd	itd	PROPN
ajlm-1363	57	19	multiplex	multiplex	PROPN
ajlm-1363	57	20	pcr	pcr	PROPN
ajlm-1363	57	21	was	be	AUX
ajlm-1363	57	22	used	use	VERB
ajlm-1363	57	23	to	to	PART
ajlm-1363	57	24	screen	screen	VERB
ajlm-1363	57	25	the	the	DET
ajlm-1363	57	26	40	40	NUM
ajlm-1363	57	27	de	de	PROPN
ajlm-1363	57	28	novo	novo	PROPN
ajlm-1363	57	29	aml	aml	PROPN
ajlm-1363	57	30	patients	patient	NOUN
ajlm-1363	57	31	for	for	ADP
ajlm-1363	57	32	the	the	DET
ajlm-1363	57	33	respective	respective	ADJ
ajlm-1363	57	34	mutations	mutation	NOUN
ajlm-1363	57	35	.	.	PUNCT
ajlm-1363	58	1	positive	positive	ADJ
ajlm-1363	58	2	and	and	CCONJ
ajlm-1363	58	3	negative	negative	ADJ
ajlm-1363	58	4	controls	control	NOUN
ajlm-1363	58	5	,	,	PUNCT
ajlm-1363	58	6	as	as	ADV
ajlm-1363	58	7	well	well	ADV
ajlm-1363	58	8	as	as	ADP
ajlm-1363	58	9	a	a	DET
ajlm-1363	58	10	no	no	DET
ajlm-1363	58	11	-	-	PUNCT
ajlm-1363	58	12	template	template	NOUN
ajlm-1363	58	13	control	control	NOUN
ajlm-1363	58	14	,	,	PUNCT
ajlm-1363	58	15	were	be	AUX
ajlm-1363	58	16	included	include	VERB
ajlm-1363	58	17	in	in	ADP
ajlm-1363	58	18	each	each	DET
ajlm-1363	58	19	subsequent	subsequent	ADJ
ajlm-1363	58	20	run	run	NOUN
ajlm-1363	58	21	for	for	ADP
ajlm-1363	58	22	quality	quality	NOUN
ajlm-1363	58	23	control	control	NOUN
ajlm-1363	58	24	purposes	purpose	NOUN
ajlm-1363	58	25	.	.	PUNCT
ajlm-1363	59	1	the	the	DET
ajlm-1363	59	2	npm1	npm1	NOUN
ajlm-1363	59	3	and	and	CCONJ
ajlm-1363	59	4	flt3	flt3	NOUN
ajlm-1363	59	5	-	-	PUNCT
ajlm-1363	59	6	itd	itd	ADJ
ajlm-1363	59	7	wild	wild	ADJ
ajlm-1363	59	8	-	-	PUNCT
ajlm-1363	59	9	type	type	NOUN
ajlm-1363	59	10	amplicon	amplicon	NOUN
ajlm-1363	59	11	sizes	size	NOUN
ajlm-1363	59	12	were	be	AUX
ajlm-1363	59	13	expected	expect	VERB
ajlm-1363	59	14	to	to	PART
ajlm-1363	59	15	be	be	AUX
ajlm-1363	59	16	170	170	NUM
ajlm-1363	59	17	base	base	NOUN
ajlm-1363	59	18	pairs	pair	NOUN
ajlm-1363	59	19	(	(	PUNCT
ajlm-1363	59	20	bp	bp	PROPN
ajlm-1363	59	21	)	)	PUNCT
ajlm-1363	59	22	and	and	CCONJ
ajlm-1363	59	23	330	330	NUM
ajlm-1363	59	24	bp	bp	NOUN
ajlm-1363	59	25	.	.	PUNCT
ajlm-1363	60	1	the	the	DET
ajlm-1363	60	2	npm1	npm1	NOUN
ajlm-1363	60	3	positive	positive	ADJ
ajlm-1363	60	4	samples	sample	NOUN
ajlm-1363	60	5	were	be	AUX
ajlm-1363	60	6	expected	expect	VERB
ajlm-1363	60	7	to	to	PART
ajlm-1363	60	8	have	have	VERB
ajlm-1363	60	9	an	an	DET
ajlm-1363	60	10	amplicon	amplicon	NOUN
ajlm-1363	60	11	at	at	ADP
ajlm-1363	60	12	170	170	NUM
ajlm-1363	60	13	bp	bp	NOUN
ajlm-1363	60	14	for	for	ADP
ajlm-1363	60	15	the	the	DET
ajlm-1363	60	16	wild	wild	ADJ
ajlm-1363	60	17	-	-	PUNCT
ajlm-1363	60	18	type	type	NOUN
ajlm-1363	60	19	and	and	CCONJ
ajlm-1363	60	20	an	an	DET
ajlm-1363	60	21	additional	additional	ADJ
ajlm-1363	60	22	amplicon	amplicon	NOUN
ajlm-1363	60	23	at	at	ADP
ajlm-1363	60	24	174	174	NUM
ajlm-1363	60	25	bp	bp	PROPN
ajlm-1363	60	26	.	.	PUNCT
ajlm-1363	61	1	fms	fms	PROPN
ajlm-1363	61	2	-	-	PUNCT
ajlm-1363	61	3	related	relate	VERB
ajlm-1363	61	4	tyrosine	tyrosine	NOUN
ajlm-1363	61	5	kinase	kinase	NOUN
ajlm-1363	61	6	3	3	NUM
ajlm-1363	61	7	-	-	PUNCT
ajlm-1363	61	8	itd	itd	ADJ
ajlm-1363	61	9	positive	positive	ADJ
ajlm-1363	61	10	samples	sample	NOUN
ajlm-1363	61	11	were	be	AUX
ajlm-1363	61	12	expected	expect	VERB
ajlm-1363	61	13	to	to	PART
ajlm-1363	61	14	have	have	VERB
ajlm-1363	61	15	an	an	DET
ajlm-1363	61	16	amplicon	amplicon	NOUN
ajlm-1363	61	17	at	at	ADP
ajlm-1363	61	18	330	330	NUM
ajlm-1363	61	19	bp	bp	NOUN
ajlm-1363	61	20	and	and	CCONJ
ajlm-1363	61	21	an	an	DET
ajlm-1363	61	22	additional	additional	ADJ
ajlm-1363	61	23	amplicon	amplicon	NOUN
ajlm-1363	61	24	larger	large	ADJ
ajlm-1363	61	25	than	than	ADP
ajlm-1363	61	26	330	330	NUM
ajlm-1363	61	27	bp	bp	NOUN
ajlm-1363	61	28	.	.	PUNCT
ajlm-1363	62	1	the	the	DET
ajlm-1363	62	2	allele	allele	NOUN
ajlm-1363	62	3	ratio	ratio	NOUN
ajlm-1363	62	4	for	for	ADP
ajlm-1363	62	5	the	the	DET
ajlm-1363	62	6	respective	respective	ADJ
ajlm-1363	62	7	mutations	mutation	NOUN
ajlm-1363	62	8	in	in	ADP
ajlm-1363	62	9	each	each	DET
ajlm-1363	62	10	patient	patient	NOUN
ajlm-1363	62	11	was	be	AUX
ajlm-1363	62	12	calculated	calculate	VERB
ajlm-1363	62	13	by	by	ADP
ajlm-1363	62	14	determining	determine	VERB
ajlm-1363	62	15	the	the	DET
ajlm-1363	62	16	area	area	NOUN
ajlm-1363	62	17	under	under	ADP
ajlm-1363	62	18	the	the	DET
ajlm-1363	62	19	curve	curve	NOUN
ajlm-1363	62	20	for	for	ADP
ajlm-1363	62	21	the	the	DET
ajlm-1363	62	22	mutant	mutant	NOUN
ajlm-1363	62	23	to	to	ADP
ajlm-1363	62	24	wild	wild	ADJ
ajlm-1363	62	25	-	-	PUNCT
ajlm-1363	62	26	type	type	NOUN
ajlm-1363	62	27	alleles	allele	NOUN
ajlm-1363	62	28	,	,	PUNCT
ajlm-1363	62	29	expressed	express	VERB
ajlm-1363	62	30	as	as	ADP
ajlm-1363	62	31	a	a	DET
ajlm-1363	62	32	percentage	percentage	NOUN
ajlm-1363	62	33	.	.	PUNCT
ajlm-1363	63	1	the	the	DET
ajlm-1363	63	2	respective	respective	ADJ
ajlm-1363	63	3	positive	positive	ADJ
ajlm-1363	63	4	and	and	CCONJ
ajlm-1363	63	5	negative	negative	ADJ
ajlm-1363	63	6	controls	control	NOUN
ajlm-1363	63	7	yielded	yield	VERB
ajlm-1363	63	8	the	the	DET
ajlm-1363	63	9	expected	expect	VERB
ajlm-1363	63	10	amplicon	amplicon	NOUN
ajlm-1363	63	11	sizes	size	NOUN
ajlm-1363	63	12	upon	upon	SCONJ
ajlm-1363	63	13	evaluation	evaluation	NOUN
ajlm-1363	63	14	of	of	ADP
ajlm-1363	63	15	the	the	DET
ajlm-1363	63	16	capillary	capillary	ADJ
ajlm-1363	63	17	electrophoresis	electrophoresis	NOUN
ajlm-1363	63	18	results	result	NOUN
ajlm-1363	63	19	(	(	PUNCT
ajlm-1363	63	20	figure	figure	NOUN
ajlm-1363	63	21	1	1	NUM
ajlm-1363	63	22	)	)	PUNCT
ajlm-1363	63	23	.	.	PUNCT
ajlm-1363	64	1	figure	figure	NOUN
ajlm-1363	64	2	1	1	NUM
ajlm-1363	64	3	:	:	PUNCT
ajlm-1363	64	4	observed	observe	VERB
ajlm-1363	64	5	capillary	capillary	ADJ
ajlm-1363	64	6	electropherograms	electropherogram	NOUN
ajlm-1363	64	7	of	of	ADP
ajlm-1363	64	8	the	the	DET
ajlm-1363	64	9	npm1	npm1	NOUN
ajlm-1363	64	10	and	and	CCONJ
ajlm-1363	64	11	flt3	flt3	PROPN
ajlm-1363	64	12	control	control	NOUN
ajlm-1363	64	13	samples	sample	NOUN
ajlm-1363	64	14	(	(	PUNCT
ajlm-1363	64	15	february	february	PROPN
ajlm-1363	64	16	2020	2020	NUM
ajlm-1363	64	17	,	,	PUNCT
ajlm-1363	64	18	bloemfontein	bloemfontein	NOUN
ajlm-1363	64	19	,	,	PUNCT
ajlm-1363	64	20	free	free	ADJ
ajlm-1363	64	21	state	state	NOUN
ajlm-1363	64	22	,	,	PUNCT
ajlm-1363	64	23	south	south	PROPN
ajlm-1363	64	24	africa	africa	PROPN
ajlm-1363	64	25	)	)	PUNCT
ajlm-1363	64	26	.	.	PUNCT
ajlm-1363	65	1	(	(	PUNCT
ajlm-1363	65	2	a	a	X
ajlm-1363	65	3	)	)	PUNCT
ajlm-1363	65	4	npm1	npm1	NOUN
ajlm-1363	65	5	positive	positive	ADJ
ajlm-1363	65	6	control	control	NOUN
ajlm-1363	65	7	with	with	ADP
ajlm-1363	65	8	an	an	DET
ajlm-1363	65	9	additional	additional	ADJ
ajlm-1363	65	10	amplicon	amplicon	NOUN
ajlm-1363	65	11	at	at	ADP
ajlm-1363	65	12	174	174	NUM
ajlm-1363	65	13	base	base	NOUN
ajlm-1363	65	14	pairs	pair	NOUN
ajlm-1363	65	15	representing	represent	VERB
ajlm-1363	65	16	the	the	DET
ajlm-1363	65	17	4	4	NUM
ajlm-1363	65	18	base	base	NOUN
ajlm-1363	65	19	pairs	pair	NOUN
ajlm-1363	65	20	insertion	insertion	NOUN
ajlm-1363	65	21	,	,	PUNCT
ajlm-1363	65	22	and	and	CCONJ
ajlm-1363	65	23	wild	wild	ADJ
ajlm-1363	65	24	-	-	PUNCT
ajlm-1363	65	25	type	type	NOUN
ajlm-1363	65	26	flt3	flt3	NOUN
ajlm-1363	65	27	-	-	PUNCT
ajlm-1363	65	28	itd	itd	NOUN
ajlm-1363	65	29	at	at	ADP
ajlm-1363	65	30	330	330	NUM
ajlm-1363	65	31	base	base	NOUN
ajlm-1363	65	32	pairs	pair	NOUN
ajlm-1363	65	33	.	.	PUNCT
ajlm-1363	66	1	(	(	PUNCT
ajlm-1363	66	2	b	b	X
ajlm-1363	66	3	)	)	PUNCT
ajlm-1363	66	4	flt3	flt3	NOUN
ajlm-1363	66	5	-	-	PUNCT
ajlm-1363	66	6	itd	itd	ADJ
ajlm-1363	66	7	positive	positive	ADJ
ajlm-1363	66	8	control	control	NOUN
ajlm-1363	66	9	with	with	ADP
ajlm-1363	66	10	an	an	DET
ajlm-1363	66	11	additional	additional	ADJ
ajlm-1363	66	12	amplicon	amplicon	NOUN
ajlm-1363	66	13	at	at	ADP
ajlm-1363	66	14	405	405	NUM
ajlm-1363	66	15	base	base	NOUN
ajlm-1363	66	16	pairs	pair	NOUN
ajlm-1363	66	17	,	,	PUNCT
ajlm-1363	66	18	representing	represent	VERB
ajlm-1363	66	19	the	the	DET
ajlm-1363	66	20	75	75	NUM
ajlm-1363	66	21	base	base	NOUN
ajlm-1363	66	22	pairs	pair	NOUN
ajlm-1363	66	23	internal	internal	ADJ
ajlm-1363	66	24	tandem	tandem	NOUN
ajlm-1363	66	25	duplication	duplication	NOUN
ajlm-1363	66	26	and	and	CCONJ
ajlm-1363	66	27	npm1	npm1	NOUN
ajlm-1363	66	28	wild	wild	ADJ
ajlm-1363	66	29	-	-	PUNCT
ajlm-1363	66	30	type	type	NOUN
ajlm-1363	66	31	at	at	ADP
ajlm-1363	66	32	170	170	NUM
ajlm-1363	66	33	base	base	NOUN
ajlm-1363	66	34	pairs	pair	NOUN
ajlm-1363	66	35	.	.	PUNCT
ajlm-1363	67	1	(	(	PUNCT
ajlm-1363	67	2	c	c	X
ajlm-1363	67	3	)	)	PUNCT
ajlm-1363	67	4	npm1	npm1	NOUN
ajlm-1363	67	5	and	and	CCONJ
ajlm-1363	67	6	flt3	flt3	NOUN
ajlm-1363	67	7	-	-	PUNCT
ajlm-1363	67	8	itd	itd	ADJ
ajlm-1363	67	9	negative	negative	ADJ
ajlm-1363	67	10	control	control	NOUN
ajlm-1363	67	11	with	with	ADP
ajlm-1363	67	12	expected	expect	VERB
ajlm-1363	67	13	amplicons	amplicon	NOUN
ajlm-1363	67	14	at	at	ADP
ajlm-1363	67	15	170	170	NUM
ajlm-1363	67	16	base	base	NOUN
ajlm-1363	67	17	pairs	pair	NOUN
ajlm-1363	67	18	and	and	CCONJ
ajlm-1363	67	19	330	330	NUM
ajlm-1363	67	20	base	base	NOUN
ajlm-1363	67	21	pairs	pair	NOUN
ajlm-1363	67	22	.	.	PUNCT
ajlm-1363	68	1	sanger	sanger	PROPN
ajlm-1363	68	2	sequencing	sequencing	NOUN
ajlm-1363	68	3	of	of	ADP
ajlm-1363	68	4	npm1	npm1	NOUN
ajlm-1363	68	5	and	and	CCONJ
ajlm-1363	68	6	flt3	flt3	NOUN
ajlm-1363	68	7	-	-	PUNCT
ajlm-1363	68	8	itd	itd	NOUN
ajlm-1363	68	9	amplicons	amplicon	NOUN
ajlm-1363	68	10	npm1	npm1	NOUN
ajlm-1363	68	11	and	and	CCONJ
ajlm-1363	68	12	flt3	flt3	NOUN
ajlm-1363	68	13	-	-	PUNCT
ajlm-1363	68	14	itd	itd	NOUN
ajlm-1363	68	15	control	control	NOUN
ajlm-1363	68	16	samples	sample	NOUN
ajlm-1363	68	17	,	,	PUNCT
ajlm-1363	68	18	as	as	ADV
ajlm-1363	68	19	well	well	ADV
ajlm-1363	68	20	as	as	ADP
ajlm-1363	68	21	the	the	DET
ajlm-1363	68	22	amplicons	amplicon	NOUN
ajlm-1363	68	23	from	from	ADP
ajlm-1363	68	24	the	the	DET
ajlm-1363	68	25	40	40	NUM
ajlm-1363	68	26	patient	patient	NOUN
ajlm-1363	68	27	samples	sample	NOUN
ajlm-1363	68	28	,	,	PUNCT
ajlm-1363	68	29	were	be	AUX
ajlm-1363	68	30	sequenced	sequence	VERB
ajlm-1363	68	31	to	to	PART
ajlm-1363	68	32	confirm	confirm	VERB
ajlm-1363	68	33	and	and	CCONJ
ajlm-1363	68	34	validate	validate	VERB
ajlm-1363	68	35	the	the	DET
ajlm-1363	68	36	pcr	pcr	ADJ
ajlm-1363	68	37	results	result	NOUN
ajlm-1363	68	38	.	.	PUNCT
ajlm-1363	69	1	sequencing	sequence	VERB
ajlm-1363	69	2	reactions	reaction	NOUN
ajlm-1363	69	3	for	for	ADP
ajlm-1363	69	4	the	the	DET
ajlm-1363	69	5	npm1	npm1	NOUN
ajlm-1363	69	6	and	and	CCONJ
ajlm-1363	69	7	flt3	flt3	NOUN
ajlm-1363	69	8	-	-	PUNCT
ajlm-1363	69	9	itd	itd	NOUN
ajlm-1363	69	10	mutations	mutation	NOUN
ajlm-1363	69	11	were	be	AUX
ajlm-1363	69	12	prepared	prepare	VERB
ajlm-1363	69	13	separately	separately	ADV
ajlm-1363	69	14	using	use	VERB
ajlm-1363	69	15	primers	primer	NOUN
ajlm-1363	69	16	as	as	ADP
ajlm-1363	69	17	listed	list	VERB
ajlm-1363	69	18	above	above	ADV
ajlm-1363	69	19	(	(	PUNCT
ajlm-1363	69	20	primers	primer	NOUN
ajlm-1363	69	21	for	for	ADP
ajlm-1363	69	22	sequencing	sequence	VERB
ajlm-1363	69	23	were	be	AUX
ajlm-1363	69	24	not	not	PART
ajlm-1363	69	25	fluorescently	fluorescently	ADV
ajlm-1363	69	26	labelled	label	VERB
ajlm-1363	69	27	)	)	PUNCT
ajlm-1363	69	28	.	.	PUNCT
ajlm-1363	70	1	the	the	DET
ajlm-1363	70	2	pcr	pcr	PROPN
ajlm-1363	70	3	products	product	NOUN
ajlm-1363	70	4	were	be	AUX
ajlm-1363	70	5	purified	purify	VERB
ajlm-1363	70	6	using	use	VERB
ajlm-1363	70	7	the	the	DET
ajlm-1363	70	8	exosap	exosap	NOUN
ajlm-1363	70	9	-	-	PUNCT
ajlm-1363	70	10	it	it	PRON
ajlm-1363	70	11	®	®	NOUN
ajlm-1363	70	12	express	express	VERB
ajlm-1363	70	13	pcr	pcr	ADJ
ajlm-1363	70	14	product	product	NOUN
ajlm-1363	70	15	clean	clean	ADJ
ajlm-1363	70	16	-	-	PUNCT
ajlm-1363	70	17	up	up	NOUN
ajlm-1363	70	18	(	(	PUNCT
ajlm-1363	70	19	affymetrix	affymetrix	ADJ
ajlm-1363	70	20	,	,	PUNCT
ajlm-1363	70	21	santa	santa	PROPN
ajlm-1363	70	22	clara	clara	PROPN
ajlm-1363	70	23	,	,	PUNCT
ajlm-1363	70	24	california	california	PROPN
ajlm-1363	70	25	,	,	PUNCT
ajlm-1363	70	26	united	united	PROPN
ajlm-1363	70	27	states	states	PROPN
ajlm-1363	70	28	)	)	PUNCT
ajlm-1363	70	29	as	as	ADP
ajlm-1363	70	30	per	per	ADP
ajlm-1363	70	31	the	the	DET
ajlm-1363	70	32	manufacturer	manufacturer	NOUN
ajlm-1363	70	33	’s	’s	PART
ajlm-1363	70	34	instructions	instruction	NOUN
ajlm-1363	70	35	.	.	PUNCT
ajlm-1363	71	1	sanger	sanger	PROPN
ajlm-1363	71	2	sequencing	sequence	VERB
ajlm-1363	71	3	reactions	reaction	NOUN
ajlm-1363	71	4	were	be	AUX
ajlm-1363	71	5	prepared	prepare	VERB
ajlm-1363	71	6	using	use	VERB
ajlm-1363	71	7	the	the	DET
ajlm-1363	71	8	bigdye	bigdye	NOUN
ajlm-1363	71	9	™	™	ADJ
ajlm-1363	71	10	terminator	terminator	NOUN
ajlm-1363	71	11	version	version	NOUN
ajlm-1363	71	12	3.1	3.1	NUM
ajlm-1363	71	13	kit	kit	NOUN
ajlm-1363	71	14	(	(	PUNCT
ajlm-1363	71	15	applied	apply	VERB
ajlm-1363	71	16	biosystems	biosystem	NOUN
ajlm-1363	71	17	,	,	PUNCT
ajlm-1363	71	18	foster	foster	ADJ
ajlm-1363	71	19	city	city	NOUN
ajlm-1363	71	20	,	,	PUNCT
ajlm-1363	71	21	california	california	PROPN
ajlm-1363	71	22	,	,	PUNCT
ajlm-1363	71	23	united	united	PROPN
ajlm-1363	71	24	states	states	PROPN
ajlm-1363	71	25	)	)	PUNCT
ajlm-1363	71	26	as	as	ADP
ajlm-1363	71	27	per	per	ADP
ajlm-1363	71	28	the	the	DET
ajlm-1363	71	29	manufacturer	manufacturer	NOUN
ajlm-1363	71	30	’s	’s	PART
ajlm-1363	71	31	instructions	instruction	NOUN
ajlm-1363	71	32	.	.	PUNCT
ajlm-1363	72	1	briefly	briefly	ADV
ajlm-1363	72	2	,	,	PUNCT
ajlm-1363	72	3	the	the	DET
ajlm-1363	72	4	sequencing	sequence	VERB
ajlm-1363	72	5	reaction	reaction	NOUN
ajlm-1363	72	6	consisted	consist	VERB
ajlm-1363	72	7	of	of	ADP
ajlm-1363	72	8	2	2	NUM
ajlm-1363	72	9	µl	µl	ADP
ajlm-1363	72	10	sequencing	sequence	VERB
ajlm-1363	72	11	reaction	reaction	NOUN
ajlm-1363	72	12	mix	mix	NOUN
ajlm-1363	72	13	(	(	PUNCT
ajlm-1363	72	14	bigdye	bigdye	NOUN
ajlm-1363	72	15	™	™	NOUN
ajlm-1363	72	16	terminator	terminator	NOUN
ajlm-1363	72	17	v3.1	v3.1	ADP
ajlm-1363	72	18	)	)	PUNCT
ajlm-1363	72	19	,	,	PUNCT
ajlm-1363	72	20	1	1	NUM
ajlm-1363	72	21	µl	µl	ADP
ajlm-1363	72	22	sequencing	sequence	VERB
ajlm-1363	72	23	buffer	buffer	NOUN
ajlm-1363	72	24	(	(	PUNCT
ajlm-1363	72	25	bigdye	bigdye	NOUN
ajlm-1363	72	26	™	™	NOUN
ajlm-1363	72	27	terminator	terminator	NOUN
ajlm-1363	72	28	v3.1	v3.1	ADP
ajlm-1363	72	29	)	)	PUNCT
ajlm-1363	72	30	,	,	PUNCT
ajlm-1363	72	31	5	5	NUM
ajlm-1363	72	32	µl	µl	ADP
ajlm-1363	72	33	nuclease	nuclease	NOUN
ajlm-1363	72	34	-	-	PUNCT
ajlm-1363	72	35	free	free	ADJ
ajlm-1363	72	36	water	water	NOUN
ajlm-1363	72	37	,	,	PUNCT
ajlm-1363	72	38	1	1	NUM
ajlm-1363	72	39	µl	µl	ADP
ajlm-1363	72	40	forward	forward	ADJ
ajlm-1363	72	41	primer	primer	NOUN
ajlm-1363	72	42	(	(	PUNCT
ajlm-1363	72	43	flt3	flt3	PROPN
ajlm-1363	72	44	or	or	CCONJ
ajlm-1363	72	45	npm1	npm1	NOUN
ajlm-1363	72	46	)	)	PUNCT
ajlm-1363	72	47	,	,	PUNCT
ajlm-1363	72	48	1	1	NUM
ajlm-1363	72	49	µl	µl	ADP
ajlm-1363	72	50	reverse	reverse	ADJ
ajlm-1363	72	51	primer	primer	NOUN
ajlm-1363	72	52	(	(	PUNCT
ajlm-1363	72	53	flt3	flt3	NOUN
ajlm-1363	72	54	-	-	PUNCT
ajlm-1363	72	55	itd	itd	NOUN
ajlm-1363	72	56	or	or	CCONJ
ajlm-1363	72	57	npm1	npm1	NOUN
ajlm-1363	72	58	)	)	PUNCT
ajlm-1363	72	59	and	and	CCONJ
ajlm-1363	72	60	1	1	NUM
ajlm-1363	72	61	µl	µl	ADP
ajlm-1363	72	62	pcr	pcr	ADJ
ajlm-1363	72	63	product	product	NOUN
ajlm-1363	72	64	.	.	PUNCT
ajlm-1363	73	1	the	the	DET
ajlm-1363	73	2	sequencing	sequence	VERB
ajlm-1363	73	3	reaction	reaction	NOUN
ajlm-1363	73	4	was	be	AUX
ajlm-1363	73	5	subjected	subject	VERB
ajlm-1363	73	6	to	to	ADP
ajlm-1363	73	7	the	the	DET
ajlm-1363	73	8	following	follow	VERB
ajlm-1363	73	9	cycling	cycling	NOUN
ajlm-1363	73	10	conditions	condition	NOUN
ajlm-1363	73	11	in	in	ADP
ajlm-1363	73	12	a	a	DET
ajlm-1363	73	13	2720	2720	NUM
ajlm-1363	73	14	thermal	thermal	ADJ
ajlm-1363	73	15	cycler	cycler	NOUN
ajlm-1363	73	16	(	(	PUNCT
ajlm-1363	73	17	applied	apply	VERB
ajlm-1363	73	18	biosystems	biosystem	NOUN
ajlm-1363	73	19	,	,	PUNCT
ajlm-1363	73	20	foster	foster	ADJ
ajlm-1363	73	21	city	city	NOUN
ajlm-1363	73	22	,	,	PUNCT
ajlm-1363	73	23	california	california	PROPN
ajlm-1363	73	24	,	,	PUNCT
ajlm-1363	73	25	united	united	PROPN
ajlm-1363	73	26	states	states	PROPN
ajlm-1363	73	27	):	):	PUNCT
ajlm-1363	73	28	one	one	NUM
ajlm-1363	73	29	cycle	cycle	NOUN
ajlm-1363	73	30	at	at	ADP
ajlm-1363	73	31	96	96	NUM
ajlm-1363	73	32	°	°	ADP
ajlm-1363	73	33	c	c	NOUN
ajlm-1363	73	34	for	for	ADP
ajlm-1363	73	35	1	1	NUM
ajlm-1363	73	36	min	min	NOUN
ajlm-1363	73	37	,	,	PUNCT
ajlm-1363	73	38	and	and	CCONJ
ajlm-1363	73	39	25	25	NUM
ajlm-1363	73	40	cycles	cycle	NOUN
ajlm-1363	73	41	at	at	ADP
ajlm-1363	73	42	96	96	NUM
ajlm-1363	73	43	°	°	ADP
ajlm-1363	73	44	c	c	NOUN
ajlm-1363	73	45	for	for	ADP
ajlm-1363	73	46	10	10	NUM
ajlm-1363	73	47	s	s	NOUN
ajlm-1363	73	48	,	,	PUNCT
ajlm-1363	73	49	50	50	NUM
ajlm-1363	73	50	°	°	NOUN
ajlm-1363	73	51	c	c	NOUN
ajlm-1363	73	52	for	for	ADP
ajlm-1363	73	53	5	5	NUM
ajlm-1363	73	54	s	s	NOUN
ajlm-1363	73	55	,	,	PUNCT
ajlm-1363	73	56	and	and	CCONJ
ajlm-1363	74	1	60	60	NUM
ajlm-1363	74	2	°	°	NUM
ajlm-1363	74	3	c	c	NOUN
ajlm-1363	74	4	for	for	ADP
ajlm-1363	74	5	4	4	NUM
ajlm-1363	74	6	min	min	NOUN
ajlm-1363	74	7	.	.	PROPN
ajlm-1363	74	8	sequence	sequence	NOUN
ajlm-1363	74	9	reactions	reaction	NOUN
ajlm-1363	74	10	were	be	AUX
ajlm-1363	74	11	cleaned	clean	VERB
ajlm-1363	74	12	up	up	ADP
ajlm-1363	74	13	with	with	ADP
ajlm-1363	74	14	the	the	DET
ajlm-1363	74	15	zymo	zymo	NOUN
ajlm-1363	74	16	research	research	NOUN
ajlm-1363	74	17	dna	dna	NOUN
ajlm-1363	74	18	sequencing	sequence	VERB
ajlm-1363	74	19	clean	clean	ADJ
ajlm-1363	74	20	-	-	PUNCT
ajlm-1363	74	21	up	up	ADP
ajlm-1363	74	22	kit	kit	NOUN
ajlm-1363	74	23	™	™	PROPN
ajlm-1363	74	24	(	(	PUNCT
ajlm-1363	74	25	promega	promega	PROPN
ajlm-1363	74	26	madison	madison	PROPN
ajlm-1363	74	27	,	,	PUNCT
ajlm-1363	74	28	wisconsin	wisconsin	PROPN
ajlm-1363	74	29	,	,	PUNCT
ajlm-1363	74	30	united	united	PROPN
ajlm-1363	74	31	states	states	PROPN
ajlm-1363	74	32	)	)	PUNCT
ajlm-1363	74	33	as	as	ADP
ajlm-1363	74	34	per	per	ADP
ajlm-1363	74	35	the	the	DET
ajlm-1363	74	36	manufacturer	manufacturer	NOUN
ajlm-1363	74	37	’s	’s	PART
ajlm-1363	74	38	instructions	instruction	NOUN
ajlm-1363	74	39	.	.	PUNCT
ajlm-1363	75	1	sequence	sequence	NOUN
ajlm-1363	75	2	raw	raw	ADJ
ajlm-1363	75	3	reads	read	NOUN
ajlm-1363	75	4	were	be	AUX
ajlm-1363	75	5	loaded	load	VERB
ajlm-1363	75	6	onto	onto	ADP
ajlm-1363	75	7	the	the	DET
ajlm-1363	75	8	3500	3500	NUM
ajlm-1363	75	9	genetic	genetic	ADJ
ajlm-1363	75	10	analyser	analyser	NOUN
ajlm-1363	75	11	(	(	PUNCT
ajlm-1363	75	12	applied	apply	VERB
ajlm-1363	75	13	biosystems	biosystem	NOUN
ajlm-1363	75	14	,	,	PUNCT
ajlm-1363	75	15	foster	foster	ADJ
ajlm-1363	75	16	city	city	NOUN
ajlm-1363	75	17	,	,	PUNCT
ajlm-1363	75	18	california	california	PROPN
ajlm-1363	75	19	,	,	PUNCT
ajlm-1363	75	20	united	united	PROPN
ajlm-1363	75	21	states	states	PROPN
ajlm-1363	75	22	)	)	PUNCT
ajlm-1363	75	23	.	.	PUNCT
ajlm-1363	76	1	for	for	ADP
ajlm-1363	76	2	comparison	comparison	NOUN
ajlm-1363	76	3	,	,	PUNCT
ajlm-1363	76	4	sample	sample	NOUN
ajlm-1363	76	5	sequences	sequence	NOUN
ajlm-1363	76	6	were	be	AUX
ajlm-1363	76	7	aligned	align	VERB
ajlm-1363	76	8	against	against	ADP
ajlm-1363	76	9	npm1	npm1	NOUN
ajlm-1363	76	10	(	(	PUNCT
ajlm-1363	76	11	genbank	genbank	NOUN
ajlm-1363	76	12	accession	accession	NOUN
ajlm-1363	76	13	:	:	PUNCT
ajlm-1363	76	14	ng_016018.1	ng_016018.1	NUM
ajlm-1363	76	15	)	)	PUNCT
ajlm-1363	76	16	and	and	CCONJ
ajlm-1363	76	17	flt3	flt3	NOUN
ajlm-1363	76	18	-	-	PUNCT
ajlm-1363	76	19	itd	itd	NOUN
ajlm-1363	76	20	(	(	PUNCT
ajlm-1363	76	21	genbank	genbank	NOUN
ajlm-1363	76	22	accession	accession	NOUN
ajlm-1363	76	23	:	:	PUNCT
ajlm-1363	76	24	ng_007066.1	ng_007066.1	NOUN
ajlm-1363	76	25	)	)	PUNCT
ajlm-1363	76	26	reference	reference	NOUN
ajlm-1363	76	27	sequences	sequence	NOUN
ajlm-1363	76	28	retrieved	retrieve	VERB
ajlm-1363	76	29	from	from	ADP
ajlm-1363	76	30	the	the	DET
ajlm-1363	76	31	national	national	ADJ
ajlm-1363	76	32	center	center	NOUN
ajlm-1363	76	33	for	for	ADP
ajlm-1363	76	34	biotechnology	biotechnology	NOUN
ajlm-1363	76	35	information	information	NOUN
ajlm-1363	76	36	using	use	VERB
ajlm-1363	76	37	the	the	DET
ajlm-1363	76	38	local	local	ADJ
ajlm-1363	76	39	pairwise	pairwise	NOUN
ajlm-1363	76	40	sequence	sequence	NOUN
ajlm-1363	76	41	alignment	alignment	NOUN
ajlm-1363	76	42	algorithm	algorithm	NOUN
ajlm-1363	76	43	software	software	NOUN
ajlm-1363	76	44	(	(	PUNCT
ajlm-1363	76	45	available	available	ADJ
ajlm-1363	76	46	at	at	ADP
ajlm-1363	76	47	https://embnet.vital-it.ch/software/lalign_form.html	https://embnet.vital-it.ch/software/lalign_form.html	PROPN
ajlm-1363	76	48	)	)	PUNCT
ajlm-1363	76	49	.	.	PUNCT
ajlm-1363	77	1	sanger	sanger	PROPN
ajlm-1363	77	2	sequence	sequence	PROPN
ajlm-1363	77	3	analysis	analysis	NOUN
ajlm-1363	77	4	confirmed	confirm	VERB
ajlm-1363	77	5	that	that	SCONJ
ajlm-1363	77	6	the	the	DET
ajlm-1363	77	7	npm1	npm1	NOUN
ajlm-1363	77	8	positive	positive	ADJ
ajlm-1363	77	9	control	control	NOUN
ajlm-1363	77	10	had	have	VERB
ajlm-1363	77	11	a	a	DET
ajlm-1363	77	12	4	4	NUM
ajlm-1363	77	13	bp	bp	NOUN
ajlm-1363	77	14	insertion	insertion	NOUN
ajlm-1363	77	15	(	(	PUNCT
ajlm-1363	77	16	bases	basis	NOUN
ajlm-1363	77	17	:	:	PUNCT
ajlm-1363	77	18	catg	catg	PROPN
ajlm-1363	77	19	)	)	PUNCT
ajlm-1363	77	20	,	,	PUNCT
ajlm-1363	77	21	and	and	CCONJ
ajlm-1363	77	22	the	the	DET
ajlm-1363	77	23	flt3	flt3	NOUN
ajlm-1363	77	24	-	-	PUNCT
ajlm-1363	77	25	itd	itd	ADJ
ajlm-1363	77	26	positive	positive	ADJ
ajlm-1363	77	27	control	control	NOUN
ajlm-1363	77	28	had	have	VERB
ajlm-1363	77	29	a	a	DET
ajlm-1363	77	30	75	75	NUM
ajlm-1363	77	31	bp	bp	NOUN
ajlm-1363	77	32	it	it	PRON
ajlm-1363	77	33	d.	d.	PROPN
ajlm-1363	77	34	the	the	DET
ajlm-1363	77	35	mutation	mutation	NOUN
ajlm-1363	77	36	-	-	PUNCT
ajlm-1363	77	37	negative	negative	ADJ
ajlm-1363	77	38	controls	control	NOUN
ajlm-1363	77	39	were	be	AUX
ajlm-1363	77	40	compared	compare	VERB
ajlm-1363	77	41	to	to	ADP
ajlm-1363	77	42	the	the	DET
ajlm-1363	77	43	respective	respective	ADJ
ajlm-1363	77	44	reference	reference	NOUN
ajlm-1363	77	45	sequences	sequence	NOUN
ajlm-1363	77	46	,	,	PUNCT
ajlm-1363	77	47	and	and	CCONJ
ajlm-1363	77	48	were	be	AUX
ajlm-1363	77	49	found	find	VERB
ajlm-1363	77	50	to	to	PART
ajlm-1363	77	51	be	be	AUX
ajlm-1363	77	52	100	100	NUM
ajlm-1363	77	53	%	%	NOUN
ajlm-1363	77	54	similar	similar	ADJ
ajlm-1363	77	55	.	.	PUNCT
ajlm-1363	78	1	data	datum	NOUN
ajlm-1363	78	2	analysis	analysis	NOUN
ajlm-1363	78	3	fragment	fragment	NOUN
ajlm-1363	78	4	analysis	analysis	NOUN
ajlm-1363	78	5	electropherograms	electropherogram	NOUN
ajlm-1363	78	6	(	(	PUNCT
ajlm-1363	78	7	figure	figure	NOUN
ajlm-1363	78	8	1	1	NUM
ajlm-1363	78	9	)	)	PUNCT
ajlm-1363	78	10	were	be	AUX
ajlm-1363	78	11	generated	generate	VERB
ajlm-1363	78	12	using	use	VERB
ajlm-1363	78	13	the	the	DET
ajlm-1363	78	14	genemapper	genemapper	PROPN
ajlm-1363	78	15	v6	v6	NOUN
ajlm-1363	78	16	software	software	NOUN
ajlm-1363	78	17	(	(	PUNCT
ajlm-1363	78	18	applied	apply	VERB
ajlm-1363	78	19	biosystems	biosystem	NOUN
ajlm-1363	78	20	,	,	PUNCT
ajlm-1363	78	21	foster	foster	ADJ
ajlm-1363	78	22	city	city	NOUN
ajlm-1363	78	23	,	,	PUNCT
ajlm-1363	78	24	california	california	PROPN
ajlm-1363	78	25	,	,	PUNCT
ajlm-1363	78	26	united	united	PROPN
ajlm-1363	78	27	states	states	PROPN
ajlm-1363	78	28	)	)	PUNCT
ajlm-1363	78	29	,	,	PUNCT
ajlm-1363	78	30	and	and	CCONJ
ajlm-1363	78	31	displayed	display	VERB
ajlm-1363	78	32	the	the	DET
ajlm-1363	78	33	size	size	NOUN
ajlm-1363	78	34	of	of	ADP
ajlm-1363	78	35	the	the	DET
ajlm-1363	78	36	alleles	allele	NOUN
ajlm-1363	78	37	obtained	obtain	VERB
ajlm-1363	78	38	for	for	ADP
ajlm-1363	78	39	the	the	DET
ajlm-1363	78	40	target	target	NOUN
ajlm-1363	78	41	pcr	pcr	NOUN
ajlm-1363	78	42	fragments	fragment	NOUN
ajlm-1363	78	43	(	(	PUNCT
ajlm-1363	78	44	applied	apply	VERB
ajlm-1363	78	45	biosystems	biosystem	NOUN
ajlm-1363	78	46	,	,	PUNCT
ajlm-1363	78	47	foster	foster	ADJ
ajlm-1363	78	48	city	city	NOUN
ajlm-1363	78	49	,	,	PUNCT
ajlm-1363	78	50	california	california	PROPN
ajlm-1363	78	51	,	,	PUNCT
ajlm-1363	78	52	united	united	PROPN
ajlm-1363	78	53	states	states	PROPN
ajlm-1363	78	54	)	)	PUNCT
ajlm-1363	78	55	.	.	PUNCT
ajlm-1363	79	1	flt3	flt3	NOUN
ajlm-1363	79	2	-	-	PUNCT
ajlm-1363	79	3	itd	itd	NOUN
ajlm-1363	79	4	allelic	allelic	ADJ
ajlm-1363	79	5	ratios	ratio	NOUN
ajlm-1363	79	6	were	be	AUX
ajlm-1363	79	7	determined	determine	VERB
ajlm-1363	79	8	by	by	ADP
ajlm-1363	79	9	calculating	calculate	VERB
ajlm-1363	79	10	the	the	DET
ajlm-1363	79	11	ratio	ratio	NOUN
ajlm-1363	79	12	of	of	ADP
ajlm-1363	79	13	the	the	DET
ajlm-1363	79	14	area	area	NOUN
ajlm-1363	79	15	under	under	ADP
ajlm-1363	79	16	the	the	DET
ajlm-1363	79	17	curve	curve	NOUN
ajlm-1363	79	18	of	of	ADP
ajlm-1363	79	19	the	the	DET
ajlm-1363	79	20	flt3	flt3	NOUN
ajlm-1363	79	21	-	-	PUNCT
ajlm-1363	79	22	itd	itd	NOUN
ajlm-1363	79	23	mutant	mutant	ADJ
ajlm-1363	79	24	allele	allele	NOUN
ajlm-1363	79	25	to	to	ADP
ajlm-1363	79	26	the	the	DET
ajlm-1363	79	27	flt3	flt3	ADJ
ajlm-1363	79	28	wild	wild	ADJ
ajlm-1363	79	29	-	-	PUNCT
ajlm-1363	79	30	type	type	NOUN
ajlm-1363	79	31	allele	allele	NOUN
ajlm-1363	79	32	as	as	SCONJ
ajlm-1363	79	33	displayed	display	VERB
ajlm-1363	79	34	by	by	ADP
ajlm-1363	79	35	genemapper	genemapper	NOUN
ajlm-1363	79	36	.	.	PUNCT
ajlm-1363	80	1	the	the	DET
ajlm-1363	80	2	sequence	sequence	NOUN
ajlm-1363	80	3	was	be	AUX
ajlm-1363	80	4	analysed	analyse	VERB
ajlm-1363	80	5	using	use	VERB
ajlm-1363	80	6	the	the	DET
ajlm-1363	80	7	sequencing	sequence	VERB
ajlm-1363	80	8	analysis	analysis	NOUN
ajlm-1363	80	9	program	program	NOUN
ajlm-1363	80	10	version	version	NOUN
ajlm-1363	80	11	5.3.1	5.3.1	PROPN
ajlm-1363	80	12	(	(	PUNCT
ajlm-1363	80	13	applied	apply	VERB
ajlm-1363	80	14	biosystems	biosystem	NOUN
ajlm-1363	80	15	,	,	PUNCT
ajlm-1363	80	16	foster	foster	ADJ
ajlm-1363	80	17	city	city	NOUN
ajlm-1363	80	18	,	,	PUNCT
ajlm-1363	80	19	california	california	PROPN
ajlm-1363	80	20	,	,	PUNCT
ajlm-1363	80	21	united	united	PROPN
ajlm-1363	80	22	states	states	PROPN
ajlm-1363	80	23	)	)	PUNCT
ajlm-1363	80	24	and	and	CCONJ
ajlm-1363	80	25	chromas	chromas	VERB
ajlm-1363	80	26	version	version	NOUN
ajlm-1363	80	27	2.6.6	2.6.6	NUM
ajlm-1363	80	28	(	(	PUNCT
ajlm-1363	80	29	technelysium	technelysium	PROPN
ajlm-1363	80	30	pty	pty	PROPN
ajlm-1363	80	31	ltd	ltd	PROPN
ajlm-1363	80	32	,	,	PUNCT
ajlm-1363	80	33	brisbane	brisbane	PROPN
ajlm-1363	80	34	,	,	PUNCT
ajlm-1363	80	35	australia	australia	PROPN
ajlm-1363	80	36	)	)	PUNCT
ajlm-1363	80	37	.	.	PUNCT
ajlm-1363	81	1	tables	table	NOUN
ajlm-1363	81	2	were	be	AUX
ajlm-1363	81	3	generated	generate	VERB
ajlm-1363	81	4	using	use	VERB
ajlm-1363	81	5	microsoft	microsoft	PROPN
ajlm-1363	81	6	word	word	PROPN
ajlm-1363	81	7	2016	2016	NUM
ajlm-1363	81	8	(	(	PUNCT
ajlm-1363	81	9	microsoft	microsoft	PROPN
ajlm-1363	81	10	,	,	PUNCT
ajlm-1363	81	11	redmond	redmond	PROPN
ajlm-1363	81	12	,	,	PUNCT
ajlm-1363	81	13	washington	washington	PROPN
ajlm-1363	81	14	,	,	PUNCT
ajlm-1363	81	15	united	united	PROPN
ajlm-1363	81	16	states	states	PROPN
ajlm-1363	81	17	)	)	PUNCT
ajlm-1363	81	18	.	.	PUNCT
ajlm-1363	82	1	patients	patient	NOUN
ajlm-1363	82	2	’	'	PUNCT
ajlm-1363	82	3	demographic	demographic	ADJ
ajlm-1363	82	4	data	datum	NOUN
ajlm-1363	82	5	and	and	CCONJ
ajlm-1363	82	6	aml	aml	PROPN
ajlm-1363	82	7	classification	classification	NOUN
ajlm-1363	82	8	were	be	AUX
ajlm-1363	82	9	summarised	summarise	VERB
ajlm-1363	82	10	in	in	ADP
ajlm-1363	82	11	table	table	NOUN
ajlm-1363	82	12	format	format	NOUN
ajlm-1363	82	13	.	.	PUNCT
ajlm-1363	83	1	ethnicity	ethnicity	NOUN
ajlm-1363	83	2	,	,	PUNCT
ajlm-1363	83	3	defined	define	VERB
ajlm-1363	83	4	as	as	ADP
ajlm-1363	83	5	either	either	CCONJ
ajlm-1363	83	6	black	black	ADJ
ajlm-1363	83	7	,	,	PUNCT
ajlm-1363	83	8	white	white	ADJ
ajlm-1363	83	9	or	or	CCONJ
ajlm-1363	83	10	mixed	mixed	ADJ
ajlm-1363	83	11	race	race	NOUN
ajlm-1363	83	12	,	,	PUNCT
ajlm-1363	83	13	was	be	AUX
ajlm-1363	83	14	based	base	VERB
ajlm-1363	83	15	on	on	ADP
ajlm-1363	83	16	patients	patient	NOUN
ajlm-1363	83	17	’	'	PUNCT
ajlm-1363	83	18	self	self	NOUN
ajlm-1363	83	19	-	-	PUNCT
ajlm-1363	83	20	proclaimed	proclaim	VERB
ajlm-1363	83	21	identity	identity	NOUN
ajlm-1363	83	22	and	and	CCONJ
ajlm-1363	83	23	accordingly	accordingly	ADV
ajlm-1363	83	24	documented	document	VERB
ajlm-1363	83	25	.	.	PUNCT
ajlm-1363	84	1	results	result	VERB
ajlm-1363	84	2	the	the	DET
ajlm-1363	84	3	aml	aml	PROPN
ajlm-1363	84	4	patients	patient	NOUN
ajlm-1363	84	5	(	(	PUNCT
ajlm-1363	84	6	fn1	fn1	NOUN
ajlm-1363	84	7	to	to	ADP
ajlm-1363	84	8	fn40	fn40	PROPN
ajlm-1363	84	9	)	)	PUNCT
ajlm-1363	84	10	were	be	AUX
ajlm-1363	84	11	all	all	PRON
ajlm-1363	84	12	successfully	successfully	ADV
ajlm-1363	84	13	screened	screen	VERB
ajlm-1363	84	14	with	with	ADP
ajlm-1363	84	15	the	the	DET
ajlm-1363	84	16	npm1	npm1	NOUN
ajlm-1363	84	17	and	and	CCONJ
ajlm-1363	84	18	flt3	flt3	PROPN
ajlm-1363	84	19	-	-	PUNCT
ajlm-1363	84	20	itd	itd	PROPN
ajlm-1363	84	21	multiplex	multiplex	PROPN
ajlm-1363	84	22	pcr	pcr	PROPN
ajlm-1363	84	23	assay	assay	VERB
ajlm-1363	84	24	.	.	PUNCT
ajlm-1363	85	1	the	the	DET
ajlm-1363	85	2	aml	aml	PROPN
ajlm-1363	85	3	patient	patient	PROPN
ajlm-1363	85	4	cohort	cohort	NOUN
ajlm-1363	85	5	had	have	VERB
ajlm-1363	85	6	a	a	DET
ajlm-1363	85	7	median	median	ADJ
ajlm-1363	85	8	age	age	NOUN
ajlm-1363	85	9	of	of	ADP
ajlm-1363	85	10	38.5	38.5	NUM
ajlm-1363	85	11	years	year	NOUN
ajlm-1363	85	12	(	(	PUNCT
ajlm-1363	85	13	range	range	NOUN
ajlm-1363	85	14	18–85	18–85	NUM
ajlm-1363	85	15	years	year	NOUN
ajlm-1363	85	16	)	)	PUNCT
ajlm-1363	85	17	at	at	ADP
ajlm-1363	85	18	presentation	presentation	NOUN
ajlm-1363	85	19	and	and	CCONJ
ajlm-1363	85	20	the	the	DET
ajlm-1363	85	21	ratio	ratio	NOUN
ajlm-1363	85	22	of	of	ADP
ajlm-1363	85	23	women	woman	NOUN
ajlm-1363	85	24	to	to	ADP
ajlm-1363	85	25	men	man	NOUN
ajlm-1363	85	26	was	be	AUX
ajlm-1363	85	27	1:1.2	1:1.2	NOUN
ajlm-1363	85	28	.	.	PUNCT
ajlm-1363	86	1	the	the	DET
ajlm-1363	86	2	cohort	cohort	NOUN
ajlm-1363	86	3	included	include	VERB
ajlm-1363	86	4	31	31	NUM
ajlm-1363	86	5	black	black	ADJ
ajlm-1363	86	6	african	african	ADJ
ajlm-1363	86	7	patients	patient	NOUN
ajlm-1363	86	8	,	,	PUNCT
ajlm-1363	86	9	four	four	NUM
ajlm-1363	86	10	white	white	ADJ
ajlm-1363	86	11	patients	patient	NOUN
ajlm-1363	86	12	,	,	PUNCT
ajlm-1363	86	13	and	and	CCONJ
ajlm-1363	86	14	five	five	NUM
ajlm-1363	86	15	patients	patient	NOUN
ajlm-1363	86	16	of	of	ADP
ajlm-1363	86	17	mixed	mixed	ADJ
ajlm-1363	86	18	ethnicity	ethnicity	NOUN
ajlm-1363	86	19	.	.	PUNCT
ajlm-1363	87	1	acute	acute	ADJ
ajlm-1363	87	2	myeloid	myeloid	ADJ
ajlm-1363	87	3	leukaemia	leukaemia	NOUN
ajlm-1363	87	4	subtypes	subtype	NOUN
ajlm-1363	87	5	in	in	ADP
ajlm-1363	87	6	our	our	PRON
ajlm-1363	87	7	patient	patient	ADJ
ajlm-1363	87	8	cohort	cohort	NOUN
ajlm-1363	87	9	comprised	comprise	VERB
ajlm-1363	87	10	of	of	ADP
ajlm-1363	87	11	aml	aml	NOUN
ajlm-1363	87	12	with	with	ADP
ajlm-1363	87	13	recurrent	recurrent	ADJ
ajlm-1363	87	14	genetic	genetic	ADJ
ajlm-1363	87	15	abnormalities	abnormality	NOUN
ajlm-1363	87	16	,	,	PUNCT
ajlm-1363	87	17	aml	aml	NOUN
ajlm-1363	87	18	with	with	ADP
ajlm-1363	87	19	myelodysplasia	myelodysplasia	NOUN
ajlm-1363	87	20	-	-	PUNCT
ajlm-1363	87	21	related	relate	VERB
ajlm-1363	87	22	changes	change	NOUN
ajlm-1363	87	23	,	,	PUNCT
ajlm-1363	87	24	and	and	CCONJ
ajlm-1363	87	25	aml	aml	PROPN
ajlm-1363	87	26	not	not	PART
ajlm-1363	87	27	otherwise	otherwise	ADV
ajlm-1363	87	28	specified	specify	VERB
ajlm-1363	87	29	(	(	PUNCT
ajlm-1363	87	30	also	also	ADV
ajlm-1363	87	31	referred	refer	VERB
ajlm-1363	87	32	to	to	ADP
ajlm-1363	87	33	as	as	ADP
ajlm-1363	87	34	cn	cn	PROPN
ajlm-1363	87	35	-	-	PUNCT
ajlm-1363	87	36	aml	aml	NOUN
ajlm-1363	87	37	)	)	PUNCT
ajlm-1363	87	38	.	.	PUNCT
ajlm-1363	88	1	acute	acute	ADJ
ajlm-1363	88	2	myeloid	myeloid	ADJ
ajlm-1363	88	3	leukaemia	leukaemia	NOUN
ajlm-1363	88	4	with	with	ADP
ajlm-1363	88	5	recurrent	recurrent	ADJ
ajlm-1363	88	6	genetic	genetic	ADJ
ajlm-1363	88	7	abnormalities	abnormality	NOUN
ajlm-1363	88	8	was	be	AUX
ajlm-1363	88	9	most	most	ADV
ajlm-1363	88	10	prevalent	prevalent	ADJ
ajlm-1363	88	11	(	(	PUNCT
ajlm-1363	88	12	57.5	57.5	NUM
ajlm-1363	88	13	%	%	NOUN
ajlm-1363	88	14	;	;	PUNCT
ajlm-1363	88	15	n	n	PROPN
ajlm-1363	88	16	=	=	SYM
ajlm-1363	88	17	23	23	NUM
ajlm-1363	88	18	)	)	PUNCT
ajlm-1363	88	19	,	,	PUNCT
ajlm-1363	88	20	of	of	ADP
ajlm-1363	88	21	which	which	PRON
ajlm-1363	88	22	acute	acute	ADJ
ajlm-1363	88	23	promyelocytic	promyelocytic	ADJ
ajlm-1363	88	24	leukaemia	leukaemia	NOUN
ajlm-1363	88	25	(	(	PUNCT
ajlm-1363	88	26	apl	apl	PROPN
ajlm-1363	88	27	)	)	PUNCT
ajlm-1363	88	28	was	be	AUX
ajlm-1363	88	29	most	most	ADV
ajlm-1363	88	30	common	common	ADJ
ajlm-1363	88	31	(	(	PUNCT
ajlm-1363	88	32	40.0	40.0	NUM
ajlm-1363	88	33	%	%	NOUN
ajlm-1363	88	34	;	;	PUNCT
ajlm-1363	88	35	n	n	PROPN
ajlm-1363	88	36	=	=	SYM
ajlm-1363	88	37	16	16	NUM
ajlm-1363	88	38	)	)	PUNCT
ajlm-1363	88	39	.	.	PUNCT
ajlm-1363	89	1	none	none	NOUN
ajlm-1363	89	2	of	of	ADP
ajlm-1363	89	3	the	the	DET
ajlm-1363	89	4	patients	patient	NOUN
ajlm-1363	89	5	had	have	VERB
ajlm-1363	89	6	the	the	DET
ajlm-1363	89	7	npm1	npm1	NOUN
ajlm-1363	89	8	mutation	mutation	NOUN
ajlm-1363	89	9	.	.	PUNCT
ajlm-1363	90	1	fms	fms	PROPN
ajlm-1363	90	2	-	-	PUNCT
ajlm-1363	90	3	related	relate	VERB
ajlm-1363	90	4	tyrosine	tyrosine	NOUN
ajlm-1363	90	5	kinase	kinase	NOUN
ajlm-1363	90	6	3	3	X
ajlm-1363	90	7	-	-	PUNCT
ajlm-1363	90	8	itd	itd	PROPN
ajlm-1363	90	9	was	be	AUX
ajlm-1363	90	10	present	present	ADJ
ajlm-1363	90	11	in	in	ADP
ajlm-1363	90	12	37.5	37.5	NUM
ajlm-1363	90	13	%	%	NOUN
ajlm-1363	90	14	(	(	PUNCT
ajlm-1363	90	15	6/16	6/16	NUM
ajlm-1363	90	16	)	)	PUNCT
ajlm-1363	90	17	of	of	ADP
ajlm-1363	90	18	apl	apl	NOUN
ajlm-1363	90	19	patients	patient	NOUN
ajlm-1363	90	20	and	and	CCONJ
ajlm-1363	90	21	in	in	ADP
ajlm-1363	90	22	one	one	NUM
ajlm-1363	90	23	(	(	PUNCT
ajlm-1363	90	24	20.0	20.0	NUM
ajlm-1363	90	25	%	%	NOUN
ajlm-1363	90	26	)	)	PUNCT
ajlm-1363	90	27	of	of	ADP
ajlm-1363	90	28	five	five	NUM
ajlm-1363	90	29	aml	aml	NOUN
ajlm-1363	90	30	patients	patient	NOUN
ajlm-1363	90	31	with	with	ADP
ajlm-1363	90	32	a	a	DET
ajlm-1363	90	33	t(8	t(8	PROPN
ajlm-1363	90	34	;	;	PUNCT
ajlm-1363	90	35	21	21	NUM
ajlm-1363	90	36	)	)	PUNCT
ajlm-1363	90	37	translocation	translocation	NOUN
ajlm-1363	90	38	(	(	PUNCT
ajlm-1363	90	39	table	table	NOUN
ajlm-1363	90	40	1	1	NUM
ajlm-1363	90	41	)	)	PUNCT
ajlm-1363	90	42	.	.	PUNCT
ajlm-1363	91	1	patients	patient	NOUN
ajlm-1363	91	2	with	with	ADP
ajlm-1363	91	3	an	an	DET
ajlm-1363	91	4	flt3	flt3	NOUN
ajlm-1363	91	5	-	-	PUNCT
ajlm-1363	91	6	itd	itd	NOUN
ajlm-1363	91	7	mutation	mutation	NOUN
ajlm-1363	91	8	had	have	VERB
ajlm-1363	91	9	a	a	DET
ajlm-1363	91	10	median	median	ADJ
ajlm-1363	91	11	age	age	NOUN
ajlm-1363	91	12	of	of	ADP
ajlm-1363	91	13	30.8	30.8	NUM
ajlm-1363	91	14	years	year	NOUN
ajlm-1363	91	15	at	at	ADP
ajlm-1363	91	16	presentation	presentation	NOUN
ajlm-1363	91	17	,	,	PUNCT
ajlm-1363	91	18	and	and	CCONJ
ajlm-1363	91	19	the	the	DET
ajlm-1363	91	20	majority	majority	NOUN
ajlm-1363	91	21	of	of	ADP
ajlm-1363	91	22	patients	patient	NOUN
ajlm-1363	91	23	were	be	AUX
ajlm-1363	91	24	black	black	ADJ
ajlm-1363	91	25	africans	africans	PROPN
ajlm-1363	91	26	(	(	PUNCT
ajlm-1363	91	27	n	n	NOUN
ajlm-1363	91	28	=	=	SYM
ajlm-1363	91	29	5/7	5/7	NUM
ajlm-1363	91	30	)	)	PUNCT
ajlm-1363	91	31	(	(	PUNCT
ajlm-1363	91	32	table	table	NOUN
ajlm-1363	91	33	2	2	NUM
ajlm-1363	91	34	)	)	PUNCT
ajlm-1363	91	35	.	.	PUNCT
ajlm-1363	92	1	internal	internal	ADJ
ajlm-1363	92	2	tandem	tandem	NOUN
ajlm-1363	92	3	duplication	duplication	NOUN
ajlm-1363	92	4	lengths	length	NOUN
ajlm-1363	92	5	of	of	ADP
ajlm-1363	92	6	the	the	DET
ajlm-1363	92	7	flt3	flt3	PROPN
ajlm-1363	92	8	mutations	mutation	NOUN
ajlm-1363	92	9	observed	observe	VERB
ajlm-1363	92	10	in	in	ADP
ajlm-1363	92	11	this	this	DET
ajlm-1363	92	12	study	study	NOUN
ajlm-1363	92	13	ranged	range	VERB
ajlm-1363	92	14	between	between	ADP
ajlm-1363	92	15	19	19	NUM
ajlm-1363	92	16	bp	bp	NOUN
ajlm-1363	92	17	and	and	CCONJ
ajlm-1363	92	18	75	75	NUM
ajlm-1363	92	19	bp	bp	NOUN
ajlm-1363	92	20	,	,	PUNCT
ajlm-1363	92	21	and	and	CCONJ
ajlm-1363	92	22	the	the	DET
ajlm-1363	92	23	flt3	flt3	NOUN
ajlm-1363	92	24	-	-	PUNCT
ajlm-1363	92	25	itd	itd	NOUN
ajlm-1363	92	26	allele	allele	NOUN
ajlm-1363	92	27	ratios	ratio	NOUN
ajlm-1363	92	28	ranged	range	VERB
ajlm-1363	92	29	between	between	ADP
ajlm-1363	92	30	17.5	17.5	NUM
ajlm-1363	92	31	%	%	NOUN
ajlm-1363	92	32	and	and	CCONJ
ajlm-1363	92	33	94.9	94.9	NUM
ajlm-1363	92	34	%	%	NOUN
ajlm-1363	92	35	.	.	PUNCT
ajlm-1363	93	1	table	table	NOUN
ajlm-1363	93	2	1	1	NUM
ajlm-1363	93	3	:	:	PUNCT
ajlm-1363	93	4	 	 	SPACE
ajlm-1363	93	5	classification	classification	NOUN
ajlm-1363	93	6	of	of	ADP
ajlm-1363	93	7	acute	acute	ADJ
ajlm-1363	93	8	myeloid	myeloid	ADJ
ajlm-1363	93	9	leukaemia	leukaemia	NOUN
ajlm-1363	93	10	patients	patient	NOUN
ajlm-1363	93	11	’	'	PUNCT
ajlm-1363	93	12	npm1	npm1	NOUN
ajlm-1363	93	13	and	and	CCONJ
ajlm-1363	93	14	flt3	flt3	NOUN
ajlm-1363	93	15	-	-	PUNCT
ajlm-1363	93	16	itd	itd	ADJ
ajlm-1363	93	17	genotypes	genotype	NOUN
ajlm-1363	93	18	(	(	PUNCT
ajlm-1363	93	19	august	august	PROPN
ajlm-1363	93	20	2020	2020	NUM
ajlm-1363	93	21	,	,	PUNCT
ajlm-1363	93	22	bloemfontein	bloemfontein	NOUN
ajlm-1363	93	23	,	,	PUNCT
ajlm-1363	93	24	free	free	ADJ
ajlm-1363	93	25	state	state	NOUN
ajlm-1363	93	26	,	,	PUNCT
ajlm-1363	93	27	south	south	PROPN
ajlm-1363	93	28	africa	africa	PROPN
ajlm-1363	93	29	)	)	PUNCT
ajlm-1363	93	30	.	.	PUNCT
ajlm-1363	94	1	table	table	NOUN
ajlm-1363	94	2	2	2	NUM
ajlm-1363	94	3	:	:	PUNCT
ajlm-1363	94	4	 	 	SPACE
ajlm-1363	94	5	acute	acute	ADJ
ajlm-1363	94	6	myeloid	myeloid	ADJ
ajlm-1363	94	7	leukaemia	leukaemia	NOUN
ajlm-1363	94	8	patients	patient	NOUN
ajlm-1363	94	9	positive	positive	ADJ
ajlm-1363	94	10	for	for	ADP
ajlm-1363	94	11	the	the	DET
ajlm-1363	94	12	flt3	flt3	NOUN
ajlm-1363	94	13	-	-	PUNCT
ajlm-1363	94	14	itd	itd	NOUN
ajlm-1363	94	15	mutation	mutation	NOUN
ajlm-1363	94	16	(	(	PUNCT
ajlm-1363	94	17	august	august	PROPN
ajlm-1363	94	18	2020	2020	NUM
ajlm-1363	94	19	,	,	PUNCT
ajlm-1363	94	20	bloemfontein	bloemfontein	NOUN
ajlm-1363	94	21	,	,	PUNCT
ajlm-1363	94	22	free	free	ADJ
ajlm-1363	94	23	state	state	NOUN
ajlm-1363	94	24	,	,	PUNCT
ajlm-1363	94	25	south	south	PROPN
ajlm-1363	94	26	africa	africa	PROPN
ajlm-1363	94	27	)	)	PUNCT
ajlm-1363	94	28	.	.	PUNCT
ajlm-1363	95	1	discussion	discussion	NOUN
ajlm-1363	95	2	acute	acute	PROPN
ajlm-1363	95	3	myeloid	myeloid	PROPN
ajlm-1363	95	4	leukaemia	leukaemia	NOUN
ajlm-1363	95	5	is	be	AUX
ajlm-1363	95	6	a	a	DET
ajlm-1363	95	7	genetically	genetically	ADV
ajlm-1363	95	8	heterogeneous	heterogeneous	ADJ
ajlm-1363	95	9	disease2	disease2	NOUN
ajlm-1363	95	10	with	with	ADP
ajlm-1363	95	11	numerous	numerous	ADJ
ajlm-1363	95	12	clinical	clinical	ADJ
ajlm-1363	95	13	and	and	CCONJ
ajlm-1363	95	14	genetic	genetic	ADJ
ajlm-1363	95	15	factors	factor	NOUN
ajlm-1363	95	16	influencing	influence	VERB
ajlm-1363	95	17	the	the	DET
ajlm-1363	95	18	final	final	ADJ
ajlm-1363	95	19	diagnosis	diagnosis	NOUN
ajlm-1363	95	20	.	.	PUNCT
ajlm-1363	96	1	the	the	DET
ajlm-1363	96	2	recognition	recognition	NOUN
ajlm-1363	96	3	of	of	ADP
ajlm-1363	96	4	additional	additional	ADJ
ajlm-1363	96	5	molecular	molecular	ADJ
ajlm-1363	96	6	abnormalities	abnormality	NOUN
ajlm-1363	96	7	,	,	PUNCT
ajlm-1363	96	8	such	such	ADJ
ajlm-1363	96	9	as	as	ADP
ajlm-1363	96	10	npm1	npm1	NOUN
ajlm-1363	96	11	and	and	CCONJ
ajlm-1363	96	12	flt3	flt3	NOUN
ajlm-1363	96	13	-	-	PUNCT
ajlm-1363	96	14	itd	itd	NOUN
ajlm-1363	96	15	in	in	ADP
ajlm-1363	96	16	aml	aml	PROPN
ajlm-1363	96	17	,	,	PUNCT
ajlm-1363	96	18	has	have	AUX
ajlm-1363	96	19	ensured	ensure	VERB
ajlm-1363	96	20	that	that	SCONJ
ajlm-1363	96	21	the	the	DET
ajlm-1363	96	22	disease	disease	NOUN
ajlm-1363	96	23	biology	biology	NOUN
ajlm-1363	96	24	is	be	AUX
ajlm-1363	96	25	better	well	ADV
ajlm-1363	96	26	understood	understand	VERB
ajlm-1363	96	27	and	and	CCONJ
ajlm-1363	96	28	has	have	AUX
ajlm-1363	96	29	allowed	allow	VERB
ajlm-1363	96	30	for	for	SCONJ
ajlm-1363	96	31	improved	improved	ADJ
ajlm-1363	96	32	risk	risk	NOUN
ajlm-1363	96	33	stratification	stratification	NOUN
ajlm-1363	96	34	to	to	PART
ajlm-1363	96	35	be	be	AUX
ajlm-1363	96	36	included	include	VERB
ajlm-1363	96	37	in	in	ADP
ajlm-1363	96	38	the	the	DET
ajlm-1363	96	39	diagnostic	diagnostic	ADJ
ajlm-1363	96	40	algorithms.3,4	algorithms.3,4	NOUN
ajlm-1363	96	41	this	this	PRON
ajlm-1363	96	42	is	be	AUX
ajlm-1363	96	43	the	the	DET
ajlm-1363	96	44	first	first	ADJ
ajlm-1363	96	45	study	study	NOUN
ajlm-1363	96	46	to	to	PART
ajlm-1363	96	47	investigate	investigate	VERB
ajlm-1363	96	48	the	the	DET
ajlm-1363	96	49	presence	presence	NOUN
ajlm-1363	96	50	of	of	ADP
ajlm-1363	96	51	npm1	npm1	NOUN
ajlm-1363	96	52	and	and	CCONJ
ajlm-1363	96	53	flt3	flt3	NOUN
ajlm-1363	96	54	-	-	PUNCT
ajlm-1363	96	55	itd	itd	NOUN
ajlm-1363	96	56	in	in	ADP
ajlm-1363	96	57	a	a	DET
ajlm-1363	96	58	central	central	ADJ
ajlm-1363	96	59	south	south	ADJ
ajlm-1363	96	60	african	african	ADJ
ajlm-1363	96	61	aml	aml	PROPN
ajlm-1363	96	62	population	population	NOUN
ajlm-1363	96	63	.	.	PUNCT
ajlm-1363	97	1	the	the	DET
ajlm-1363	97	2	npm1	npm1	NOUN
ajlm-1363	97	3	was	be	AUX
ajlm-1363	97	4	absent	absent	ADJ
ajlm-1363	97	5	in	in	ADP
ajlm-1363	97	6	this	this	DET
ajlm-1363	97	7	study	study	NOUN
ajlm-1363	97	8	population	population	NOUN
ajlm-1363	97	9	,	,	PUNCT
ajlm-1363	97	10	while	while	SCONJ
ajlm-1363	97	11	the	the	DET
ajlm-1363	97	12	flt3	flt3	NOUN
ajlm-1363	97	13	-	-	PUNCT
ajlm-1363	97	14	itd	itd	NOUN
ajlm-1363	97	15	mutation	mutation	NOUN
ajlm-1363	97	16	predominated	predominate	VERB
ajlm-1363	97	17	in	in	ADP
ajlm-1363	97	18	the	the	DET
ajlm-1363	97	19	apl	apl	NOUN
ajlm-1363	97	20	subtype	subtype	NOUN
ajlm-1363	97	21	.	.	PUNCT
ajlm-1363	98	1	furthermore	furthermore	ADV
ajlm-1363	98	2	,	,	PUNCT
ajlm-1363	98	3	the	the	DET
ajlm-1363	98	4	majority	majority	NOUN
ajlm-1363	98	5	of	of	ADP
ajlm-1363	98	6	patients	patient	NOUN
ajlm-1363	98	7	that	that	PRON
ajlm-1363	98	8	were	be	AUX
ajlm-1363	98	9	positive	positive	ADJ
ajlm-1363	98	10	for	for	ADP
ajlm-1363	98	11	the	the	DET
ajlm-1363	98	12	flt3	flt3	NOUN
ajlm-1363	98	13	-	-	PUNCT
ajlm-1363	98	14	itd	itd	NOUN
ajlm-1363	98	15	mutation	mutation	NOUN
ajlm-1363	98	16	had	have	VERB
ajlm-1363	98	17	long	long	ADV
ajlm-1363	98	18	it	it	PRON
ajlm-1363	98	19	d	d	PROPN
ajlm-1363	98	20	lengths	length	NOUN
ajlm-1363	98	21	and	and	CCONJ
ajlm-1363	98	22	allelic	allelic	ADJ
ajlm-1363	98	23	ratios	ratio	NOUN
ajlm-1363	98	24	above	above	ADP
ajlm-1363	98	25	50	50	NUM
ajlm-1363	98	26	%	%	NOUN
ajlm-1363	98	27	.	.	PUNCT
ajlm-1363	99	1	it	it	PRON
ajlm-1363	99	2	was	be	AUX
ajlm-1363	99	3	notable	notable	ADJ
ajlm-1363	99	4	that	that	SCONJ
ajlm-1363	99	5	the	the	DET
ajlm-1363	99	6	median	median	ADJ
ajlm-1363	99	7	age	age	NOUN
ajlm-1363	99	8	of	of	ADP
ajlm-1363	99	9	our	our	PRON
ajlm-1363	99	10	patient	patient	ADJ
ajlm-1363	99	11	cohort	cohort	NOUN
ajlm-1363	99	12	was	be	AUX
ajlm-1363	99	13	38.5	38.5	NUM
ajlm-1363	99	14	years	year	NOUN
ajlm-1363	99	15	.	.	PUNCT
ajlm-1363	100	1	the	the	DET
ajlm-1363	100	2	global	global	ADJ
ajlm-1363	100	3	median	median	ADJ
ajlm-1363	100	4	age	age	NOUN
ajlm-1363	100	5	at	at	ADP
ajlm-1363	100	6	presentation	presentation	NOUN
ajlm-1363	100	7	for	for	ADP
ajlm-1363	100	8	aml	aml	PROPN
ajlm-1363	100	9	is	be	AUX
ajlm-1363	100	10	67	67	NUM
ajlm-1363	100	11	years18	years18	NOUN
ajlm-1363	100	12	and	and	CCONJ
ajlm-1363	100	13	,	,	PUNCT
ajlm-1363	100	14	in	in	ADP
ajlm-1363	100	15	comparison	comparison	NOUN
ajlm-1363	100	16	,	,	PUNCT
ajlm-1363	100	17	the	the	DET
ajlm-1363	100	18	current	current	ADJ
ajlm-1363	100	19	patient	patient	ADJ
ajlm-1363	100	20	cohort	cohort	NOUN
ajlm-1363	100	21	presented	present	VERB
ajlm-1363	100	22	with	with	ADP
ajlm-1363	100	23	the	the	DET
ajlm-1363	100	24	disease	disease	NOUN
ajlm-1363	100	25	at	at	ADP
ajlm-1363	100	26	a	a	DET
ajlm-1363	100	27	considerably	considerably	ADV
ajlm-1363	100	28	younger	young	ADJ
ajlm-1363	100	29	age	age	NOUN
ajlm-1363	100	30	.	.	PUNCT
ajlm-1363	101	1	this	this	DET
ajlm-1363	101	2	finding	finding	NOUN
ajlm-1363	101	3	was	be	AUX
ajlm-1363	101	4	similar	similar	ADJ
ajlm-1363	101	5	to	to	ADP
ajlm-1363	101	6	a	a	DET
ajlm-1363	101	7	previous	previous	ADJ
ajlm-1363	101	8	south	south	ADJ
ajlm-1363	101	9	african	african	ADJ
ajlm-1363	101	10	study	study	NOUN
ajlm-1363	101	11	,	,	PUNCT
ajlm-1363	101	12	where	where	SCONJ
ajlm-1363	101	13	adult	adult	NOUN
ajlm-1363	101	14	aml	aml	NOUN
ajlm-1363	101	15	patients	patient	NOUN
ajlm-1363	101	16	presented	present	VERB
ajlm-1363	101	17	with	with	ADP
ajlm-1363	101	18	the	the	DET
ajlm-1363	101	19	disease	disease	NOUN
ajlm-1363	101	20	at	at	ADP
ajlm-1363	101	21	a	a	DET
ajlm-1363	101	22	median	median	ADJ
ajlm-1363	101	23	age	age	NOUN
ajlm-1363	101	24	of	of	ADP
ajlm-1363	101	25	41	41	NUM
ajlm-1363	101	26	years.15	years.15	NOUN
ajlm-1363	101	27	most	most	ADJ
ajlm-1363	101	28	patients	patient	NOUN
ajlm-1363	101	29	in	in	ADP
ajlm-1363	101	30	this	this	DET
ajlm-1363	101	31	study	study	NOUN
ajlm-1363	101	32	were	be	AUX
ajlm-1363	101	33	self	self	NOUN
ajlm-1363	101	34	-	-	PUNCT
ajlm-1363	101	35	proclaimed	proclaim	VERB
ajlm-1363	101	36	black	black	ADJ
ajlm-1363	101	37	africans	africans	PROPN
ajlm-1363	101	38	,	,	PUNCT
ajlm-1363	101	39	and	and	CCONJ
ajlm-1363	101	40	there	there	PRON
ajlm-1363	101	41	was	be	VERB
ajlm-1363	101	42	no	no	DET
ajlm-1363	101	43	predominant	predominant	ADJ
ajlm-1363	101	44	disease	disease	NOUN
ajlm-1363	101	45	presentation	presentation	NOUN
ajlm-1363	101	46	based	base	VERB
ajlm-1363	101	47	on	on	ADP
ajlm-1363	101	48	sex	sex	NOUN
ajlm-1363	101	49	.	.	PUNCT
ajlm-1363	102	1	two	two	NUM
ajlm-1363	102	2	other	other	ADJ
ajlm-1363	102	3	african	african	ADJ
ajlm-1363	102	4	studies	study	NOUN
ajlm-1363	102	5	found	find	VERB
ajlm-1363	102	6	a	a	DET
ajlm-1363	102	7	similar	similar	ADJ
ajlm-1363	102	8	age	age	NOUN
ajlm-1363	102	9	distribution	distribution	NOUN
ajlm-1363	102	10	and	and	CCONJ
ajlm-1363	102	11	sex	sex	NOUN
ajlm-1363	102	12	ratio.19,20	ratio.19,20	NOUN
ajlm-1363	102	13	the	the	DET
ajlm-1363	102	14	flt3	flt3	NOUN
ajlm-1363	102	15	-	-	PUNCT
ajlm-1363	102	16	itd	itd	NOUN
ajlm-1363	102	17	mutation	mutation	NOUN
ajlm-1363	102	18	was	be	AUX
ajlm-1363	102	19	only	only	ADV
ajlm-1363	102	20	detected	detect	VERB
ajlm-1363	102	21	in	in	ADP
ajlm-1363	102	22	patients	patient	NOUN
ajlm-1363	102	23	with	with	ADP
ajlm-1363	102	24	aml	aml	PROPN
ajlm-1363	102	25	with	with	ADP
ajlm-1363	102	26	recurrent	recurrent	ADJ
ajlm-1363	102	27	genetic	genetic	ADJ
ajlm-1363	102	28	abnormalities	abnormality	NOUN
ajlm-1363	102	29	,	,	PUNCT
ajlm-1363	102	30	of	of	ADP
ajlm-1363	102	31	which	which	PRON
ajlm-1363	102	32	apl	apl	NOUN
ajlm-1363	102	33	predominated	predominate	VERB
ajlm-1363	102	34	.	.	PUNCT
ajlm-1363	103	1	compared	compare	VERB
ajlm-1363	103	2	to	to	ADP
ajlm-1363	103	3	a	a	DET
ajlm-1363	103	4	reported	report	VERB
ajlm-1363	103	5	frequency	frequency	NOUN
ajlm-1363	103	6	of	of	ADP
ajlm-1363	103	7	flt3	flt3	PROPN
ajlm-1363	103	8	-	-	PUNCT
ajlm-1363	103	9	itd	itd	NOUN
ajlm-1363	103	10	mutations	mutation	NOUN
ajlm-1363	103	11	in	in	ADP
ajlm-1363	103	12	apl	apl	NOUN
ajlm-1363	103	13	of	of	ADP
ajlm-1363	103	14	up	up	ADP
ajlm-1363	103	15	to	to	ADP
ajlm-1363	103	16	40%,16	40%,16	NOUN
ajlm-1363	103	17	our	our	PRON
ajlm-1363	103	18	results	result	NOUN
ajlm-1363	103	19	were	be	AUX
ajlm-1363	103	20	not	not	PART
ajlm-1363	103	21	surprising	surprising	ADJ
ajlm-1363	103	22	.	.	PUNCT
ajlm-1363	104	1	however	however	ADV
ajlm-1363	104	2	,	,	PUNCT
ajlm-1363	104	3	flt3	flt3	NOUN
ajlm-1363	104	4	-	-	PUNCT
ajlm-1363	104	5	itd	itd	NOUN
ajlm-1363	104	6	mutations	mutation	NOUN
ajlm-1363	104	7	in	in	ADP
ajlm-1363	104	8	aml	aml	NOUN
ajlm-1363	104	9	with	with	ADP
ajlm-1363	104	10	a	a	DET
ajlm-1363	104	11	t(8;21	t(8;21	PROPN
ajlm-1363	104	12	)	)	PUNCT
ajlm-1363	104	13	translocation	translocation	NOUN
ajlm-1363	104	14	,	,	PUNCT
ajlm-1363	104	15	detected	detect	VERB
ajlm-1363	104	16	in	in	ADP
ajlm-1363	104	17	one	one	NUM
ajlm-1363	104	18	of	of	ADP
ajlm-1363	104	19	our	our	PRON
ajlm-1363	104	20	patients	patient	NOUN
ajlm-1363	104	21	,	,	PUNCT
ajlm-1363	104	22	is	be	AUX
ajlm-1363	104	23	thought	think	VERB
ajlm-1363	104	24	to	to	PART
ajlm-1363	104	25	be	be	AUX
ajlm-1363	104	26	uncommon	uncommon	ADJ
ajlm-1363	104	27	,	,	PUNCT
ajlm-1363	104	28	occurring	occur	VERB
ajlm-1363	104	29	in	in	ADP
ajlm-1363	104	30	less	less	ADJ
ajlm-1363	104	31	than	than	ADP
ajlm-1363	104	32	10	10	NUM
ajlm-1363	104	33	%	%	NOUN
ajlm-1363	104	34	of	of	ADP
ajlm-1363	104	35	aml	aml	PROPN
ajlm-1363	104	36	cases.21	cases.21	PROPN
ajlm-1363	104	37	the	the	DET
ajlm-1363	104	38	reported	report	VERB
ajlm-1363	104	39	frequency	frequency	NOUN
ajlm-1363	104	40	of	of	ADP
ajlm-1363	104	41	flt3	flt3	PROPN
ajlm-1363	104	42	-	-	PUNCT
ajlm-1363	104	43	itd	itd	NOUN
ajlm-1363	104	44	mutations	mutation	NOUN
ajlm-1363	104	45	in	in	ADP
ajlm-1363	104	46	cn	cn	PROPN
ajlm-1363	104	47	-	-	NOUN
ajlm-1363	104	48	aml	aml	NOUN
ajlm-1363	104	49	in	in	ADP
ajlm-1363	104	50	african	african	ADJ
ajlm-1363	104	51	populations	population	NOUN
ajlm-1363	104	52	varies	vary	VERB
ajlm-1363	104	53	significantly	significantly	ADV
ajlm-1363	104	54	from	from	ADP
ajlm-1363	104	55	11	11	NUM
ajlm-1363	104	56	%	%	NOUN
ajlm-1363	104	57	in	in	ADP
ajlm-1363	104	58	south	south	ADJ
ajlm-1363	104	59	african	african	ADJ
ajlm-1363	104	60	patients	patient	NOUN
ajlm-1363	104	61	to	to	PART
ajlm-1363	104	62	up	up	ADP
ajlm-1363	104	63	to	to	PART
ajlm-1363	104	64	34.6	34.6	NUM
ajlm-1363	104	65	%	%	NOUN
ajlm-1363	104	66	in	in	ADP
ajlm-1363	104	67	an	an	DET
ajlm-1363	104	68	egyptian	egyptian	ADJ
ajlm-1363	104	69	cohort	cohort	NOUN
ajlm-1363	104	70	,	,	PUNCT
ajlm-1363	104	71	which	which	PRON
ajlm-1363	104	72	is	be	AUX
ajlm-1363	104	73	more	more	ADJ
ajlm-1363	104	74	in	in	ADP
ajlm-1363	104	75	line	line	NOUN
ajlm-1363	104	76	with	with	ADP
ajlm-1363	104	77	data	datum	NOUN
ajlm-1363	104	78	from	from	ADP
ajlm-1363	104	79	high	high	ADJ
ajlm-1363	104	80	-	-	PUNCT
ajlm-1363	104	81	income	income	NOUN
ajlm-1363	104	82	countries.9,15,22	countries.9,15,22	NOUN
ajlm-1363	104	83	the	the	DET
ajlm-1363	104	84	absence	absence	NOUN
ajlm-1363	104	85	of	of	ADP
ajlm-1363	104	86	flt3	flt3	NOUN
ajlm-1363	104	87	-	-	PUNCT
ajlm-1363	104	88	itd	itd	NOUN
ajlm-1363	104	89	in	in	ADP
ajlm-1363	104	90	cn	cn	PROPN
ajlm-1363	104	91	-	-	PUNCT
ajlm-1363	104	92	aml	aml	ADJ
ajlm-1363	104	93	patients	patient	NOUN
ajlm-1363	104	94	in	in	ADP
ajlm-1363	104	95	our	our	PRON
ajlm-1363	104	96	study	study	NOUN
ajlm-1363	104	97	was	be	AUX
ajlm-1363	104	98	unexpected	unexpected	ADJ
ajlm-1363	104	99	,	,	PUNCT
ajlm-1363	104	100	but	but	CCONJ
ajlm-1363	104	101	could	could	AUX
ajlm-1363	104	102	likely	likely	ADV
ajlm-1363	104	103	be	be	AUX
ajlm-1363	104	104	attributed	attribute	VERB
ajlm-1363	104	105	to	to	ADP
ajlm-1363	104	106	the	the	DET
ajlm-1363	104	107	small	small	ADJ
ajlm-1363	104	108	study	study	NOUN
ajlm-1363	104	109	cohort	cohort	NOUN
ajlm-1363	104	110	.	.	PUNCT
ajlm-1363	105	1	we	we	PRON
ajlm-1363	105	2	recommend	recommend	VERB
ajlm-1363	105	3	that	that	SCONJ
ajlm-1363	105	4	the	the	DET
ajlm-1363	105	5	flt3	flt3	NOUN
ajlm-1363	105	6	-	-	PUNCT
ajlm-1363	105	7	itd	itd	NOUN
ajlm-1363	105	8	frequency	frequency	NOUN
ajlm-1363	105	9	should	should	AUX
ajlm-1363	105	10	be	be	AUX
ajlm-1363	105	11	investigated	investigate	VERB
ajlm-1363	105	12	in	in	ADP
ajlm-1363	105	13	a	a	DET
ajlm-1363	105	14	larger	large	ADJ
ajlm-1363	105	15	central	central	ADJ
ajlm-1363	105	16	south	south	ADJ
ajlm-1363	105	17	african	african	ADJ
ajlm-1363	105	18	cn	cn	PROPN
ajlm-1363	105	19	-	-	PUNCT
ajlm-1363	105	20	aml	aml	NOUN
ajlm-1363	105	21	population	population	NOUN
ajlm-1363	105	22	.	.	PUNCT
ajlm-1363	106	1	internal	internal	ADJ
ajlm-1363	106	2	tandem	tandem	NOUN
ajlm-1363	106	3	duplication	duplication	NOUN
ajlm-1363	106	4	lengths	length	NOUN
ajlm-1363	106	5	of	of	ADP
ajlm-1363	106	6	the	the	DET
ajlm-1363	106	7	flt3	flt3	PROPN
ajlm-1363	106	8	mutations	mutation	NOUN
ajlm-1363	106	9	observed	observe	VERB
ajlm-1363	106	10	in	in	ADP
ajlm-1363	106	11	this	this	DET
ajlm-1363	106	12	study	study	NOUN
ajlm-1363	106	13	ranged	range	VERB
ajlm-1363	106	14	between	between	ADP
ajlm-1363	106	15	19	19	NUM
ajlm-1363	106	16	bp	bp	NOUN
ajlm-1363	106	17	and	and	CCONJ
ajlm-1363	106	18	75	75	NUM
ajlm-1363	106	19	bp	bp	PROPN
ajlm-1363	106	20	and	and	CCONJ
ajlm-1363	106	21	were	be	AUX
ajlm-1363	106	22	found	find	VERB
ajlm-1363	106	23	in	in	ADP
ajlm-1363	106	24	the	the	DET
ajlm-1363	106	25	juxtamembrane	juxtamembrane	ADJ
ajlm-1363	106	26	domain	domain	NOUN
ajlm-1363	106	27	of	of	ADP
ajlm-1363	106	28	the	the	DET
ajlm-1363	106	29	gene	gene	NOUN
ajlm-1363	106	30	.	.	PUNCT
ajlm-1363	107	1	according	accord	VERB
ajlm-1363	107	2	to	to	ADP
ajlm-1363	107	3	liu	liu	PROPN
ajlm-1363	107	4	et	et	PROPN
ajlm-1363	107	5	al	al	PROPN
ajlm-1363	107	6	.	.	PROPN
ajlm-1363	107	7	,23	,23	PUNCT
ajlm-1363	107	8	longer	long	ADV
ajlm-1363	107	9	it	it	PRON
ajlm-1363	107	10	d	d	NOUN
ajlm-1363	107	11	lengths	length	NOUN
ajlm-1363	107	12	(	(	PUNCT
ajlm-1363	107	13	more	more	ADJ
ajlm-1363	107	14	than	than	ADP
ajlm-1363	107	15	39	39	NUM
ajlm-1363	107	16	bp	bp	NOUN
ajlm-1363	107	17	)	)	PUNCT
ajlm-1363	107	18	have	have	AUX
ajlm-1363	107	19	been	be	AUX
ajlm-1363	107	20	associated	associate	VERB
ajlm-1363	107	21	with	with	ADP
ajlm-1363	107	22	a	a	DET
ajlm-1363	107	23	worse	bad	ADJ
ajlm-1363	107	24	prognosis	prognosis	NOUN
ajlm-1363	107	25	,	,	PUNCT
ajlm-1363	107	26	the	the	DET
ajlm-1363	107	27	possible	possible	ADJ
ajlm-1363	107	28	reason	reason	NOUN
ajlm-1363	107	29	being	be	AUX
ajlm-1363	107	30	that	that	ADV
ajlm-1363	107	31	longer	long	ADJ
ajlm-1363	107	32	insertions	insertion	NOUN
ajlm-1363	107	33	in	in	ADP
ajlm-1363	107	34	the	the	DET
ajlm-1363	107	35	juxtamembrane	juxtamembrane	PROPN
ajlm-1363	107	36	domain	domain	NOUN
ajlm-1363	107	37	may	may	AUX
ajlm-1363	107	38	cause	cause	VERB
ajlm-1363	107	39	more	more	ADV
ajlm-1363	107	40	significant	significant	ADJ
ajlm-1363	107	41	disruption	disruption	NOUN
ajlm-1363	107	42	of	of	ADP
ajlm-1363	107	43	the	the	DET
ajlm-1363	107	44	domain	domain	NOUN
ajlm-1363	107	45	’s	’s	PART
ajlm-1363	107	46	auto	auto	NOUN
ajlm-1363	107	47	-	-	PUNCT
ajlm-1363	107	48	inhibitory	inhibitory	ADJ
ajlm-1363	107	49	function.23	function.23	NOUN
ajlm-1363	107	50	in	in	ADP
ajlm-1363	107	51	our	our	PRON
ajlm-1363	107	52	study	study	NOUN
ajlm-1363	107	53	,	,	PUNCT
ajlm-1363	107	54	71.4	71.4	NUM
ajlm-1363	107	55	%	%	NOUN
ajlm-1363	107	56	(	(	PUNCT
ajlm-1363	107	57	5/7	5/7	NUM
ajlm-1363	107	58	)	)	PUNCT
ajlm-1363	107	59	of	of	ADP
ajlm-1363	107	60	the	the	DET
ajlm-1363	107	61	patients	patient	NOUN
ajlm-1363	107	62	with	with	ADP
ajlm-1363	107	63	flt3	flt3	NOUN
ajlm-1363	107	64	-	-	PUNCT
ajlm-1363	107	65	itd	itd	NOUN
ajlm-1363	107	66	mutations	mutation	NOUN
ajlm-1363	107	67	had	have	VERB
ajlm-1363	107	68	an	an	DET
ajlm-1363	107	69	it	it	PRON
ajlm-1363	107	70	d	d	ADJ
ajlm-1363	107	71	length	length	NOUN
ajlm-1363	107	72	of	of	ADP
ajlm-1363	107	73	39	39	NUM
ajlm-1363	107	74	bp	bp	NOUN
ajlm-1363	107	75	or	or	CCONJ
ajlm-1363	107	76	longer	long	ADV
ajlm-1363	107	77	.	.	PUNCT
ajlm-1363	108	1	further	further	ADJ
ajlm-1363	108	2	investigations	investigation	NOUN
ajlm-1363	108	3	are	be	AUX
ajlm-1363	108	4	needed	need	VERB
ajlm-1363	108	5	to	to	PART
ajlm-1363	108	6	determine	determine	VERB
ajlm-1363	108	7	whether	whether	SCONJ
ajlm-1363	108	8	the	the	DET
ajlm-1363	108	9	high	high	ADJ
ajlm-1363	108	10	prevalence	prevalence	NOUN
ajlm-1363	108	11	of	of	ADP
ajlm-1363	108	12	flt3	flt3	NOUN
ajlm-1363	108	13	-	-	PUNCT
ajlm-1363	108	14	itd	itd	NOUN
ajlm-1363	108	15	mutations	mutation	NOUN
ajlm-1363	108	16	in	in	ADP
ajlm-1363	108	17	our	our	PRON
ajlm-1363	108	18	apl	apl	NOUN
ajlm-1363	108	19	cohort	cohort	NOUN
ajlm-1363	108	20	confers	confer	NOUN
ajlm-1363	108	21	a	a	DET
ajlm-1363	108	22	worse	bad	ADJ
ajlm-1363	108	23	prognosis	prognosis	NOUN
ajlm-1363	108	24	.	.	PUNCT
ajlm-1363	109	1	this	this	DET
ajlm-1363	109	2	investigation	investigation	NOUN
ajlm-1363	109	3	would	would	AUX
ajlm-1363	109	4	be	be	AUX
ajlm-1363	109	5	justified	justify	VERB
ajlm-1363	109	6	considering	consider	VERB
ajlm-1363	109	7	that	that	SCONJ
ajlm-1363	109	8	the	the	DET
ajlm-1363	109	9	majority	majority	NOUN
ajlm-1363	109	10	(	(	PUNCT
ajlm-1363	109	11	4	4	NUM
ajlm-1363	109	12	of	of	ADP
ajlm-1363	109	13	6	6	NUM
ajlm-1363	109	14	)	)	PUNCT
ajlm-1363	109	15	of	of	ADP
ajlm-1363	109	16	apl	apl	NOUN
ajlm-1363	109	17	patients	patient	NOUN
ajlm-1363	109	18	with	with	ADP
ajlm-1363	109	19	flt3	flt3	NOUN
ajlm-1363	109	20	-	-	PUNCT
ajlm-1363	109	21	itd	itd	NOUN
ajlm-1363	109	22	mutations	mutation	NOUN
ajlm-1363	109	23	had	have	VERB
ajlm-1363	109	24	allele	allele	NOUN
ajlm-1363	109	25	ratios	ratio	NOUN
ajlm-1363	109	26	above	above	ADP
ajlm-1363	109	27	50	50	NUM
ajlm-1363	109	28	%	%	NOUN
ajlm-1363	109	29	and	and	CCONJ
ajlm-1363	109	30	in	in	ADP
ajlm-1363	109	31	other	other	ADJ
ajlm-1363	109	32	aml	aml	PROPN
ajlm-1363	109	33	subgroups	subgroup	NOUN
ajlm-1363	109	34	,	,	PUNCT
ajlm-1363	109	35	allelic	allelic	ADJ
ajlm-1363	109	36	ratios	ratio	NOUN
ajlm-1363	109	37	above	above	ADP
ajlm-1363	109	38	50	50	NUM
ajlm-1363	109	39	%	%	NOUN
ajlm-1363	109	40	are	be	AUX
ajlm-1363	109	41	stratified	stratify	VERB
ajlm-1363	109	42	as	as	ADP
ajlm-1363	109	43	an	an	DET
ajlm-1363	109	44	adverse	adverse	ADJ
ajlm-1363	109	45	prognostic	prognostic	ADJ
ajlm-1363	109	46	risk.24	risk.24	NOUN
ajlm-1363	109	47	an	an	DET
ajlm-1363	109	48	interesting	interesting	ADJ
ajlm-1363	109	49	observation	observation	NOUN
ajlm-1363	109	50	was	be	AUX
ajlm-1363	109	51	the	the	DET
ajlm-1363	109	52	unusually	unusually	ADV
ajlm-1363	109	53	high	high	ADJ
ajlm-1363	109	54	number	number	NOUN
ajlm-1363	109	55	of	of	ADP
ajlm-1363	109	56	apl	apl	NOUN
ajlm-1363	109	57	cases	case	NOUN
ajlm-1363	109	58	among	among	ADP
ajlm-1363	109	59	our	our	PRON
ajlm-1363	109	60	aml	aml	NOUN
ajlm-1363	109	61	cohort	cohort	NOUN
ajlm-1363	109	62	,	,	PUNCT
ajlm-1363	109	63	which	which	PRON
ajlm-1363	109	64	,	,	PUNCT
ajlm-1363	109	65	according	accord	VERB
ajlm-1363	109	66	to	to	ADP
ajlm-1363	109	67	the	the	DET
ajlm-1363	109	68	revised	revised	ADJ
ajlm-1363	109	69	4th	4th	ADJ
ajlm-1363	109	70	edition	edition	NOUN
ajlm-1363	109	71	of	of	ADP
ajlm-1363	109	72	the	the	DET
ajlm-1363	109	73	classification	classification	NOUN
ajlm-1363	109	74	of	of	ADP
ajlm-1363	109	75	tumours	tumour	NOUN
ajlm-1363	109	76	of	of	ADP
ajlm-1363	109	77	haemopoietic	haemopoietic	ADJ
ajlm-1363	109	78	and	and	CCONJ
ajlm-1363	109	79	lymphoid	lymphoid	ADJ
ajlm-1363	109	80	tissues	tissue	NOUN
ajlm-1363	109	81	,	,	PUNCT
ajlm-1363	109	82	only	only	ADV
ajlm-1363	109	83	accounts	account	VERB
ajlm-1363	109	84	for	for	ADP
ajlm-1363	109	85	5	5	NUM
ajlm-1363	109	86	%	%	NOUN
ajlm-1363	109	87	–	–	PUNCT
ajlm-1363	109	88	8	8	NUM
ajlm-1363	109	89	%	%	NOUN
ajlm-1363	109	90	of	of	ADP
ajlm-1363	109	91	aml	aml	PROPN
ajlm-1363	109	92	cases.16	cases.16	PROPN
ajlm-1363	109	93	notably	notably	ADV
ajlm-1363	109	94	,	,	PUNCT
ajlm-1363	109	95	eight	eight	NUM
ajlm-1363	109	96	of	of	ADP
ajlm-1363	109	97	our	our	PRON
ajlm-1363	109	98	apl	apl	NOUN
ajlm-1363	109	99	patients	patient	NOUN
ajlm-1363	109	100	presented	present	VERB
ajlm-1363	109	101	within	within	ADP
ajlm-1363	109	102	a	a	DET
ajlm-1363	109	103	single	single	ADJ
ajlm-1363	109	104	month	month	NOUN
ajlm-1363	109	105	.	.	PUNCT
ajlm-1363	110	1	several	several	ADJ
ajlm-1363	110	2	studies	study	NOUN
ajlm-1363	110	3	,	,	PUNCT
ajlm-1363	110	4	including	include	VERB
ajlm-1363	110	5	a	a	DET
ajlm-1363	110	6	south	south	ADJ
ajlm-1363	110	7	african	african	ADJ
ajlm-1363	110	8	study	study	NOUN
ajlm-1363	110	9	,	,	PUNCT
ajlm-1363	110	10	have	have	AUX
ajlm-1363	110	11	alluded	allude	VERB
ajlm-1363	110	12	to	to	ADP
ajlm-1363	110	13	the	the	DET
ajlm-1363	110	14	association	association	NOUN
ajlm-1363	110	15	between	between	ADP
ajlm-1363	110	16	apl	apl	PROPN
ajlm-1363	110	17	clustering	clustering	NOUN
ajlm-1363	110	18	and	and	CCONJ
ajlm-1363	110	19	seasonality.25,26,27	seasonality.25,26,27	NOUN
ajlm-1363	110	20	with	with	ADP
ajlm-1363	110	21	such	such	DET
ajlm-1363	110	22	a	a	DET
ajlm-1363	110	23	small	small	ADJ
ajlm-1363	110	24	study	study	NOUN
ajlm-1363	110	25	cohort	cohort	NOUN
ajlm-1363	110	26	,	,	PUNCT
ajlm-1363	110	27	one	one	PRON
ajlm-1363	110	28	can	can	AUX
ajlm-1363	110	29	only	only	ADV
ajlm-1363	110	30	speculate	speculate	VERB
ajlm-1363	110	31	that	that	SCONJ
ajlm-1363	110	32	seasonality	seasonality	NOUN
ajlm-1363	110	33	may	may	AUX
ajlm-1363	110	34	have	have	AUX
ajlm-1363	110	35	contributed	contribute	VERB
ajlm-1363	110	36	and	and	CCONJ
ajlm-1363	110	37	warrants	warrant	NOUN
ajlm-1363	110	38	further	further	ADJ
ajlm-1363	110	39	investigation	investigation	NOUN
ajlm-1363	110	40	.	.	PUNCT
ajlm-1363	111	1	similar	similar	ADJ
ajlm-1363	111	2	to	to	ADP
ajlm-1363	111	3	a	a	DET
ajlm-1363	111	4	sudanese	sudanese	ADJ
ajlm-1363	111	5	study	study	NOUN
ajlm-1363	111	6	involving	involve	VERB
ajlm-1363	111	7	100	100	NUM
ajlm-1363	111	8	aml	aml	NOUN
ajlm-1363	111	9	patients,14	patients,14	ADP
ajlm-1363	111	10	none	none	NOUN
ajlm-1363	111	11	of	of	ADP
ajlm-1363	111	12	the	the	DET
ajlm-1363	111	13	patients	patient	NOUN
ajlm-1363	111	14	in	in	ADP
ajlm-1363	111	15	this	this	DET
ajlm-1363	111	16	study	study	NOUN
ajlm-1363	111	17	had	have	VERB
ajlm-1363	111	18	an	an	DET
ajlm-1363	111	19	npm1	npm1	NOUN
ajlm-1363	111	20	mutation	mutation	NOUN
ajlm-1363	111	21	.	.	PUNCT
ajlm-1363	112	1	however	however	ADV
ajlm-1363	112	2	,	,	PUNCT
ajlm-1363	112	3	npm1	npm1	NOUN
ajlm-1363	112	4	mutations	mutation	NOUN
ajlm-1363	112	5	were	be	AUX
ajlm-1363	112	6	detected	detect	VERB
ajlm-1363	112	7	in	in	ADP
ajlm-1363	112	8	28.3	28.3	NUM
ajlm-1363	112	9	%	%	NOUN
ajlm-1363	112	10	of	of	ADP
ajlm-1363	112	11	egyptian	egyptian	ADJ
ajlm-1363	112	12	cn	cn	PROPN
ajlm-1363	112	13	-	-	PUNCT
ajlm-1363	112	14	aml	aml	NOUN
ajlm-1363	112	15	patients	patient	NOUN
ajlm-1363	112	16	and	and	CCONJ
ajlm-1363	112	17	7.5	7.5	NUM
ajlm-1363	112	18	%	%	NOUN
ajlm-1363	112	19	of	of	ADP
ajlm-1363	112	20	south	south	ADJ
ajlm-1363	112	21	african	african	ADJ
ajlm-1363	112	22	aml	aml	PROPN
ajlm-1363	112	23	patients.13,15	patients.13,15	VERB
ajlm-1363	112	24	the	the	DET
ajlm-1363	112	25	complete	complete	ADJ
ajlm-1363	112	26	absence	absence	NOUN
ajlm-1363	112	27	of	of	ADP
ajlm-1363	112	28	the	the	DET
ajlm-1363	112	29	npm1	npm1	NOUN
ajlm-1363	112	30	mutation	mutation	NOUN
ajlm-1363	112	31	in	in	ADP
ajlm-1363	112	32	this	this	DET
ajlm-1363	112	33	study	study	NOUN
ajlm-1363	112	34	could	could	AUX
ajlm-1363	112	35	be	be	AUX
ajlm-1363	112	36	attributed	attribute	VERB
ajlm-1363	112	37	to	to	ADP
ajlm-1363	112	38	the	the	DET
ajlm-1363	112	39	low	low	ADJ
ajlm-1363	112	40	median	median	ADJ
ajlm-1363	112	41	age	age	NOUN
ajlm-1363	112	42	at	at	ADP
ajlm-1363	112	43	disease	disease	NOUN
ajlm-1363	112	44	presentation	presentation	NOUN
ajlm-1363	112	45	in	in	ADP
ajlm-1363	112	46	the	the	DET
ajlm-1363	112	47	study	study	NOUN
ajlm-1363	112	48	cohort	cohort	NOUN
ajlm-1363	112	49	,	,	PUNCT
ajlm-1363	112	50	especially	especially	ADV
ajlm-1363	112	51	considering	consider	VERB
ajlm-1363	112	52	that	that	SCONJ
ajlm-1363	112	53	the	the	DET
ajlm-1363	112	54	frequency	frequency	NOUN
ajlm-1363	112	55	of	of	ADP
ajlm-1363	112	56	npm1	npm1	NOUN
ajlm-1363	112	57	mutations	mutation	NOUN
ajlm-1363	112	58	increases	increase	VERB
ajlm-1363	112	59	proportionally	proportionally	ADV
ajlm-1363	112	60	with	with	ADP
ajlm-1363	112	61	age.28	age.28	NOUN
ajlm-1363	112	62	in	in	ADP
ajlm-1363	112	63	addition	addition	NOUN
ajlm-1363	112	64	,	,	PUNCT
ajlm-1363	112	65	npm1	npm1	NOUN
ajlm-1363	112	66	mutations	mutation	NOUN
ajlm-1363	112	67	are	be	AUX
ajlm-1363	112	68	more	more	ADV
ajlm-1363	112	69	commonly	commonly	ADV
ajlm-1363	112	70	associated	associate	VERB
ajlm-1363	112	71	with	with	ADP
ajlm-1363	112	72	cn	cn	PROPN
ajlm-1363	112	73	-	-	PUNCT
ajlm-1363	112	74	aml,16	aml,16	NOUN
ajlm-1363	112	75	which	which	PRON
ajlm-1363	112	76	accounted	account	VERB
ajlm-1363	112	77	for	for	ADP
ajlm-1363	112	78	only	only	ADV
ajlm-1363	112	79	35	35	NUM
ajlm-1363	112	80	%	%	NOUN
ajlm-1363	112	81	(	(	PUNCT
ajlm-1363	112	82	n	n	NOUN
ajlm-1363	112	83	=	=	SYM
ajlm-1363	112	84	14	14	NUM
ajlm-1363	112	85	)	)	PUNCT
ajlm-1363	112	86	of	of	ADP
ajlm-1363	112	87	all	all	DET
ajlm-1363	112	88	cases	case	NOUN
ajlm-1363	112	89	in	in	ADP
ajlm-1363	112	90	this	this	PRON
ajlm-1363	112	91	study.4,9	study.4,9	ADP
ajlm-1363	112	92	the	the	DET
ajlm-1363	112	93	cancer	cancer	NOUN
ajlm-1363	112	94	genome	genome	NOUN
ajlm-1363	112	95	atlas	atlas	PROPN
ajlm-1363	112	96	research	research	PROPN
ajlm-1363	112	97	network	network	NOUN
ajlm-1363	112	98	reported	report	VERB
ajlm-1363	112	99	that	that	SCONJ
ajlm-1363	112	100	nearly	nearly	ADV
ajlm-1363	112	101	50	50	NUM
ajlm-1363	112	102	%	%	NOUN
ajlm-1363	112	103	of	of	ADP
ajlm-1363	112	104	all	all	DET
ajlm-1363	112	105	aml	aml	NOUN
ajlm-1363	112	106	patients	patient	NOUN
ajlm-1363	112	107	are	be	AUX
ajlm-1363	112	108	cn	cn	ADJ
ajlm-1363	112	109	-	-	PUNCT
ajlm-1363	112	110	aml	aml	NOUN
ajlm-1363	112	111	cases	case	NOUN
ajlm-1363	112	112	,	,	PUNCT
ajlm-1363	112	113	and	and	CCONJ
ajlm-1363	112	114	the	the	DET
ajlm-1363	112	115	observed	observed	ADJ
ajlm-1363	112	116	prevalence	prevalence	NOUN
ajlm-1363	112	117	of	of	ADP
ajlm-1363	112	118	cn	cn	PROPN
ajlm-1363	112	119	-	-	NOUN
ajlm-1363	112	120	aml	aml	NOUN
ajlm-1363	112	121	in	in	ADP
ajlm-1363	112	122	the	the	DET
ajlm-1363	112	123	current	current	ADJ
ajlm-1363	112	124	study	study	NOUN
ajlm-1363	112	125	was	be	AUX
ajlm-1363	112	126	lower.6	lower.6	NOUN
ajlm-1363	112	127	the	the	DET
ajlm-1363	112	128	lower	low	ADJ
ajlm-1363	112	129	prevalence	prevalence	NOUN
ajlm-1363	112	130	of	of	ADP
ajlm-1363	112	131	cn	cn	PROPN
ajlm-1363	112	132	-	-	PUNCT
ajlm-1363	112	133	aml	aml	NOUN
ajlm-1363	112	134	relative	relative	NOUN
ajlm-1363	112	135	to	to	ADP
ajlm-1363	112	136	aml	aml	NOUN
ajlm-1363	112	137	with	with	ADP
ajlm-1363	112	138	recurrent	recurrent	ADJ
ajlm-1363	112	139	genetic	genetic	ADJ
ajlm-1363	112	140	abnormalities	abnormality	NOUN
ajlm-1363	112	141	in	in	ADP
ajlm-1363	112	142	our	our	PRON
ajlm-1363	112	143	study	study	NOUN
ajlm-1363	112	144	,	,	PUNCT
ajlm-1363	112	145	and	and	CCONJ
ajlm-1363	112	146	,	,	PUNCT
ajlm-1363	112	147	by	by	ADP
ajlm-1363	112	148	association	association	NOUN
ajlm-1363	112	149	,	,	PUNCT
ajlm-1363	112	150	the	the	DET
ajlm-1363	112	151	lower	low	ADJ
ajlm-1363	112	152	prevalence	prevalence	NOUN
ajlm-1363	112	153	of	of	ADP
ajlm-1363	112	154	these	these	DET
ajlm-1363	112	155	two	two	NUM
ajlm-1363	112	156	mutations	mutation	NOUN
ajlm-1363	112	157	commonly	commonly	ADV
ajlm-1363	112	158	linked	link	VERB
ajlm-1363	112	159	with	with	ADP
ajlm-1363	112	160	cn	cn	PROPN
ajlm-1363	112	161	-	-	PUNCT
ajlm-1363	112	162	aml	aml	NOUN
ajlm-1363	112	163	,	,	PUNCT
ajlm-1363	112	164	might	might	AUX
ajlm-1363	112	165	be	be	AUX
ajlm-1363	112	166	attributed	attribute	VERB
ajlm-1363	112	167	to	to	ADP
ajlm-1363	112	168	race	race	NOUN
ajlm-1363	112	169	,	,	PUNCT
ajlm-1363	112	170	as	as	SCONJ
ajlm-1363	112	171	black	black	ADJ
ajlm-1363	112	172	patients	patient	NOUN
ajlm-1363	112	173	were	be	AUX
ajlm-1363	112	174	previously	previously	ADV
ajlm-1363	112	175	found	find	VERB
ajlm-1363	112	176	to	to	PART
ajlm-1363	112	177	be	be	AUX
ajlm-1363	112	178	more	more	ADV
ajlm-1363	112	179	likely	likely	ADJ
ajlm-1363	112	180	to	to	PART
ajlm-1363	112	181	have	have	VERB
ajlm-1363	112	182	aml	aml	PROPN
ajlm-1363	112	183	associated	associate	VERB
ajlm-1363	112	184	with	with	ADP
ajlm-1363	112	185	cytogenetic	cytogenetic	ADJ
ajlm-1363	112	186	abnormalities.18,29	abnormalities.18,29	ADJ
ajlm-1363	112	187	limitations	limitation	NOUN
ajlm-1363	112	188	this	this	DET
ajlm-1363	112	189	study	study	NOUN
ajlm-1363	112	190	was	be	AUX
ajlm-1363	112	191	limited	limit	VERB
ajlm-1363	112	192	by	by	ADP
ajlm-1363	112	193	a	a	DET
ajlm-1363	112	194	small	small	ADJ
ajlm-1363	112	195	sample	sample	NOUN
ajlm-1363	112	196	population	population	NOUN
ajlm-1363	112	197	.	.	PUNCT
ajlm-1363	113	1	in	in	ADP
ajlm-1363	113	2	addition	addition	NOUN
ajlm-1363	113	3	,	,	PUNCT
ajlm-1363	113	4	the	the	DET
ajlm-1363	113	5	predominance	predominance	NOUN
ajlm-1363	113	6	of	of	ADP
ajlm-1363	113	7	apl	apl	NOUN
ajlm-1363	113	8	cases	case	NOUN
ajlm-1363	113	9	in	in	ADP
ajlm-1363	113	10	our	our	PRON
ajlm-1363	113	11	cohort	cohort	NOUN
ajlm-1363	113	12	may	may	AUX
ajlm-1363	113	13	have	have	AUX
ajlm-1363	113	14	contributed	contribute	VERB
ajlm-1363	113	15	to	to	ADP
ajlm-1363	113	16	a	a	DET
ajlm-1363	113	17	biased	biased	ADJ
ajlm-1363	113	18	prevalence	prevalence	NOUN
ajlm-1363	113	19	of	of	ADP
ajlm-1363	113	20	the	the	DET
ajlm-1363	113	21	flt3	flt3	NOUN
ajlm-1363	113	22	-	-	PUNCT
ajlm-1363	113	23	itd	itd	NOUN
ajlm-1363	113	24	mutation	mutation	NOUN
ajlm-1363	113	25	.	.	PUNCT
ajlm-1363	114	1	an	an	DET
ajlm-1363	114	2	association	association	NOUN
ajlm-1363	114	3	between	between	ADP
ajlm-1363	114	4	phenotype	phenotype	NOUN
ajlm-1363	114	5	and	and	CCONJ
ajlm-1363	114	6	genotype	genotype	NOUN
ajlm-1363	114	7	was	be	AUX
ajlm-1363	114	8	also	also	ADV
ajlm-1363	114	9	not	not	PART
ajlm-1363	114	10	determined	determine	VERB
ajlm-1363	114	11	.	.	PUNCT
ajlm-1363	115	1	conclusion	conclusion	VERB
ajlm-1363	115	2	the	the	DET
ajlm-1363	115	3	flt3	flt3	NOUN
ajlm-1363	115	4	-	-	PUNCT
ajlm-1363	115	5	itd	itd	NOUN
ajlm-1363	115	6	mutation	mutation	NOUN
ajlm-1363	115	7	was	be	AUX
ajlm-1363	115	8	mainly	mainly	ADV
ajlm-1363	115	9	found	find	VERB
ajlm-1363	115	10	in	in	ADP
ajlm-1363	115	11	apl	apl	NOUN
ajlm-1363	115	12	cases	case	NOUN
ajlm-1363	115	13	at	at	ADP
ajlm-1363	115	14	a	a	DET
ajlm-1363	115	15	similar	similar	ADJ
ajlm-1363	115	16	prevalence	prevalence	NOUN
ajlm-1363	115	17	as	as	SCONJ
ajlm-1363	115	18	reported	report	VERB
ajlm-1363	115	19	in	in	ADP
ajlm-1363	115	20	the	the	DET
ajlm-1363	115	21	literature	literature	NOUN
ajlm-1363	115	22	.	.	PUNCT
ajlm-1363	116	1	high	high	ADJ
ajlm-1363	116	2	flt3	flt3	PROPN
ajlm-1363	116	3	-	-	PUNCT
ajlm-1363	116	4	itd	itd	NOUN
ajlm-1363	116	5	allele	allele	NOUN
ajlm-1363	116	6	ratios	ratio	NOUN
ajlm-1363	116	7	and	and	CCONJ
ajlm-1363	116	8	long	long	ADV
ajlm-1363	116	9	it	it	PRON
ajlm-1363	116	10	d	d	NOUN
ajlm-1363	116	11	lengths	length	NOUN
ajlm-1363	116	12	predominated	predominate	VERB
ajlm-1363	116	13	.	.	PUNCT
ajlm-1363	117	1	no	no	DET
ajlm-1363	117	2	npm1	npm1	PROPN
ajlm-1363	117	3	mutations	mutation	NOUN
ajlm-1363	117	4	were	be	AUX
ajlm-1363	117	5	detected	detect	VERB
ajlm-1363	117	6	.	.	PUNCT
ajlm-1363	118	1	the	the	DET
ajlm-1363	118	2	absence	absence	NOUN
ajlm-1363	118	3	and	and	CCONJ
ajlm-1363	118	4	lower	low	ADJ
ajlm-1363	118	5	frequency	frequency	NOUN
ajlm-1363	118	6	of	of	ADP
ajlm-1363	118	7	npm1	npm1	NOUN
ajlm-1363	118	8	and	and	CCONJ
ajlm-1363	118	9	flt3	flt3	NOUN
ajlm-1363	118	10	-	-	PUNCT
ajlm-1363	118	11	itd	itd	NOUN
ajlm-1363	118	12	mutations	mutation	NOUN
ajlm-1363	118	13	could	could	AUX
ajlm-1363	118	14	possibly	possibly	ADV
ajlm-1363	118	15	be	be	AUX
ajlm-1363	118	16	attributed	attribute	VERB
ajlm-1363	118	17	to	to	ADP
ajlm-1363	118	18	the	the	DET
ajlm-1363	118	19	low	low	ADJ
ajlm-1363	118	20	median	median	ADJ
ajlm-1363	118	21	age	age	NOUN
ajlm-1363	118	22	at	at	ADP
ajlm-1363	118	23	presentation	presentation	NOUN
ajlm-1363	118	24	and	and	CCONJ
ajlm-1363	118	25	the	the	DET
ajlm-1363	118	26	majority	majority	NOUN
ajlm-1363	118	27	of	of	ADP
ajlm-1363	118	28	patients	patient	NOUN
ajlm-1363	118	29	presenting	present	VERB
ajlm-1363	118	30	with	with	ADP
ajlm-1363	118	31	aml	aml	NOUN
ajlm-1363	118	32	with	with	ADP
ajlm-1363	118	33	recurrent	recurrent	ADJ
ajlm-1363	118	34	genetic	genetic	ADJ
ajlm-1363	118	35	abnormalities	abnormality	NOUN
ajlm-1363	118	36	.	.	PUNCT
ajlm-1363	119	1	acknowledgements	acknowledgement	NOUN
ajlm-1363	119	2	the	the	DET
ajlm-1363	119	3	authors	author	NOUN
ajlm-1363	119	4	acknowledge	acknowledge	VERB
ajlm-1363	119	5	the	the	DET
ajlm-1363	119	6	national	national	PROPN
ajlm-1363	119	7	health	health	PROPN
ajlm-1363	119	8	laboratory	laboratory	PROPN
ajlm-1363	119	9	service	service	NOUN
ajlm-1363	119	10	for	for	ADP
ajlm-1363	119	11	funding	fund	VERB
ajlm-1363	119	12	the	the	DET
ajlm-1363	119	13	project	project	NOUN
ajlm-1363	119	14	,	,	PUNCT
ajlm-1363	119	15	ms	ms	PROPN
ajlm-1363	119	16	leandi	leandi	PROPN
ajlm-1363	119	17	du	du	PROPN
ajlm-1363	119	18	plessis	plessis	PROPN
ajlm-1363	119	19	for	for	ADP
ajlm-1363	119	20	technical	technical	ADJ
ajlm-1363	119	21	assistance	assistance	NOUN
ajlm-1363	119	22	and	and	CCONJ
ajlm-1363	119	23	dr	dr	PROPN
ajlm-1363	119	24	daleen	daleen	PROPN
ajlm-1363	119	25	struwig	struwig	PROPN
ajlm-1363	119	26	for	for	ADP
ajlm-1363	119	27	assistance	assistance	NOUN
ajlm-1363	119	28	with	with	ADP
ajlm-1363	119	29	the	the	DET
ajlm-1363	119	30	technical	technical	ADJ
ajlm-1363	119	31	and	and	CCONJ
ajlm-1363	119	32	editorial	editorial	ADJ
ajlm-1363	119	33	preparation	preparation	NOUN
ajlm-1363	119	34	of	of	ADP
ajlm-1363	119	35	the	the	DET
ajlm-1363	119	36	manuscript	manuscript	NOUN
ajlm-1363	119	37	.	.	PUNCT
ajlm-1363	120	1	competing	compete	VERB
ajlm-1363	120	2	interests	interest	NOUN
ajlm-1363	120	3	the	the	DET
ajlm-1363	120	4	authors	author	NOUN
ajlm-1363	120	5	declare	declare	VERB
ajlm-1363	120	6	that	that	SCONJ
ajlm-1363	120	7	they	they	PRON
ajlm-1363	120	8	have	have	VERB
ajlm-1363	120	9	no	no	DET
ajlm-1363	120	10	financial	financial	ADJ
ajlm-1363	120	11	or	or	CCONJ
ajlm-1363	120	12	personal	personal	ADJ
ajlm-1363	120	13	relationships	relationship	NOUN
ajlm-1363	120	14	that	that	PRON
ajlm-1363	120	15	may	may	AUX
ajlm-1363	120	16	have	have	AUX
ajlm-1363	120	17	inappropriately	inappropriately	ADV
ajlm-1363	120	18	influenced	influence	VERB
ajlm-1363	120	19	them	they	PRON
ajlm-1363	120	20	in	in	ADP
ajlm-1363	120	21	writing	write	VERB
ajlm-1363	120	22	this	this	DET
ajlm-1363	120	23	article	article	NOUN
ajlm-1363	120	24	.	.	PUNCT
ajlm-1363	121	1	authors	author	NOUN
ajlm-1363	121	2	’	’	PART
ajlm-1363	121	3	contributions	contribution	NOUN
ajlm-1363	121	4	j.f.k	j.f.k	NOUN
ajlm-1363	121	5	.	.	PUNCT
ajlm-1363	121	6	was	be	AUX
ajlm-1363	121	7	involved	involve	VERB
ajlm-1363	121	8	in	in	ADP
ajlm-1363	121	9	the	the	DET
ajlm-1363	121	10	study	study	NOUN
ajlm-1363	121	11	design	design	NOUN
ajlm-1363	121	12	,	,	PUNCT
ajlm-1363	121	13	assisted	assist	VERB
ajlm-1363	121	14	in	in	ADP
ajlm-1363	121	15	performing	perform	VERB
ajlm-1363	121	16	the	the	DET
ajlm-1363	121	17	study	study	NOUN
ajlm-1363	121	18	,	,	PUNCT
ajlm-1363	121	19	performed	perform	VERB
ajlm-1363	121	20	data	datum	NOUN
ajlm-1363	121	21	analysis	analysis	NOUN
ajlm-1363	121	22	and	and	CCONJ
ajlm-1363	121	23	contributed	contribute	VERB
ajlm-1363	121	24	to	to	ADP
ajlm-1363	121	25	writing	write	VERB
ajlm-1363	121	26	the	the	DET
ajlm-1363	121	27	manuscript	manuscript	NOUN
ajlm-1363	121	28	.	.	PUNCT
ajlm-1363	122	1	a.-c.v.m	a.-c.v.m	PROPN
ajlm-1363	122	2	.	.	PUNCT
ajlm-1363	123	1	analysed	analyse	VERB
ajlm-1363	123	2	clinical	clinical	ADJ
ajlm-1363	123	3	data	datum	NOUN
ajlm-1363	123	4	and	and	CCONJ
ajlm-1363	123	5	contributed	contribute	VERB
ajlm-1363	123	6	to	to	ADP
ajlm-1363	123	7	writing	write	VERB
ajlm-1363	123	8	the	the	DET
ajlm-1363	123	9	manuscript	manuscript	NOUN
ajlm-1363	123	10	.	.	PUNCT
ajlm-1363	124	1	j.c	j.c	PROPN
ajlm-1363	124	2	.	.	PROPN
ajlm-1363	124	3	assisted	assist	VERB
ajlm-1363	124	4	in	in	ADP
ajlm-1363	124	5	performing	perform	VERB
ajlm-1363	124	6	the	the	DET
ajlm-1363	124	7	study	study	NOUN
ajlm-1363	124	8	and	and	CCONJ
ajlm-1363	124	9	critically	critically	ADV
ajlm-1363	124	10	evaluated	evaluate	VERB
ajlm-1363	124	11	the	the	DET
ajlm-1363	124	12	manuscript	manuscript	NOUN
ajlm-1363	124	13	.	.	PUNCT
ajlm-1363	125	1	a.d.k	a.d.k	PROPN
ajlm-1363	125	2	.	.	PROPN
ajlm-1363	126	1	was	be	AUX
ajlm-1363	126	2	involved	involve	VERB
ajlm-1363	126	3	in	in	ADP
ajlm-1363	126	4	the	the	DET
ajlm-1363	126	5	study	study	NOUN
ajlm-1363	126	6	design	design	NOUN
ajlm-1363	126	7	,	,	PUNCT
ajlm-1363	126	8	supervised	supervise	VERB
ajlm-1363	126	9	the	the	DET
ajlm-1363	126	10	study	study	NOUN
ajlm-1363	126	11	and	and	CCONJ
ajlm-1363	126	12	critically	critically	ADV
ajlm-1363	126	13	evaluated	evaluate	VERB
ajlm-1363	126	14	the	the	DET
ajlm-1363	126	15	manuscript	manuscript	NOUN
ajlm-1363	126	16	.	.	PUNCT
ajlm-1363	127	1	all	all	DET
ajlm-1363	127	2	the	the	DET
ajlm-1363	127	3	authors	author	NOUN
ajlm-1363	127	4	approved	approve	VERB
ajlm-1363	127	5	the	the	DET
ajlm-1363	127	6	final	final	ADJ
ajlm-1363	127	7	version	version	NOUN
ajlm-1363	127	8	of	of	ADP
ajlm-1363	127	9	the	the	DET
ajlm-1363	127	10	article	article	NOUN
ajlm-1363	127	11	prior	prior	ADV
ajlm-1363	127	12	to	to	ADP
ajlm-1363	127	13	submission	submission	NOUN
ajlm-1363	127	14	.	.	PUNCT
ajlm-1363	128	1	sources	source	NOUN
ajlm-1363	128	2	of	of	ADP
ajlm-1363	128	3	support	support	NOUN
ajlm-1363	128	4	funding	funding	NOUN
ajlm-1363	128	5	was	be	AUX
ajlm-1363	128	6	received	receive	VERB
ajlm-1363	128	7	from	from	ADP
ajlm-1363	128	8	the	the	DET
ajlm-1363	128	9	national	national	PROPN
ajlm-1363	128	10	health	health	PROPN
ajlm-1363	128	11	laboratory	laboratory	PROPN
ajlm-1363	128	12	service	service	PROPN
ajlm-1363	128	13	research	research	NOUN
ajlm-1363	128	14	development	development	NOUN
ajlm-1363	128	15	grant	grant	NOUN
ajlm-1363	128	16	(	(	PUNCT
ajlm-1363	128	17	grant004_94767	grant004_94767	PROPN
ajlm-1363	128	18	)	)	PUNCT
ajlm-1363	128	19	.	.	PUNCT
ajlm-1363	129	1	data	datum	NOUN
ajlm-1363	129	2	availability	availability	NOUN
ajlm-1363	129	3	data	datum	NOUN
ajlm-1363	129	4	are	be	AUX
ajlm-1363	129	5	available	available	ADJ
ajlm-1363	129	6	from	from	ADP
ajlm-1363	129	7	the	the	DET
ajlm-1363	129	8	corresponding	corresponding	ADJ
ajlm-1363	129	9	author	author	NOUN
ajlm-1363	129	10	upon	upon	SCONJ
ajlm-1363	129	11	reasonable	reasonable	ADJ
ajlm-1363	129	12	request	request	NOUN
ajlm-1363	129	13	.	.	PUNCT
ajlm-1363	130	1	disclaimer	disclaimer	VERB
ajlm-1363	130	2	the	the	DET
ajlm-1363	130	3	views	view	NOUN
ajlm-1363	130	4	and	and	CCONJ
ajlm-1363	130	5	opinions	opinion	NOUN
ajlm-1363	130	6	expressed	express	VERB
ajlm-1363	130	7	in	in	ADP
ajlm-1363	130	8	this	this	DET
ajlm-1363	130	9	article	article	NOUN
ajlm-1363	130	10	are	be	AUX
ajlm-1363	130	11	those	those	PRON
ajlm-1363	130	12	of	of	ADP
ajlm-1363	130	13	the	the	DET
ajlm-1363	130	14	authors	author	NOUN
ajlm-1363	130	15	and	and	CCONJ
ajlm-1363	130	16	do	do	AUX
ajlm-1363	130	17	not	not	PART
ajlm-1363	130	18	necessarily	necessarily	ADV
ajlm-1363	130	19	reflect	reflect	VERB
ajlm-1363	130	20	the	the	DET
ajlm-1363	130	21	official	official	ADJ
ajlm-1363	130	22	policy	policy	NOUN
ajlm-1363	130	23	or	or	CCONJ
ajlm-1363	130	24	position	position	NOUN
ajlm-1363	130	25	of	of	ADP
ajlm-1363	130	26	any	any	DET
ajlm-1363	130	27	affiliated	affiliated	ADJ
ajlm-1363	130	28	agency	agency	NOUN
ajlm-1363	130	29	of	of	ADP
ajlm-1363	130	30	the	the	DET
ajlm-1363	130	31	authors	author	NOUN
ajlm-1363	130	32	.	.	PUNCT
ajlm-1363	131	1	references	reference	NOUN
ajlm-1363	131	2	shanmugam	shanmugam	PROPN
ajlm-1363	131	3	v	v	PROPN
ajlm-1363	131	4	,	,	PUNCT
ajlm-1363	131	5	kim	kim	PROPN
ajlm-1363	131	6	as	as	ADP
ajlm-1363	131	7	.	.	PUNCT
ajlm-1363	132	1	molecular	molecular	ADJ
ajlm-1363	132	2	versus	versus	ADP
ajlm-1363	132	3	morphological	morphological	ADJ
ajlm-1363	132	4	classifications	classification	NOUN
ajlm-1363	132	5	of	of	ADP
ajlm-1363	132	6	myeloproliferative	myeloproliferative	ADJ
ajlm-1363	132	7	neoplasms	neoplasm	NOUN
ajlm-1363	132	8	:	:	PUNCT
ajlm-1363	132	9	you	you	PRON
ajlm-1363	132	10	do	do	AUX
ajlm-1363	132	11	n’t	not	PART
ajlm-1363	132	12	know	know	VERB
ajlm-1363	132	13	jak	jak	PROPN
ajlm-1363	132	14	!	!	PUNCT
ajlm-1363	133	1	the	the	DET
ajlm-1363	133	2	hematologist	hematologist	NOUN
ajlm-1363	133	3	:	:	PUNCT
ajlm-1363	133	4	ash	ash	NOUN
ajlm-1363	133	5	news	news	NOUN
ajlm-1363	133	6	and	and	CCONJ
ajlm-1363	133	7	reports	report	NOUN
ajlm-1363	133	8	[	[	X
ajlm-1363	133	9	serial	serial	ADJ
ajlm-1363	133	10	online	online	NOUN
ajlm-1363	133	11	]	]	PUNCT
ajlm-1363	133	12	.	.	PUNCT
ajlm-1363	134	1	2019;16(1):12–13	2019;16(1):12–13	X
ajlm-1363	134	2	.	.	PUNCT
ajlm-1363	134	3	available	available	ADJ
ajlm-1363	134	4	from	from	ADP
ajlm-1363	134	5	:	:	PUNCT
ajlm-1363	134	6	https://pdfs.semanticscholar.org/5ac1/b04d4eed355331e2c6910a351efdc79b6c39.pdf?_ga=2.24175993.2125433055.1594648374-906043641.1594648374	https://pdfs.semanticscholar.org/5ac1/b04d4eed355331e2c6910a351efdc79b6c39.pdf?_ga=2.24175993.2125433055.1594648374-906043641.1594648374	VERB
ajlm-1363	134	7	haferlach	haferlach	PROPN
ajlm-1363	134	8	t	t	PROPN
ajlm-1363	134	9	,	,	PUNCT
ajlm-1363	134	10	schmidts	schmidts	PROPN
ajlm-1363	134	11	i.	i.	PROPN
ajlm-1363	134	12	the	the	DET
ajlm-1363	134	13	power	power	NOUN
ajlm-1363	134	14	and	and	CCONJ
ajlm-1363	134	15	potential	potential	NOUN
ajlm-1363	134	16	of	of	ADP
ajlm-1363	134	17	integrated	integrated	ADJ
ajlm-1363	134	18	diagnostics	diagnostic	NOUN
ajlm-1363	134	19	in	in	ADP
ajlm-1363	134	20	acute	acute	ADJ
ajlm-1363	134	21	myeloid	myeloid	ADJ
ajlm-1363	134	22	leukaemia	leukaemia	NOUN
ajlm-1363	134	23	.	.	PUNCT
ajlm-1363	135	1	br	br	X
ajlm-1363	135	2	j	j	PROPN
ajlm-1363	135	3	haematol	haematol	NOUN
ajlm-1363	135	4	.	.	PUNCT
ajlm-1363	136	1	2020;188(1):36–48	2020;188(1):36–48	X
ajlm-1363	136	2	.	.	PUNCT
ajlm-1363	137	1	https://doi.org/10.1111/bjh.16360	https://doi.org/10.1111/bjh.16360	PROPN
ajlm-1363	137	2	kansal	kansal	PROPN
ajlm-1363	137	3	r.	r.	PROPN
ajlm-1363	137	4	acute	acute	PROPN
ajlm-1363	137	5	myeloid	myeloid	PROPN
ajlm-1363	137	6	leukemia	leukemia	NOUN
ajlm-1363	137	7	in	in	ADP
ajlm-1363	137	8	the	the	DET
ajlm-1363	137	9	era	era	NOUN
ajlm-1363	137	10	of	of	ADP
ajlm-1363	137	11	precision	precision	NOUN
ajlm-1363	137	12	medicine	medicine	NOUN
ajlm-1363	137	13	:	:	PUNCT
ajlm-1363	137	14	recent	recent	ADJ
ajlm-1363	137	15	advances	advance	NOUN
ajlm-1363	137	16	in	in	ADP
ajlm-1363	137	17	diagnostic	diagnostic	ADJ
ajlm-1363	137	18	classification	classification	NOUN
ajlm-1363	137	19	and	and	CCONJ
ajlm-1363	137	20	risk	risk	NOUN
ajlm-1363	137	21	stratification	stratification	NOUN
ajlm-1363	137	22	.	.	PUNCT
ajlm-1363	138	1	cancer	cancer	NOUN
ajlm-1363	138	2	biol	biol	PROPN
ajlm-1363	138	3	med	me	VERB
ajlm-1363	138	4	.	.	PUNCT
ajlm-1363	139	1	2016;13(1):41–54	2016;13(1):41–54	X
ajlm-1363	139	2	.	.	NOUN
ajlm-1363	139	3	https://doi.org/10.20892/j.issn.2095-3941.2016.0001	https://doi.org/10.20892/j.issn.2095-3941.2016.0001	PROPN
ajlm-1363	139	4	roloff	roloff	PROPN
ajlm-1363	139	5	gw	gw	PROPN
ajlm-1363	139	6	,	,	PUNCT
ajlm-1363	139	7	griffiths	griffiths	PROPN
ajlm-1363	139	8	ea	ea	PROPN
ajlm-1363	139	9	.	.	PUNCT
ajlm-1363	140	1	when	when	SCONJ
ajlm-1363	140	2	to	to	PART
ajlm-1363	140	3	obtain	obtain	VERB
ajlm-1363	140	4	genomic	genomic	ADJ
ajlm-1363	140	5	data	datum	NOUN
ajlm-1363	140	6	in	in	ADP
ajlm-1363	140	7	acute	acute	ADJ
ajlm-1363	140	8	myeloid	myeloid	NOUN
ajlm-1363	140	9	leukemia	leukemia	NOUN
ajlm-1363	140	10	(	(	PUNCT
ajlm-1363	140	11	aml	aml	PROPN
ajlm-1363	140	12	)	)	PUNCT
ajlm-1363	140	13	and	and	CCONJ
ajlm-1363	140	14	which	which	DET
ajlm-1363	140	15	mutations	mutation	NOUN
ajlm-1363	140	16	matter	matter	VERB
ajlm-1363	140	17	.	.	PUNCT
ajlm-1363	141	1	blood	blood	PROPN
ajlm-1363	141	2	adv	adv	PROPN
ajlm-1363	141	3	.	.	PUNCT
ajlm-1363	141	4	2018;2(21):3070–3080	2018;2(21):3070–3080	PROPN
ajlm-1363	141	5	.	.	PUNCT
ajlm-1363	142	1	https://doi.org/10.1182/bloodadvances.2018020206	https://doi.org/10.1182/bloodadvances.2018020206	NOUN
ajlm-1363	142	2	patel	patel	PROPN
ajlm-1363	142	3	jp	jp	PROPN
ajlm-1363	142	4	,	,	PUNCT
ajlm-1363	142	5	gönen	gönen	PROPN
ajlm-1363	142	6	m	m	PROPN
ajlm-1363	142	7	,	,	PUNCT
ajlm-1363	142	8	figueroa	figueroa	PROPN
ajlm-1363	142	9	me	me	PROPN
ajlm-1363	142	10	,	,	PUNCT
ajlm-1363	142	11	et	et	PROPN
ajlm-1363	142	12	al	al	PROPN
ajlm-1363	142	13	.	.	PUNCT
ajlm-1363	143	1	prognostic	prognostic	ADJ
ajlm-1363	143	2	relevance	relevance	NOUN
ajlm-1363	143	3	of	of	ADP
ajlm-1363	143	4	integrated	integrate	VERB
ajlm-1363	143	5	genetic	genetic	ADJ
ajlm-1363	143	6	profiling	profiling	NOUN
ajlm-1363	143	7	in	in	ADP
ajlm-1363	143	8	acute	acute	ADJ
ajlm-1363	143	9	myeloid	myeloid	ADJ
ajlm-1363	143	10	leukemia	leukemia	NOUN
ajlm-1363	143	11	.	.	PUNCT
ajlm-1363	144	1	n	n	PROPN
ajlm-1363	144	2	engl	engl	PROPN
ajlm-1363	144	3	j	j	PROPN
ajlm-1363	144	4	med	med	PROPN
ajlm-1363	144	5	.	.	PUNCT
ajlm-1363	145	1	2012;366(12):1079–1089	2012;366(12):1079–1089	NUM
ajlm-1363	145	2	.	.	PUNCT
ajlm-1363	146	1	https://doi.org/10.1056/nejmoa1112304	https://doi.org/10.1056/nejmoa1112304	PROPN
ajlm-1363	146	2	cancer	cancer	NOUN
ajlm-1363	146	3	genome	genome	NOUN
ajlm-1363	146	4	atlas	atlas	PROPN
ajlm-1363	146	5	research	research	PROPN
ajlm-1363	146	6	network	network	NOUN
ajlm-1363	146	7	,	,	PUNCT
ajlm-1363	146	8	ley	ley	PROPN
ajlm-1363	146	9	tj	tj	PROPN
ajlm-1363	146	10	,	,	PUNCT
ajlm-1363	146	11	miller	miller	PROPN
ajlm-1363	146	12	c	c	PROPN
ajlm-1363	146	13	,	,	PUNCT
ajlm-1363	146	14	et	et	PROPN
ajlm-1363	146	15	al	al	PROPN
ajlm-1363	146	16	.	.	PROPN
ajlm-1363	147	1	genomic	genomic	NOUN
ajlm-1363	147	2	and	and	CCONJ
ajlm-1363	147	3	epigenomic	epigenomic	ADJ
ajlm-1363	147	4	landscapes	landscape	NOUN
ajlm-1363	147	5	of	of	ADP
ajlm-1363	147	6	adult	adult	X
ajlm-1363	147	7	de	de	X
ajlm-1363	147	8	novo	novo	PROPN
ajlm-1363	147	9	acute	acute	PROPN
ajlm-1363	147	10	myeloid	myeloid	NOUN
ajlm-1363	147	11	leukemia	leukemia	NOUN
ajlm-1363	147	12	.	.	PUNCT
ajlm-1363	148	1	n	n	PROPN
ajlm-1363	148	2	engl	engl	PROPN
ajlm-1363	148	3	j	j	PROPN
ajlm-1363	148	4	med	med	PROPN
ajlm-1363	148	5	.	.	PUNCT
ajlm-1363	149	1	2013;368(22):2059–2074	2013;368(22):2059–2074	NUM
ajlm-1363	149	2	.	.	PUNCT
ajlm-1363	150	1	https://doi.org/10.1056/nejmoa1301689	https://doi.org/10.1056/nejmoa1301689	NOUN
ajlm-1363	150	2	chen	chen	PROPN
ajlm-1363	151	1	f	f	X
ajlm-1363	151	2	,	,	PUNCT
ajlm-1363	151	3	sun	sun	PROPN
ajlm-1363	151	4	j	j	PROPN
ajlm-1363	151	5	,	,	PUNCT
ajlm-1363	151	6	yin	yin	PROPN
ajlm-1363	151	7	c	c	X
ajlm-1363	151	8	,	,	PUNCT
ajlm-1363	151	9	et	et	PROPN
ajlm-1363	151	10	al	al	PROPN
ajlm-1363	151	11	.	.	PROPN
ajlm-1363	151	12	impact	impact	NOUN
ajlm-1363	151	13	of	of	ADP
ajlm-1363	151	14	flt3	flt3	NOUN
ajlm-1363	151	15	-	-	PUNCT
ajlm-1363	151	16	itd	itd	NOUN
ajlm-1363	151	17	allele	allele	NOUN
ajlm-1363	151	18	ratio	ratio	NOUN
ajlm-1363	151	19	and	and	CCONJ
ajlm-1363	151	20	it	it	PRON
ajlm-1363	151	21	d	d	ADV
ajlm-1363	151	22	length	length	NOUN
ajlm-1363	151	23	on	on	ADP
ajlm-1363	151	24	therapeutic	therapeutic	ADJ
ajlm-1363	151	25	outcome	outcome	NOUN
ajlm-1363	151	26	in	in	ADP
ajlm-1363	151	27	cytogenetically	cytogenetically	PROPN
ajlm-1363	151	28	normal	normal	ADJ
ajlm-1363	151	29	aml	aml	NOUN
ajlm-1363	151	30	patients	patient	NOUN
ajlm-1363	151	31	without	without	ADP
ajlm-1363	151	32	npm1	npm1	NOUN
ajlm-1363	151	33	mutation	mutation	NOUN
ajlm-1363	151	34	.	.	PUNCT
ajlm-1363	152	1	bone	bone	NOUN
ajlm-1363	152	2	marrow	marrow	PROPN
ajlm-1363	152	3	transplant	transplant	NOUN
ajlm-1363	152	4	.	.	PUNCT
ajlm-1363	153	1	2020;55(4):740–748	2020;55(4):740–748	X
ajlm-1363	153	2	.	.	PUNCT
ajlm-1363	153	3	https://doi.org/10.1038/s41409-019-0721-z	https://doi.org/10.1038/s41409-019-0721-z	PROPN
ajlm-1363	153	4	bhattacharyya	bhattacharyya	PROPN
ajlm-1363	153	5	j	j	PROPN
ajlm-1363	153	6	,	,	PUNCT
ajlm-1363	153	7	nath	nath	PROPN
ajlm-1363	153	8	s	s	PROPN
ajlm-1363	153	9	,	,	PUNCT
ajlm-1363	153	10	saikia	saikia	PROPN
ajlm-1363	153	11	kk	kk	PROPN
ajlm-1363	153	12	,	,	PUNCT
ajlm-1363	153	13	et	et	PROPN
ajlm-1363	153	14	al	al	PROPN
ajlm-1363	153	15	.	.	PUNCT
ajlm-1363	154	1	prevalence	prevalence	NOUN
ajlm-1363	154	2	and	and	CCONJ
ajlm-1363	154	3	clinical	clinical	ADJ
ajlm-1363	154	4	significance	significance	NOUN
ajlm-1363	154	5	of	of	ADP
ajlm-1363	154	6	flt3	flt3	PROPN
ajlm-1363	154	7	and	and	CCONJ
ajlm-1363	154	8	npm1	npm1	NOUN
ajlm-1363	154	9	mutations	mutation	NOUN
ajlm-1363	154	10	in	in	ADP
ajlm-1363	154	11	acute	acute	ADJ
ajlm-1363	154	12	myeloid	myeloid	ADJ
ajlm-1363	154	13	leukaemia	leukaemia	NOUN
ajlm-1363	154	14	patients	patient	NOUN
ajlm-1363	154	15	of	of	ADP
ajlm-1363	154	16	assam	assam	PROPN
ajlm-1363	154	17	,	,	PUNCT
ajlm-1363	154	18	india	india	PROPN
ajlm-1363	154	19	.	.	PUNCT
ajlm-1363	155	1	indian	indian	PROPN
ajlm-1363	155	2	j	j	PROPN
ajlm-1363	155	3	hematol	hematol	PROPN
ajlm-1363	155	4	blood	blood	NOUN
ajlm-1363	155	5	transfus	transfus	PROPN
ajlm-1363	155	6	.	.	PUNCT
ajlm-1363	156	1	2018;34(1):32–42	2018;34(1):32–42	X
ajlm-1363	156	2	.	.	PUNCT
ajlm-1363	156	3	https://doi.org/10.1007/s12288-017-0821-0	https://doi.org/10.1007/s12288-017-0821-0	NUM
ajlm-1363	156	4	döhner	döhner	NOUN
ajlm-1363	156	5	h	h	NOUN
ajlm-1363	156	6	,	,	PUNCT
ajlm-1363	156	7	weisdorf	weisdorf	PROPN
ajlm-1363	156	8	dj	dj	PROPN
ajlm-1363	156	9	,	,	PUNCT
ajlm-1363	156	10	bloomfield	bloomfield	PROPN
ajlm-1363	156	11	cd	cd	PROPN
ajlm-1363	156	12	.	.	PROPN
ajlm-1363	156	13	acute	acute	PROPN
ajlm-1363	156	14	myeloid	myeloid	ADJ
ajlm-1363	156	15	leukemia	leukemia	NOUN
ajlm-1363	156	16	.	.	PUNCT
ajlm-1363	157	1	n	n	PROPN
ajlm-1363	157	2	engl	engl	PROPN
ajlm-1363	157	3	j	j	PROPN
ajlm-1363	157	4	med	med	PROPN
ajlm-1363	157	5	.	.	PUNCT
ajlm-1363	158	1	2015;373(12):1136–1152	2015;373(12):1136–1152	NUM
ajlm-1363	158	2	.	.	PUNCT
ajlm-1363	159	1	https://doi.org/10.1056/nejmra1406184	https://doi.org/10.1056/nejmra1406184	VERB
ajlm-1363	159	2	falini	falini	PROPN
ajlm-1363	159	3	b	b	NOUN
ajlm-1363	159	4	,	,	PUNCT
ajlm-1363	159	5	mecucci	mecucci	NOUN
ajlm-1363	159	6	c	c	X
ajlm-1363	159	7	,	,	PUNCT
ajlm-1363	159	8	tiacci	tiacci	NOUN
ajlm-1363	159	9	e	e	NOUN
ajlm-1363	159	10	,	,	PUNCT
ajlm-1363	159	11	et	et	PROPN
ajlm-1363	159	12	al	al	PROPN
ajlm-1363	159	13	.	.	PUNCT
ajlm-1363	159	14	cytoplasmic	cytoplasmic	ADJ
ajlm-1363	159	15	nucleophosmin	nucleophosmin	PROPN
ajlm-1363	159	16	in	in	ADP
ajlm-1363	159	17	acute	acute	ADJ
ajlm-1363	159	18	myelogenous	myelogenous	ADJ
ajlm-1363	159	19	leukemia	leukemia	NOUN
ajlm-1363	159	20	with	with	ADP
ajlm-1363	159	21	a	a	DET
ajlm-1363	159	22	normal	normal	ADJ
ajlm-1363	159	23	karyotype	karyotype	NOUN
ajlm-1363	159	24	.	.	PUNCT
ajlm-1363	160	1	n	n	PROPN
ajlm-1363	160	2	engl	engl	PROPN
ajlm-1363	160	3	j	j	PROPN
ajlm-1363	160	4	med	med	PROPN
ajlm-1363	160	5	.	.	PUNCT
ajlm-1363	161	1	2005;352(3):254–266	2005;352(3):254–266	X
ajlm-1363	161	2	.	.	PUNCT
ajlm-1363	161	3	https://doi.org/10.1056/nejmoa041974	https://doi.org/10.1056/nejmoa041974	PROPN
ajlm-1363	161	4	bacher	bacher	PROPN
ajlm-1363	161	5	u	u	PROPN
ajlm-1363	161	6	,	,	PUNCT
ajlm-1363	161	7	kohlmann	kohlmann	PROPN
ajlm-1363	161	8	a	a	PRON
ajlm-1363	161	9	,	,	PUNCT
ajlm-1363	161	10	haferlach	haferlach	PROPN
ajlm-1363	161	11	c	c	NOUN
ajlm-1363	161	12	,	,	PUNCT
ajlm-1363	161	13	haferlach	haferlach	NOUN
ajlm-1363	161	14	t.	t.	NOUN
ajlm-1363	161	15	gene	gene	NOUN
ajlm-1363	161	16	expression	expression	NOUN
ajlm-1363	161	17	profiling	profiling	NOUN
ajlm-1363	161	18	in	in	ADP
ajlm-1363	161	19	acute	acute	ADJ
ajlm-1363	161	20	myeloid	myeloid	NOUN
ajlm-1363	161	21	leukaemia	leukaemia	NOUN
ajlm-1363	161	22	(	(	PUNCT
ajlm-1363	161	23	aml	aml	PROPN
ajlm-1363	161	24	)	)	PUNCT
ajlm-1363	161	25	.	.	PUNCT
ajlm-1363	162	1	best	good	ADJ
ajlm-1363	162	2	pract	pract	PROPN
ajlm-1363	162	3	res	re	NOUN
ajlm-1363	162	4	clin	clin	PROPN
ajlm-1363	162	5	haematol	haematol	NOUN
ajlm-1363	162	6	.	.	PUNCT
ajlm-1363	163	1	2009;22(2	2009;22(2	NUM
ajlm-1363	163	2	):	):	PUNCT
ajlm-1363	164	1	169–180	169–180	NUM
ajlm-1363	164	2	.	.	PUNCT
ajlm-1363	164	3	https://doi.org/10.1016/j.beha.2009.04.003	https://doi.org/10.1016/j.beha.2009.04.003	NUM
ajlm-1363	164	4	el	el	PROPN
ajlm-1363	164	5	gammal	gammal	PROPN
ajlm-1363	164	6	mm	mm	PROPN
ajlm-1363	164	7	,	,	PUNCT
ajlm-1363	164	8	ebid	ebid	PROPN
ajlm-1363	164	9	gt	gt	PROPN
ajlm-1363	164	10	,	,	PUNCT
ajlm-1363	164	11	madney	madney	PROPN
ajlm-1363	164	12	ym	ym	PROPN
ajlm-1363	164	13	,	,	PUNCT
ajlm-1363	164	14	et	et	PROPN
ajlm-1363	164	15	al	al	PROPN
ajlm-1363	164	16	.	.	PROPN
ajlm-1363	165	1	clinical	clinical	ADJ
ajlm-1363	165	2	effect	effect	NOUN
ajlm-1363	165	3	of	of	ADP
ajlm-1363	165	4	combined	combined	ADJ
ajlm-1363	165	5	mutations	mutation	NOUN
ajlm-1363	165	6	in	in	ADP
ajlm-1363	165	7	dnmt3a	dnmt3a	NOUN
ajlm-1363	165	8	,	,	PUNCT
ajlm-1363	165	9	flt3	flt3	NOUN
ajlm-1363	165	10	-	-	PUNCT
ajlm-1363	165	11	itd	itd	NOUN
ajlm-1363	165	12	,	,	PUNCT
ajlm-1363	165	13	and	and	CCONJ
ajlm-1363	165	14	npm1	npm1	NOUN
ajlm-1363	165	15	among	among	ADP
ajlm-1363	165	16	egyptian	egyptian	ADJ
ajlm-1363	165	17	acute	acute	PROPN
ajlm-1363	165	18	myeloid	myeloid	PROPN
ajlm-1363	165	19	leukemia	leukemia	NOUN
ajlm-1363	165	20	patients	patient	NOUN
ajlm-1363	165	21	.	.	PUNCT
ajlm-1363	166	1	clin	clin	PROPN
ajlm-1363	166	2	lymphoma	lymphoma	PROPN
ajlm-1363	166	3	myeloma	myeloma	PROPN
ajlm-1363	166	4	leuk	leuk	PROPN
ajlm-1363	166	5	.	.	PUNCT
ajlm-1363	167	1	2019;19(6):e281	2019;19(6):e281	X
ajlm-1363	167	2	–	–	PUNCT
ajlm-1363	167	3	e290	e290	NUM
ajlm-1363	167	4	.	.	PUNCT
ajlm-1363	167	5	https://doi.org/10.1016/j.clml.2019.02.001	https://doi.org/10.1016/j.clml.2019.02.001	PROPN
ajlm-1363	167	6	sofan	sofan	PROPN
ajlm-1363	167	7	ma	ma	PROPN
ajlm-1363	167	8	,	,	PUNCT
ajlm-1363	167	9	elmasry	elmasry	PROPN
ajlm-1363	167	10	sa	sa	PROPN
ajlm-1363	167	11	,	,	PUNCT
ajlm-1363	167	12	salem	salem	PROPN
ajlm-1363	167	13	da	da	PROPN
ajlm-1363	167	14	,	,	PUNCT
ajlm-1363	167	15	et	et	PROPN
ajlm-1363	167	16	al	al	PROPN
ajlm-1363	167	17	.	.	PUNCT
ajlm-1363	168	1	npm1	npm1	PROPN
ajlm-1363	168	2	gene	gene	NOUN
ajlm-1363	168	3	mutation	mutation	NOUN
ajlm-1363	168	4	in	in	ADP
ajlm-1363	168	5	egyptian	egyptian	ADJ
ajlm-1363	168	6	patients	patient	NOUN
ajlm-1363	168	7	with	with	ADP
ajlm-1363	168	8	cytogenetically	cytogenetically	PROPN
ajlm-1363	168	9	normal	normal	ADJ
ajlm-1363	168	10	acute	acute	NOUN
ajlm-1363	168	11	myeloid	myeloid	NOUN
ajlm-1363	168	12	leukemia	leukemia	NOUN
ajlm-1363	168	13	.	.	PUNCT
ajlm-1363	169	1	clin	clin	PROPN
ajlm-1363	169	2	lab	lab	PROPN
ajlm-1363	169	3	.	.	PUNCT
ajlm-1363	170	1	2014;60(11):1813–1822	2014;60(11):1813–1822	X
ajlm-1363	170	2	.	.	PUNCT
ajlm-1363	171	1	https://doi.org/10.7754/clin.lab.2014.140121	https://doi.org/10.7754/clin.lab.2014.140121	ADJ
ajlm-1363	171	2	elzain	elzain	NOUN
ajlm-1363	171	3	e	e	NOUN
ajlm-1363	171	4	,	,	PUNCT
ajlm-1363	171	5	khalil	khalil	PROPN
ajlm-1363	171	6	hb	hb	PROPN
ajlm-1363	171	7	.	.	PROPN
ajlm-1363	171	8	frequency	frequency	PROPN
ajlm-1363	171	9	and	and	CCONJ
ajlm-1363	171	10	prognostic	prognostic	ADJ
ajlm-1363	171	11	value	value	NOUN
ajlm-1363	171	12	of	of	ADP
ajlm-1363	171	13	npm1	npm1	NOUN
ajlm-1363	171	14	mutations	mutation	NOUN
ajlm-1363	171	15	in	in	ADP
ajlm-1363	171	16	sudanese	sudanese	ADJ
ajlm-1363	171	17	acute	acute	PROPN
ajlm-1363	171	18	myeloid	myeloid	NOUN
ajlm-1363	171	19	leukemia	leukemia	NOUN
ajlm-1363	171	20	patients	patient	NOUN
ajlm-1363	171	21	.	.	PUNCT
ajlm-1363	172	1	biorxiv	biorxiv	NOUN
ajlm-1363	172	2	.	.	PUNCT
ajlm-1363	173	1	2020	2020	NUM
ajlm-1363	173	2	(	(	PUNCT
ajlm-1363	173	3	pre	pre	NOUN
ajlm-1363	173	4	-	-	NOUN
ajlm-1363	173	5	print	print	NOUN
ajlm-1363	173	6	)	)	PUNCT
ajlm-1363	173	7	.	.	PUNCT
ajlm-1363	174	1	https://doi.org/10.1101/2020.05.31.126334	https://doi.org/10.1101/2020.05.31.126334	PROPN
ajlm-1363	174	2	marshall	marshall	PROPN
ajlm-1363	174	3	rc	rc	PROPN
ajlm-1363	174	4	,	,	PUNCT
ajlm-1363	174	5	tlagadi	tlagadi	VERB
ajlm-1363	174	6	a	a	PRON
ajlm-1363	174	7	,	,	PUNCT
ajlm-1363	174	8	bronze	bronze	NOUN
ajlm-1363	174	9	m	m	PROPN
ajlm-1363	174	10	,	,	PUNCT
ajlm-1363	174	11	kana	kana	PROPN
ajlm-1363	174	12	v	v	PROPN
ajlm-1363	174	13	,	,	PUNCT
ajlm-1363	174	14	wiggil	wiggil	PROPN
ajlm-1363	174	15	tm	tm	PROPN
ajlm-1363	174	16	,	,	PUNCT
ajlm-1363	174	17	carmona	carmona	PROPN
ajlm-1363	174	18	sc	sc	PROPN
ajlm-1363	174	19	.	.	PUNCT
ajlm-1363	174	20	lower	low	ADJ
ajlm-1363	174	21	frequency	frequency	NOUN
ajlm-1363	174	22	of	of	ADP
ajlm-1363	174	23	npm1	npm1	NOUN
ajlm-1363	174	24	and	and	CCONJ
ajlm-1363	174	25	flt3	flt3	NOUN
ajlm-1363	174	26	-	-	PUNCT
ajlm-1363	174	27	itd	itd	NOUN
ajlm-1363	174	28	mutations	mutation	NOUN
ajlm-1363	174	29	in	in	ADP
ajlm-1363	174	30	a	a	DET
ajlm-1363	174	31	south	south	ADJ
ajlm-1363	174	32	african	african	ADJ
ajlm-1363	174	33	de	de	X
ajlm-1363	174	34	novo	novo	PROPN
ajlm-1363	174	35	aml	aml	PROPN
ajlm-1363	174	36	cohort	cohort	PROPN
ajlm-1363	174	37	.	.	PUNCT
ajlm-1363	175	1	int	int	NOUN
ajlm-1363	175	2	j	j	PROPN
ajlm-1363	175	3	lab	lab	NOUN
ajlm-1363	175	4	hematol	hematol	NOUN
ajlm-1363	175	5	.	.	PUNCT
ajlm-1363	176	1	2014;36(6):656–664	2014;36(6):656–664	NUM
ajlm-1363	176	2	.	.	PUNCT
ajlm-1363	176	3	https://doi.org/10.1111/ijlh.12204	https://doi.org/10.1111/ijlh.12204	ADJ
ajlm-1363	176	4	arber	arber	PROPN
ajlm-1363	176	5	da	da	PROPN
ajlm-1363	176	6	,	,	PUNCT
ajlm-1363	176	7	brunning	brunne	VERB
ajlm-1363	176	8	rd	rd	PROPN
ajlm-1363	176	9	,	,	PUNCT
ajlm-1363	176	10	le	le	X
ajlm-1363	176	11	beau	beau	PROPN
ajlm-1363	176	12	mm	mm	PROPN
ajlm-1363	176	13	,	,	PUNCT
ajlm-1363	176	14	et	et	PROPN
ajlm-1363	176	15	al	al	PROPN
ajlm-1363	176	16	.	.	PROPN
ajlm-1363	176	17	acute	acute	PROPN
ajlm-1363	176	18	myeloid	myeloid	PROPN
ajlm-1363	176	19	leukaemia	leukaemia	NOUN
ajlm-1363	176	20	with	with	ADP
ajlm-1363	176	21	recurrent	recurrent	ADJ
ajlm-1363	176	22	genetic	genetic	ADJ
ajlm-1363	176	23	abnormalities	abnormality	NOUN
ajlm-1363	176	24	.	.	PUNCT
ajlm-1363	177	1	in	in	ADP
ajlm-1363	177	2	:	:	PUNCT
ajlm-1363	177	3	swerdlow	swerdlow	NOUN
ajlm-1363	177	4	sh	sh	PROPN
ajlm-1363	177	5	,	,	PUNCT
ajlm-1363	177	6	campo	campo	PROPN
ajlm-1363	177	7	e	e	PROPN
ajlm-1363	177	8	,	,	PUNCT
ajlm-1363	177	9	harris	harris	PROPN
ajlm-1363	177	10	nl	nl	PROPN
ajlm-1363	177	11	,	,	PUNCT
ajlm-1363	177	12	et	et	PROPN
ajlm-1363	177	13	al	al	PROPN
ajlm-1363	177	14	.	.	PUNCT
ajlm-1363	177	15	editors	editor	NOUN
ajlm-1363	177	16	.	.	PUNCT
ajlm-1363	178	1	who	who	PRON
ajlm-1363	178	2	classification	classification	NOUN
ajlm-1363	178	3	of	of	ADP
ajlm-1363	178	4	tumours	tumour	NOUN
ajlm-1363	178	5	of	of	ADP
ajlm-1363	178	6	haematopoietic	haematopoietic	ADJ
ajlm-1363	178	7	and	and	CCONJ
ajlm-1363	178	8	lymphoid	lymphoid	ADJ
ajlm-1363	178	9	tissues	tissue	NOUN
ajlm-1363	178	10	.	.	PUNCT
ajlm-1363	179	1	revised	revise	VERB
ajlm-1363	179	2	4th	4th	ADJ
ajlm-1363	179	3	ed	ed	NOUN
ajlm-1363	179	4	.	.	PUNCT
ajlm-1363	180	1	lyon	lyon	PROPN
ajlm-1363	180	2	:	:	PUNCT
ajlm-1363	180	3	iarc	iarc	NOUN
ajlm-1363	180	4	,	,	PUNCT
ajlm-1363	180	5	2017	2017	NUM
ajlm-1363	180	6	;	;	PUNCT
ajlm-1363	180	7	p.	p.	PROPN
ajlm-1363	180	8	129–170	129–170	NUM
ajlm-1363	180	9	.	.	PUNCT
ajlm-1363	181	1	huang	huang	PROPN
ajlm-1363	181	2	q	q	PROPN
ajlm-1363	181	3	,	,	PUNCT
ajlm-1363	181	4	chen	chen	PROPN
ajlm-1363	181	5	w	w	PROPN
ajlm-1363	181	6	,	,	PUNCT
ajlm-1363	181	7	gaal	gaal	PROPN
ajlm-1363	181	8	kk	kk	PROPN
ajlm-1363	181	9	,	,	PUNCT
ajlm-1363	181	10	et	et	PROPN
ajlm-1363	181	11	al	al	PROPN
ajlm-1363	181	12	.	.	PUNCT
ajlm-1363	182	1	a	a	DET
ajlm-1363	182	2	rapid	rapid	ADJ
ajlm-1363	182	3	,	,	PUNCT
ajlm-1363	182	4	one	one	NUM
ajlm-1363	182	5	step	step	NOUN
ajlm-1363	182	6	assay	assay	VERB
ajlm-1363	182	7	for	for	ADP
ajlm-1363	182	8	simultaneous	simultaneous	ADJ
ajlm-1363	182	9	detection	detection	NOUN
ajlm-1363	182	10	of	of	ADP
ajlm-1363	182	11	flt3	flt3	PROPN
ajlm-1363	182	12	/	/	SYM
ajlm-1363	182	13	itd	itd	NOUN
ajlm-1363	182	14	and	and	CCONJ
ajlm-1363	182	15	npm1	npm1	VERB
ajlm-1363	182	16	mutations	mutation	NOUN
ajlm-1363	182	17	in	in	ADP
ajlm-1363	182	18	aml	aml	NOUN
ajlm-1363	182	19	with	with	ADP
ajlm-1363	182	20	normal	normal	ADJ
ajlm-1363	182	21	cytogenetics	cytogenetic	NOUN
ajlm-1363	182	22	br	br	NOUN
ajlm-1363	182	23	j	j	PROPN
ajlm-1363	182	24	haematol	haematol	NOUN
ajlm-1363	182	25	.	.	PUNCT
ajlm-1363	183	1	2008;142(3):489–492	2008;142(3):489–492	PROPN
ajlm-1363	183	2	.	.	PUNCT
ajlm-1363	184	1	https://doi.org/10.1111/j.1365-2141.2008.07205.x	https://doi.org/10.1111/j.1365-2141.2008.07205.x	PROPN
ajlm-1363	184	2	national	national	PROPN
ajlm-1363	184	3	cancer	cancer	PROPN
ajlm-1363	184	4	institute	institute	PROPN
ajlm-1363	184	5	.	.	PUNCT
ajlm-1363	185	1	seer	seer	PROPN
ajlm-1363	185	2	program	program	PROPN
ajlm-1363	185	3	.	.	PUNCT
ajlm-1363	186	1	cancer	cancer	NOUN
ajlm-1363	186	2	stat	stat	PROPN
ajlm-1363	186	3	facts	fact	VERB
ajlm-1363	186	4	:	:	PUNCT
ajlm-1363	186	5	leukemia	leukemia	NOUN
ajlm-1363	186	6	–	–	PUNCT
ajlm-1363	186	7	acute	acute	ADJ
ajlm-1363	186	8	myeloid	myeloid	NOUN
ajlm-1363	186	9	leukemia	leukemia	NOUN
ajlm-1363	186	10	(	(	PUNCT
ajlm-1363	186	11	aml	aml	PROPN
ajlm-1363	186	12	)	)	PUNCT
ajlm-1363	187	1	[	[	X
ajlm-1363	187	2	homepage	homepage	NOUN
ajlm-1363	187	3	on	on	ADP
ajlm-1363	187	4	the	the	DET
ajlm-1363	187	5	internet	internet	NOUN
ajlm-1363	187	6	]	]	PUNCT
ajlm-1363	187	7	.	.	PUNCT
ajlm-1363	188	1	available	available	ADJ
ajlm-1363	188	2	from	from	ADP
ajlm-1363	188	3	:	:	PUNCT
ajlm-1363	188	4	https://seer.cancer.gov/statfacts/html/amyl.html	https://seer.cancer.gov/statfacts/html/amyl.html	VERB
ajlm-1363	188	5	gmidène	gmidène	ADJ
ajlm-1363	188	6	a	a	PRON
ajlm-1363	188	7	,	,	PUNCT
ajlm-1363	188	8	sennana	sennana	PROPN
ajlm-1363	188	9	h	h	NOUN
ajlm-1363	188	10	,	,	PUNCT
ajlm-1363	188	11	wahchi	wahchi	PROPN
ajlm-1363	188	12	i	i	PRON
ajlm-1363	188	13	,	,	PUNCT
ajlm-1363	188	14	et	et	PROPN
ajlm-1363	188	15	al	al	PROPN
ajlm-1363	188	16	.	.	PUNCT
ajlm-1363	189	1	cytogenetic	cytogenetic	ADJ
ajlm-1363	189	2	profile	profile	NOUN
ajlm-1363	189	3	of	of	ADP
ajlm-1363	189	4	a	a	DET
ajlm-1363	189	5	large	large	ADJ
ajlm-1363	189	6	cohort	cohort	NOUN
ajlm-1363	189	7	of	of	ADP
ajlm-1363	189	8	tunisian	tunisian	PROPN
ajlm-1363	189	9	de	de	PROPN
ajlm-1363	189	10	novo	novo	PROPN
ajlm-1363	189	11	acute	acute	PROPN
ajlm-1363	189	12	myeloid	myeloid	ADJ
ajlm-1363	189	13	leukemia	leukemia	NOUN
ajlm-1363	189	14	.	.	PUNCT
ajlm-1363	190	1	hematology	hematology	NOUN
ajlm-1363	190	2	.	.	PUNCT
ajlm-1363	191	1	2012;17(1):9–14	2012;17(1):9–14	X
ajlm-1363	191	2	.	.	PUNCT
ajlm-1363	192	1	https://doi.org/10.1179/102453312x13221316477417	https://doi.org/10.1179/102453312x13221316477417	DET
ajlm-1363	192	2	khoubila	khoubila	PROPN
ajlm-1363	192	3	n	n	CCONJ
ajlm-1363	192	4	,	,	PUNCT
ajlm-1363	192	5	bendari	bendari	PROPN
ajlm-1363	192	6	m	m	NOUN
ajlm-1363	192	7	,	,	PUNCT
ajlm-1363	192	8	hda	hda	VERB
ajlm-1363	192	9	n	n	CCONJ
ajlm-1363	192	10	,	,	PUNCT
ajlm-1363	192	11	et	et	PROPN
ajlm-1363	192	12	al	al	PROPN
ajlm-1363	192	13	.	.	PUNCT
ajlm-1363	192	14	cytogenetic	cytogenetic	ADJ
ajlm-1363	192	15	profile	profile	NOUN
ajlm-1363	192	16	of	of	ADP
ajlm-1363	192	17	a	a	DET
ajlm-1363	192	18	representative	representative	ADJ
ajlm-1363	192	19	cohort	cohort	NOUN
ajlm-1363	192	20	of	of	ADP
ajlm-1363	192	21	young	young	ADJ
ajlm-1363	192	22	adults	adult	NOUN
ajlm-1363	192	23	with	with	ADP
ajlm-1363	192	24	de	de	X
ajlm-1363	192	25	novo	novo	PROPN
ajlm-1363	192	26	acute	acute	PROPN
ajlm-1363	192	27	myéloblastic	myéloblastic	PROPN
ajlm-1363	192	28	leukaemia	leukaemia	NOUN
ajlm-1363	192	29	in	in	ADP
ajlm-1363	192	30	morocco	morocco	PROPN
ajlm-1363	192	31	.	.	PUNCT
ajlm-1363	193	1	cancer	cancer	NOUN
ajlm-1363	193	2	genet	genet	PROPN
ajlm-1363	193	3	.	.	PUNCT
ajlm-1363	194	1	2019;238:1–9	2019;238:1–9	NOUN
ajlm-1363	194	2	.	.	PUNCT
ajlm-1363	195	1	https://doi.org/10.1016/j.cancergen.2019.06.010	https://doi.org/10.1016/j.cancergen.2019.06.010	PROPN
ajlm-1363	195	2	lin	lin	PROPN
ajlm-1363	195	3	p	p	PROPN
ajlm-1363	195	4	,	,	PUNCT
ajlm-1363	195	5	chen	chen	PROPN
ajlm-1363	195	6	l	l	PROPN
ajlm-1363	195	7	,	,	PUNCT
ajlm-1363	195	8	luthra	luthra	ADJ
ajlm-1363	195	9	r	r	NOUN
ajlm-1363	195	10	,	,	PUNCT
ajlm-1363	195	11	konoplev	konoplev	PROPN
ajlm-1363	195	12	sn	sn	PROPN
ajlm-1363	195	13	,	,	PUNCT
ajlm-1363	195	14	wang	wang	PROPN
ajlm-1363	195	15	x	x	PROPN
ajlm-1363	195	16	,	,	PUNCT
ajlm-1363	195	17	medeiros	medeiros	PROPN
ajlm-1363	195	18	j.	j.	PROPN
ajlm-1363	195	19	acute	acute	PROPN
ajlm-1363	195	20	myeloid	myeloid	PROPN
ajlm-1363	195	21	leukemia	leukemia	NOUN
ajlm-1363	195	22	harboring	harboring	NOUN
ajlm-1363	195	23	t(8;21)(q22;q22	t(8;21)(q22;q22	NOUN
ajlm-1363	195	24	):	):	PUNCT
ajlm-1363	195	25	a	a	DET
ajlm-1363	195	26	heterogeneous	heterogeneous	ADJ
ajlm-1363	195	27	disease	disease	NOUN
ajlm-1363	195	28	with	with	ADP
ajlm-1363	195	29	poor	poor	ADJ
ajlm-1363	195	30	outcome	outcome	NOUN
ajlm-1363	195	31	in	in	ADP
ajlm-1363	195	32	a	a	DET
ajlm-1363	195	33	subset	subset	NOUN
ajlm-1363	195	34	of	of	ADP
ajlm-1363	195	35	patients	patient	NOUN
ajlm-1363	195	36	unrelated	unrelated	ADJ
ajlm-1363	195	37	to	to	ADP
ajlm-1363	195	38	secondary	secondary	ADJ
ajlm-1363	195	39	cytogenetic	cytogenetic	ADJ
ajlm-1363	195	40	aberrations	aberration	NOUN
ajlm-1363	195	41	.	.	PUNCT
ajlm-1363	196	1	mod	mod	PROPN
ajlm-1363	196	2	pathol	pathol	PROPN
ajlm-1363	196	3	.	.	PUNCT
ajlm-1363	197	1	2008;21(8):1029–1036	2008;21(8):1029–1036	NOUN
ajlm-1363	197	2	.	.	PUNCT
ajlm-1363	198	1	https://doi.org/10.1038/modpathol.2008.92	https://doi.org/10.1038/modpathol.2008.92	PROPN
ajlm-1363	198	2	shamaa	shamaa	VERB
ajlm-1363	198	3	s	s	PROPN
ajlm-1363	198	4	,	,	PUNCT
ajlm-1363	198	5	laimon	laimon	PROPN
ajlm-1363	198	6	n	n	CCONJ
ajlm-1363	198	7	,	,	PUNCT
ajlm-1363	198	8	aladle	aladle	PROPN
ajlm-1363	198	9	da	da	PROPN
ajlm-1363	198	10	,	,	PUNCT
ajlm-1363	198	11	et	et	PROPN
ajlm-1363	198	12	al	al	PROPN
ajlm-1363	198	13	.	.	PUNCT
ajlm-1363	199	1	prognostic	prognostic	ADJ
ajlm-1363	199	2	implications	implication	NOUN
ajlm-1363	199	3	of	of	ADP
ajlm-1363	199	4	npm1	npm1	NOUN
ajlm-1363	199	5	mutations	mutation	NOUN
ajlm-1363	199	6	and	and	CCONJ
ajlm-1363	199	7	flt3	flt3	PROPN
ajlm-1363	199	8	internal	internal	ADJ
ajlm-1363	199	9	tandem	tandem	NOUN
ajlm-1363	199	10	duplications	duplication	NOUN
ajlm-1363	199	11	in	in	ADP
ajlm-1363	199	12	egyptian	egyptian	ADJ
ajlm-1363	199	13	patients	patient	NOUN
ajlm-1363	199	14	with	with	ADP
ajlm-1363	199	15	cytogenetically	cytogenetically	PROPN
ajlm-1363	199	16	normal	normal	ADJ
ajlm-1363	199	17	acute	acute	NOUN
ajlm-1363	199	18	myeloid	myeloid	NOUN
ajlm-1363	199	19	leukemia	leukemia	NOUN
ajlm-1363	199	20	.	.	PUNCT
ajlm-1363	200	1	hematology	hematology	NOUN
ajlm-1363	200	2	.	.	PUNCT
ajlm-1363	201	1	2014;19(1):22–30	2014;19(1):22–30	X
ajlm-1363	201	2	.	.	PUNCT
ajlm-1363	202	1	https://doi.org/10.1179/1607845413y.0000000085	https://doi.org/10.1179/1607845413y.0000000085	PROPN
ajlm-1363	202	2	liu	liu	PROPN
ajlm-1363	202	3	sb	sb	PROPN
ajlm-1363	202	4	,	,	PUNCT
ajlm-1363	202	5	dong	dong	PROPN
ajlm-1363	202	6	hj	hj	PROPN
ajlm-1363	202	7	,	,	PUNCT
ajlm-1363	202	8	bao	bao	PROPN
ajlm-1363	202	9	xb	xb	PROPN
ajlm-1363	202	10	,	,	PUNCT
ajlm-1363	202	11	et	et	PROPN
ajlm-1363	202	12	al	al	PROPN
ajlm-1363	202	13	.	.	PROPN
ajlm-1363	202	14	impact	impact	NOUN
ajlm-1363	202	15	of	of	ADP
ajlm-1363	202	16	flt3	flt3	NOUN
ajlm-1363	202	17	-	-	PUNCT
ajlm-1363	202	18	itd	itd	NOUN
ajlm-1363	202	19	length	length	NOUN
ajlm-1363	202	20	on	on	ADP
ajlm-1363	202	21	prognosis	prognosis	NOUN
ajlm-1363	202	22	of	of	ADP
ajlm-1363	202	23	acute	acute	ADJ
ajlm-1363	202	24	myeloid	myeloid	ADJ
ajlm-1363	202	25	leukemia	leukemia	NOUN
ajlm-1363	202	26	.	.	PUNCT
ajlm-1363	203	1	haematologica	haematologica	PROPN
ajlm-1363	203	2	.	.	PUNCT
ajlm-1363	204	1	2019;104(1):e9	2019;104(1):e9	NOUN
ajlm-1363	204	2	–	–	PUNCT
ajlm-1363	204	3	e12	e12	NOUN
ajlm-1363	204	4	.	.	PUNCT
ajlm-1363	205	1	https://doi.org/10.3324/haematol.2018.191809	https://doi.org/10.3324/haematol.2018.191809	PROPN
ajlm-1363	205	2	tallman	tallman	PROPN
ajlm-1363	205	3	ms	ms	PROPN
ajlm-1363	205	4	,	,	PUNCT
ajlm-1363	205	5	wang	wang	PROPN
ajlm-1363	205	6	es	es	PROPN
ajlm-1363	205	7	,	,	PUNCT
ajlm-1363	205	8	altman	altman	PROPN
ajlm-1363	205	9	jk	jk	PROPN
ajlm-1363	205	10	,	,	PUNCT
ajlm-1363	205	11	et	et	PROPN
ajlm-1363	205	12	al	al	PROPN
ajlm-1363	205	13	.	.	PROPN
ajlm-1363	205	14	acute	acute	PROPN
ajlm-1363	205	15	myeloid	myeloid	ADJ
ajlm-1363	205	16	leukemia	leukemia	NOUN
ajlm-1363	205	17	,	,	PUNCT
ajlm-1363	205	18	version	version	NOUN
ajlm-1363	205	19	3.2019	3.2019	NUM
ajlm-1363	205	20	,	,	PUNCT
ajlm-1363	205	21	nccn	nccn	ADJ
ajlm-1363	205	22	clinical	clinical	ADJ
ajlm-1363	205	23	practice	practice	NOUN
ajlm-1363	205	24	guidelines	guideline	NOUN
ajlm-1363	205	25	in	in	ADP
ajlm-1363	205	26	oncology	oncology	NOUN
ajlm-1363	205	27	.	.	PUNCT
ajlm-1363	206	1	j	j	PROPN
ajlm-1363	206	2	natl	natl	PROPN
ajlm-1363	206	3	compr	compr	PROPN
ajlm-1363	206	4	canc	canc	PROPN
ajlm-1363	206	5	netw	netw	PROPN
ajlm-1363	206	6	.	.	PUNCT
ajlm-1363	207	1	2019;17(6):721–749	2019;17(6):721–749	X
ajlm-1363	207	2	.	.	PUNCT
ajlm-1363	208	1	https://doi.org/10.6004/jnccn.2019.0028	https://doi.org/10.6004/jnccn.2019.0028	PROPN
ajlm-1363	208	2	nunes	nune	VERB
ajlm-1363	208	3	barroso	barroso	PROPN
ajlm-1363	208	4	ks	ks	PROPN
ajlm-1363	208	5	,	,	PUNCT
ajlm-1363	208	6	lorand	lorand	NOUN
ajlm-1363	208	7	-	-	PUNCT
ajlm-1363	208	8	metze	metze	NOUN
ajlm-1363	208	9	i	i	PROPN
ajlm-1363	208	10	,	,	PUNCT
ajlm-1363	208	11	pagnano	pagnano	PROPN
ajlm-1363	208	12	kb	kb	PROPN
ajlm-1363	208	13	,	,	PUNCT
ajlm-1363	208	14	et	et	PROPN
ajlm-1363	208	15	al	al	PROPN
ajlm-1363	208	16	.	.	PUNCT
ajlm-1363	208	17	evaluation	evaluation	NOUN
ajlm-1363	208	18	of	of	ADP
ajlm-1363	208	19	seasonality	seasonality	NOUN
ajlm-1363	208	20	in	in	ADP
ajlm-1363	208	21	the	the	DET
ajlm-1363	208	22	incidence	incidence	NOUN
ajlm-1363	208	23	of	of	ADP
ajlm-1363	208	24	promyelocytic	promyelocytic	ADJ
ajlm-1363	208	25	leukemia	leukemia	NOUN
ajlm-1363	208	26	in	in	ADP
ajlm-1363	208	27	brazil	brazil	PROPN
ajlm-1363	208	28	.	.	PUNCT
ajlm-1363	209	1	blood	blood	NOUN
ajlm-1363	209	2	.	.	PUNCT
ajlm-1363	210	1	2013;122	2013;122	NUM
ajlm-1363	211	1	(	(	PUNCT
ajlm-1363	211	2	21):5005	21):5005	NUM
ajlm-1363	211	3	.	.	PUNCT
ajlm-1363	212	1	https://doi.org/10.1182/blood.v122.21.5005.5005	https://doi.org/10.1182/blood.v122.21.5005.5005	PROPN
ajlm-1363	212	2	mohammed	mohammed	PROPN
ajlm-1363	212	3	as	as	ADP
ajlm-1363	212	4	,	,	PUNCT
ajlm-1363	212	5	ali	ali	PROPN
ajlm-1363	212	6	th	th	PROPN
ajlm-1363	212	7	,	,	PUNCT
ajlm-1363	213	1	alwan	alwan	PROPN
ajlm-1363	213	2	af	af	PROPN
ajlm-1363	213	3	.	.	PUNCT
ajlm-1363	213	4	seasonality	seasonality	NOUN
ajlm-1363	213	5	in	in	ADP
ajlm-1363	213	6	acute	acute	ADJ
ajlm-1363	213	7	promyelocytic	promyelocytic	ADJ
ajlm-1363	213	8	leukemia	leukemia	NOUN
ajlm-1363	213	9	:	:	PUNCT
ajlm-1363	213	10	fact	fact	NOUN
ajlm-1363	213	11	or	or	CCONJ
ajlm-1363	213	12	myth	myth	NOUN
ajlm-1363	213	13	?	?	PUNCT
ajlm-1363	214	1	iraqi	iraqi	ADJ
ajlm-1363	214	2	j	j	PROPN
ajlm-1363	214	3	hematol	hematol	NOUN
ajlm-1363	214	4	.	.	PUNCT
ajlm-1363	215	1	2020;9(2):113	2020;9(2):113	NUM
ajlm-1363	215	2	.	.	PUNCT
ajlm-1363	216	1	https://doi.org/10.4103/ijh.ijh_27_20	https://doi.org/10.4103/ijh.ijh_27_20	PROPN
ajlm-1363	216	2	gilbert	gilbert	PROPN
ajlm-1363	216	3	rd	rd	PROPN
ajlm-1363	216	4	,	,	PUNCT
ajlm-1363	216	5	karabus	karabus	PROPN
ajlm-1363	216	6	cd	cd	PROPN
ajlm-1363	216	7	,	,	PUNCT
ajlm-1363	216	8	mills	mills	PROPN
ajlm-1363	216	9	ae	ae	PROPN
ajlm-1363	216	10	.	.	PUNCT
ajlm-1363	217	1	acute	acute	PROPN
ajlm-1363	217	2	promyelocytic	promyelocytic	ADJ
ajlm-1363	217	3	leukemia	leukemia	NOUN
ajlm-1363	217	4	.	.	PUNCT
ajlm-1363	218	1	a	a	DET
ajlm-1363	218	2	childhood	childhood	NOUN
ajlm-1363	218	3	cluster	cluster	NOUN
ajlm-1363	218	4	.	.	PUNCT
ajlm-1363	219	1	cancer	cancer	NOUN
ajlm-1363	219	2	.	.	PUNCT
ajlm-1363	220	1	1987;59(5):933–935	1987;59(5):933–935	X
ajlm-1363	220	2	.	.	PUNCT
ajlm-1363	221	1	https://doi.org/10.1002/1097-0142(19870301)59:5%3c933::aid-cncr2820590513%3e3.0.co;2-r	https://doi.org/10.1002/1097-0142(19870301)59:5%3c933::aid-cncr2820590513%3e3.0.co;2-r	ADJ
ajlm-1363	221	2	verhaak	verhaak	NOUN
ajlm-1363	221	3	rg	rg	PROPN
ajlm-1363	221	4	,	,	PUNCT
ajlm-1363	221	5	goudswaard	goudswaard	ADV
ajlm-1363	221	6	cs	cs	PROPN
ajlm-1363	221	7	,	,	PUNCT
ajlm-1363	221	8	van	van	PROPN
ajlm-1363	221	9	putten	putten	PROPN
ajlm-1363	221	10	w	w	PROPN
ajlm-1363	221	11	,	,	PUNCT
ajlm-1363	221	12	et	et	PROPN
ajlm-1363	221	13	al	al	PROPN
ajlm-1363	221	14	.	.	PUNCT
ajlm-1363	221	15	mutations	mutation	NOUN
ajlm-1363	221	16	in	in	ADP
ajlm-1363	221	17	nucleophosmin	nucleophosmin	NOUN
ajlm-1363	221	18	(	(	PUNCT
ajlm-1363	221	19	npm1	npm1	NOUN
ajlm-1363	221	20	)	)	PUNCT
ajlm-1363	221	21	in	in	ADP
ajlm-1363	221	22	acute	acute	ADJ
ajlm-1363	221	23	myeloid	myeloid	NOUN
ajlm-1363	221	24	leukemia	leukemia	NOUN
ajlm-1363	221	25	(	(	PUNCT
ajlm-1363	221	26	aml	aml	PROPN
ajlm-1363	221	27	):	):	PUNCT
ajlm-1363	221	28	association	association	NOUN
ajlm-1363	221	29	with	with	ADP
ajlm-1363	221	30	other	other	ADJ
ajlm-1363	221	31	gene	gene	NOUN
ajlm-1363	221	32	abnormalities	abnormality	NOUN
ajlm-1363	221	33	and	and	CCONJ
ajlm-1363	221	34	previously	previously	ADV
ajlm-1363	221	35	established	establish	VERB
ajlm-1363	221	36	gene	gene	NOUN
ajlm-1363	221	37	expression	expression	NOUN
ajlm-1363	221	38	signatures	signature	NOUN
ajlm-1363	221	39	and	and	CCONJ
ajlm-1363	221	40	their	their	PRON
ajlm-1363	221	41	favorable	favorable	ADJ
ajlm-1363	221	42	prognostic	prognostic	ADJ
ajlm-1363	221	43	expression	expression	NOUN
ajlm-1363	221	44	significance	significance	NOUN
ajlm-1363	221	45	.	.	PUNCT
ajlm-1363	222	1	blood	blood	NOUN
ajlm-1363	222	2	.	.	PUNCT
ajlm-1363	223	1	2005;106(12):3747–3754	2005;106(12):3747–3754	NUM
ajlm-1363	223	2	.	.	NOUN
ajlm-1363	223	3	https://doi.org/10.1182/blood-2005-05-2168	https://doi.org/10.1182/blood-2005-05-2168	NOUN
ajlm-1363	223	4	sekeres	sekeres	PROPN
ajlm-1363	223	5	ma	ma	PROPN
ajlm-1363	223	6	,	,	PUNCT
ajlm-1363	223	7	peterson	peterson	PROPN
ajlm-1363	223	8	b	b	PROPN
ajlm-1363	223	9	,	,	PUNCT
ajlm-1363	223	10	dodge	dodge	VERB
ajlm-1363	223	11	rk	rk	PRON
ajlm-1363	223	12	,	,	PUNCT
ajlm-1363	223	13	et	et	PROPN
ajlm-1363	223	14	al	al	PROPN
ajlm-1363	223	15	.	.	PROPN
ajlm-1363	223	16	differences	difference	NOUN
ajlm-1363	223	17	in	in	ADP
ajlm-1363	223	18	prognostic	prognostic	ADJ
ajlm-1363	223	19	factors	factor	NOUN
ajlm-1363	223	20	and	and	CCONJ
ajlm-1363	223	21	outcomes	outcome	NOUN
ajlm-1363	223	22	in	in	ADP
ajlm-1363	223	23	african	african	ADJ
ajlm-1363	223	24	americans	americans	PROPN
ajlm-1363	223	25	and	and	CCONJ
ajlm-1363	223	26	whites	white	NOUN
ajlm-1363	223	27	with	with	ADP
ajlm-1363	223	28	acute	acute	ADJ
ajlm-1363	223	29	myeloid	myeloid	ADJ
ajlm-1363	223	30	leukemia	leukemia	NOUN
ajlm-1363	223	31	.	.	PUNCT
ajlm-1363	224	1	blood	blood	NOUN
ajlm-1363	224	2	.	.	PUNCT
ajlm-1363	225	1	2004;103(11):4036–4042	2004;103(11):4036–4042	NUM
ajlm-1363	225	2	.	.	X
ajlm-1363	225	3	https://doi.org/10.1182/blood-2003-09-3118	https://doi.org/10.1182/blood-2003-09-3118	X